<?xml version="1.0" encoding="UTF-8"?><document id="28321817CBC09BB77ECA74E4A363C3D7" ID-DOI="10.5281/zenodo.1145711" ID-Zenodo-Dep="1145711" checkinTime="1515670456044" checkinUser="plazi" docAuthor="The rgp120 HIV Vaccine Study Group" docDate="2005" docId="FFD35C795E2DFF87FFABEF1FFFCF3534" docName="191-5-654.pdf" docOrigin="The journal of infectious diseases 191" docStyle="DocumentStyle{}" docTitle="Placebo-Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV-1 Infection" docVersion="5" lastPageNumber="665" pageNumber="654" updateTime="1634696474195" updateUser="ExternalLinkService">
<mods:mods xmlns:mods="http://www.loc.gov/mods/v3" id="119BB99BDE49BFC63479D7C517310ACF">
<mods:titleInfo id="4F44AB2BE362ED3894132FE7F1D703B0">
<mods:title id="EB4093954287791C341D028C5C7E9636">Placebo-Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV-1 Infection</mods:title>
</mods:titleInfo>
<mods:name id="2108B6E230759031299236C1CCB08B19" type="personal">
<mods:role id="E3CC0FEB0165E8E073F4867416F16A39">
<mods:roleTerm id="A7FE9D0CC18C5AD4C2CD9569905AFE8B">Author</mods:roleTerm>
</mods:role>
<mods:namePart id="F10787A02FFEB98ADFD8F77EFB0BF995">The rgp120 HIV Vaccine Study Group</mods:namePart>
</mods:name>
<mods:typeOfResource id="F4215F407CFABAE92ECB7F26BE889F62">text</mods:typeOfResource>
<mods:relatedItem id="E153E1C76C95F2DDF3C06D2E2CF6A404" type="host">
<mods:titleInfo id="A38F0914BECB2CF8514E5AC8D643A391">
<mods:title id="28F7579AFDF6AD152F3AF6D62A28DDAD">The journal of infectious diseases</mods:title>
</mods:titleInfo>
<mods:part id="84469CAB14A61FFD7AD1EF7CEA161D92">
<mods:date id="785BA98B4BDD451971EDA0F02C05F79A">2005</mods:date>
<mods:detail id="3EE8B04892B39A18E98D629AEF27C557" type="pubDate">
<mods:number id="9B4B4554305591ADC1218B69837F0923">2005-12-31</mods:number>
</mods:detail>
<mods:detail id="8A7F3CE341761E3FF376867A455E223F" type="volume">
<mods:number id="213CDD0DA21899A8F63D90F86DBD7A69">191</mods:number>
</mods:detail>
<mods:extent id="69391DB624BB52F25944FA46F8859605" unit="page">
<mods:start id="4E8CEF3937F54B1FD647FF6DE1B6AFBF">654</mods:start>
<mods:end id="EE32C0D35B6CE9EC426F9AC93A6CC8B5">665</mods:end>
</mods:extent>
</mods:part>
</mods:relatedItem>
<mods:classification id="D6C1BFDB052FB39E126BE103D6D85623">journal article</mods:classification>
<mods:identifier id="0C3088B4D87D48D26235C4449609F59A" type="DOI">10.5281/zenodo.1145711</mods:identifier>
<mods:identifier id="DFD042894EE23953B17856B584AAD0AD" type="Zenodo-Dep">1145711</mods:identifier>
</mods:mods>
<paragraph id="8BFC95175E2DFF87FE9CEE4EFA4034B2" blockId="0.[311,1462,337,454]" box="[311,1423,337,390]" pageId="0" pageNumber="654">Placebo-Controlled Phase 3 Trial of a Recombinant</paragraph>
<paragraph id="8BFC95175E2DFF87FE9CEE8FFA7934F1" blockId="0.[311,1462,337,454]" box="[311,1462,400,454]" pageId="0" pageNumber="654">Glycoprotein 120 Vaccine to Prevent HIV-1 Infection</paragraph>
<paragraph id="8BFC95175E2DFF87FE9CEEE1FD7D3733" blockId="0.[311,1476,507,1016]" box="[311,690,507,531]" pageId="0" pageNumber="654">
<heading id="D0B4227B5E2DFF87FE9CEEE1FD7D3733" bold="true" box="[311,690,507,531]" fontSize="9" level="2" pageId="0" pageNumber="654" reason="6">
<!--emphasis removed-->The rgp120 HIV Vaccine Study Group
<!--emphasis removed-->a
</heading>
</paragraph>
<paragraph id="8BFC95175E2DFF87FE9CED35FEB63769" blockId="0.[311,1476,507,1016]" pageId="0" pageNumber="654">
<!--emphasis removed-->(See the article by Gilbert et al., on pages 666–77, and the editorial commentary by Graham and Mascola, on pages 647–9.)
</paragraph>
<paragraph id="8BFC95175E2DFF87FEFBED7AFA5D3748" blockId="0.[311,1476,507,1016]" box="[336,1426,613,636]" pageId="0" pageNumber="654">
<!--emphasis removed-->Background.
A vaccine is needed to prevent human immunodeficienc virus type 1 (HIV-1) infection.
</paragraph>
<paragraph id="8BFC95175E2DFF87FEFBED9DFC3F37C5" blockId="0.[311,1476,507,1016]" pageId="0" pageNumber="654">
<!--emphasis removed-->Methods.
A double-blind, randomized trial of a recombinant HIV-1 envelope glycoprotein subunit (rgp120) vaccine was conducted among men who have sex with men and among women at high risk for heterosexual transmission of HIV-1. Volunteers received 7 injections of either vaccine or placebo (ratio, 2:1) over 30 months. The primary end point was HIV-1 seroconversion over 36 months.
</paragraph>
<paragraph id="8BFC95175E2DFF87FEFBEDE8FD40368A" blockId="0.[311,1476,507,1016]" pageId="0" pageNumber="654">
<!--emphasis removed-->Results.
A total of 5403 volunteers (5095 men and 308 women) were evaluated. The vaccine did not prevent HIV-1 acquisition: infection rates were 6.7% in 3598 vaccinees and 7.0% in 1805 placebo recipients; vaccineefficac (VE) was estimated as 6% (95% confidenc interval, 17% to 24%). There were no significan differences in viral loads, rates of antiretroviral-therapy initiation, or the genetic characteristics of the infecting HIV-1 strains between treatment arms. Exploratory subgroup analyses showed nonsignifican trends toward efficac inpreventinginfection in the highest risk (VE, 43%; 
<!--emphasis removed-->n
p 247) and nonwhite (VE, 47%; 
<!--emphasis removed-->n
p 914) volunteers (
<!--emphasis removed-->P
p.10, adjusted for multiple subgroup comparisons).
</paragraph>
<paragraph id="8BFC95175E2DFF87FEFBECDBFCB936CC" blockId="0.[311,1476,507,1016]" pageId="0" pageNumber="654">
<!--emphasis removed-->Conclusions.
There was no overall protective effect. The efficac trends in subgroups may provide clues for the development of effective immunization approaches.
</paragraph>
<paragraph id="8BFC95175E2DFF87FE9CEB3BFCAF30A0" blockId="0.[311,870,1060,1428]" pageId="0" pageNumber="654">
The creation of a vaccine to combat the global HIV-1 pandemic is an international public-health priority [
<bibRefCitation id="EFD2E8E65E2DFF87FCF8EB58FC903168" author="Esparza J &amp; Bhamarapravati N." box="[851,863,1095,1116]" journalOrPublisher="Lancet" pageId="0" pageNumber="654" pagination="2061 - 6" part="355" refString="1. Esparza J, Bhamarapravati N. Accelerating the development and future availability of HIV- 1 vaccines: why, when, where, and how? Lancet 2000; 355: 2061 - 6." title="Accelerating the development and future availability of HIV- 1 vaccines: why, when, where, and how" type="journal article" year="2000">1</bibRefCitation>
, 
<bibRefCitation id="EFD2E8E65E2DFF87FE9CEB76FE8831B4" author="Spearman P. HIV" box="[311,327,1129,1152]" journalOrPublisher="Curr HIV Res" pageId="0" pageNumber="654" pagination="101 - 20" part="1" refString="2. Spearman P. HIV vaccine development: lessons from the past and promise for the future. Curr HIV Res 2003; 1: 101 - 20." title="vaccine development: lessons from the past and promise for the future" type="journal article" year="2003">2</bibRefCitation>
]. Although infection leads to the development of an HIV-specifi immune response, the immune system is generally unable to effectively control replication of the virusortopreventimmunosuppression[
<bibRefCitation id="EFD2E8E65E2DFF87FD60EBCFFD1931D3" author="Nathanson N &amp; Mathieson BJ." box="[715,726,1232,1255]" journalOrPublisher="J Infect Dis" pageId="0" pageNumber="654" pagination="579 - 89" part="182" refString="3. Nathanson N, Mathieson BJ. Biological considerations in the development of a human immunodeficienc virus vaccine. J Infect Dis 2000; 182: 579 - 89." title="Biological considerations in the development of a human immunodeficienc virus vaccine" type="journal article" year="2000">3</bibRefCitation>
].Nonetheless, there is evidence of a protective immune response in certain special circumstances [
<bibRefCitation id="EFD2E8E65E2DFF87FDCEEA0AFDBC3018" author="Fowke KR &amp; Nagelkerke NJD &amp; Kimani J" box="[613,627,1301,1324]" journalOrPublisher="Lancet" pageId="0" pageNumber="654" pagination="1347 - 51" part="348" refString="4. Fowke KR, Nagelkerke NJD, Kimani J, et al. Resistance to HIV- 1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996; 348: 1347 - 51." title="Resistance to HIV- 1 infection among persistently seronegative prostitutes in Nairobi, Kenya" type="journal article" year="1996">4</bibRefCitation>
– 
<bibRefCitation id="EFD2E8E65E2DFF87FD28EA0AFD5F3018" author="Liu R &amp; Paxton WA &amp; Choe S" box="[643,656,1301,1324]" journalOrPublisher="Cell" pageId="0" pageNumber="654" pagination="367 - 77" part="86" refString="9. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV- 1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV- 1 infection. Cell 1996; 86: 367 - 77." title="Homozygous defect in HIV- 1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV- 1 infection" type="journal article" year="1996">9</bibRefCitation>
]. There has also been considerable debate with regard to whether antibodymediated or cell-mediated responses are of primary importance in providing protective immunity [
<bibRefCitation id="EFD2E8E65E2DFF87FD53EA61FCC930A7" author="Nathanson N &amp; Mathieson BJ." box="[760,774,1406,1427]" journalOrPublisher="J Infect Dis" pageId="0" pageNumber="654" pagination="579 - 89" part="182" refString="3. Nathanson N, Mathieson BJ. Biological considerations in the development of a human immunodeficienc virus vaccine. J Infect Dis 2000; 182: 579 - 89." title="Biological considerations in the development of a human immunodeficienc virus vaccine" type="journal article" year="2000">3</bibRefCitation>
, 
<bibRefCitation id="EFD2E8E65E2DFF87FCB8EA61FCE230A7" author="Zinkernagel RM." box="[787,813,1406,1427]" journalOrPublisher="Curr Opin Immunol" pageId="0" pageNumber="654" pagination="462 - 70" part="7" refString="10. Zinkernagel RM. Are HIV-specifi CTL responses salutary or pathogenic? Curr Opin Immunol 1995; 7: 462 - 70." title="Are HIV-specifi CTL responses salutary or pathogenic" type="journal article" year="1995">10</bibRefCitation>
, 
<bibRefCitation id="EFD2E8E65E2DFF87FC92EA62FC9B30A0" author="McMichael AJ &amp; Hanke T. HIV" box="[825,852,1405,1428]" journalOrPublisher="Nat Med" pageId="0" pageNumber="654" pagination="874 - 80" part="9" refString="11. McMichael AJ, Hanke T. HIV vaccines 1983 - 2003. Nat Med 2003; 9: 874 - 80." title="vaccines 1983 - 2003" type="journal article" year="2003">11</bibRefCitation>
].
</paragraph>
<paragraph id="8BFC95175E2DFF87FC05EB3BFAA33018" blockId="0.[917,1475,1060,1669]" pageId="0" pageNumber="654">
Protection of chimpanzees from intravenous and mucosal challenge with homologous and heterologous HIV-1 strains has been achieved with recombinant HIV- 1 envelope glycoprotein subunit (rgp120 and rgp160) vaccines [
<bibRefCitation id="EFD2E8E65E2DFF87FC53EBB1FBDC31F1" author="Berman PW &amp; Gregory TJ &amp; Riddle L" box="[1016,1043,1198,1221]" journalOrPublisher="Nature" pageId="0" pageNumber="654" pagination="622 - 5" part="345" refString="12. Berman PW, Gregory TJ, Riddle L, et al. Protection of chimpanzeesfrom infection by HIV- 1 after vaccination with recombinant glycoprotein gp 120 but not gp 160. Nature 1990; 345: 622 - 5." title="Protection of chimpanzeesfrom infection by HIV- 1 after vaccination with recombinant glycoprotein gp 120 but not gp 160" type="journal article" year="1990">12</bibRefCitation>
– 
<bibRefCitation id="EFD2E8E65E2DFF87FB89EBB1FBF231F1" author="Berman PW &amp; Murthy KK &amp; Wrin T" box="[1058,1085,1198,1221]" journalOrPublisher="J Infect Dis" pageId="0" pageNumber="654" pagination="52 - 9" part="173" refString="14. Berman PW, Murthy KK, Wrin T, et al. Protection of MN-rgp 120 - immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficienc virus type 1. J Infect Dis 1996; 173: 52 - 9." title="Protection of MN-rgp 120 - immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficienc virus type 1" type="journal article" year="1996">14</bibRefCitation>
]. Phase 1 and 2 studies in uninfected humans have demonstrated that rgp120 is safe and able to generate antibody responses similar to those observed in the protected chimpanzees [
<bibRefCitation id="EFD2E8E65E2DFF87FAB7EA0AFAF93018" author="Belshe RB &amp; Graham BS &amp; Keefer MC" box="[1308,1334,1301,1324]" journalOrPublisher="JAMA" pageId="0" pageNumber="654" pagination="475 - 80" part="272" refString="15. Belshe RB, Graham BS, Keefer MC, et al. Neutralizing antibodies to HIV- 1 in seronegative volunteers immunized with recombinant gp 120 from the MN strain of HIV- 1. NIAID AIDS Vaccine Clinical Trials Network. JAMA 1994; 272: 475 - 80." title="Neutralizing antibodies to HIV- 1 in seronegative volunteers immunized with recombinant gp 120 from the MN strain of HIV- 1. NIAID AIDS Vaccine Clinical Trials Network" type="journal article" year="1994">15</bibRefCitation>
– 
<bibRefCitation id="EFD2E8E65E2DFF87FAEDEA0AFAAE3018" author="Francis DP &amp; Gregory T &amp; McElrath MJ" box="[1350,1377,1301,1324]" journalOrPublisher="AIDS Res Hum Retroviruses" pageId="0" pageNumber="654" pagination="325 - 31" part="14" refString="17. Francis DP, Gregory T, McElrath MJ, et al. Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 1998; 14 (Suppl 3): S 325 - 31." title="Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3" type="journal article" year="1998">17</bibRefCitation>
].
</paragraph>
<paragraph id="8BFC95175E2DFF87FC05EA26FAD633B1" blockId="0.[917,1475,1060,1669]" pageId="0" pageNumber="654">
Two versions of an rgp120 vaccinecandidateadvanced to phase 3 studies in 1998–1999. The firs study was to evaluate a bivalent subtype B/B rgp120 vaccine in individuals in North AmericaandTheNetherlandswhowere at risk for infection via sexual exposure, whereas the second study was to evaluate a bivalent subtype B/E rgp120 vaccine in injection drug users in Thailand [
<bibRefCitation id="EFD2E8E65E2DFF87FA08E917FA713329" author="Francis DP &amp; Gregory T &amp; McElrath MJ" box="[1443,1470,1544,1565]" journalOrPublisher="AIDS Res Hum Retroviruses" pageId="0" pageNumber="654" pagination="325 - 31" part="14" refString="17. Francis DP, Gregory T, McElrath MJ, et al. Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 1998; 14 (Suppl 3): S 325 - 31." title="Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3" type="journal article" year="1998">17</bibRefCitation>
, 
<bibRefCitation id="EFD2E8E65E2DFF87FC3EE936FC7E3374" author="Berman PW &amp; Huang W &amp; Riddle L" box="[917,945,1577,1600]" journalOrPublisher="Virology" pageId="0" pageNumber="654" pagination="1 - 9" part="265" refString="18. Berman PW, Huang W, Riddle L, et al. Development of bivalent (B / E) vaccines able to neutralize CCR 5 - dependent viruses fromtheUnited States and Thailand. Virology 1999; 265: 1 - 9." title="Development of bivalent (B / E) vaccines able to neutralize CCR 5 - dependent viruses fromtheUnited States and Thailand" type="journal article" year="1999">18</bibRefCitation>
]. Here, we report the resultsofthefirs ofthesestudies designed to evaluate whether an rgp120 vaccine canconfer protection against HIV-1 infection.
</paragraph>
<footnote id="E85889195E2DFF87FEE2EAF2FDE632B0" pageId="0" pageNumber="654">
<paragraph id="8BFC95175E2DFF87FEE2EAF2FE7E3322" blockId="0.[311,871,1517,1924]" pageId="0" pageNumber="654">
Received 13 July 2004; accepted 15 November 2004; electronically published 27 January 
<docYear id="932579EC5E2DFF87FE21E91AFE623322" box="[394,429,1541,1558]" pageId="0" pageNumber="654">2005</docYear>
.
</paragraph>
<paragraph id="8BFC95175E2DFF87FEE2E902FD733372" blockId="0.[311,871,1517,1924]" pageId="0" pageNumber="654">Reprints or correspondence: Dr. Marc Gurwith, VaxGen, 1000 Marina Blvd., Ste. 200, Brisbane, CA 94005-1841 (mgurwith@vaxgen.com).</paragraph>
<paragraph id="8BFC95175E2DFF87FEE2E952FD0033B9" blockId="0.[311,871,1517,1924]" pageId="0" pageNumber="654">Presented in part: 43rd Annual Interscience Meeting on Antimicrobial Agents and Chemotherapy, Chicago, 14–17 September 2003 (abstract H-1942); AIDS Vaccine 2003, New York, September 18–21 (abstract 148).</paragraph>
<paragraph id="8BFC95175E2DFF87FEE2E98AFE7133E1" blockId="0.[311,871,1517,1924]" pageId="0" pageNumber="654">Financial support: VaxGen; Centers for Disease Control and Prevention;National Institutes of Health; Science Applications International Corporation–Frederick (contract 23XS119).</paragraph>
<paragraph id="8BFC95175E2DFF87FC3EE9B2FBA833D0" blockId="0.[917,1285,1709,1764]" pageId="0" pageNumber="654">VOLUNTEERS, MATERIALS, AND METHODS</paragraph>
<paragraph id="8BFC95175E2DFF87FEE2E9C2FDD23232" blockId="0.[311,871,1517,1924]" pageId="0" pageNumber="654">Potential conflicts of interest: listed after the text with the members of the Writing and Analysis Committee.</paragraph>
<paragraph id="8BFC95175E2DFF87FEE2E815FE2F3201" blockId="0.[311,871,1517,1924]" pageId="0" pageNumber="654">a Study group members and members of the Writing and Analysis Committee are listed after the text.</paragraph>
<paragraph id="8BFC95175E2DFF87FC3EE81AFBD8322F" blockId="0.[917,1475,1797,1927]" box="[917,1047,1797,1819]" pageId="0" pageNumber="654">
<heading id="D0B4227B5E2DFF87FC3EE81AFBD8322F" bold="true" box="[917,1047,1797,1819]" fontSize="9" level="2" pageId="0" pageNumber="654" reason="6">
<!--emphasis removed-->Study Design
</heading>
</paragraph>
<paragraph id="8BFC95175E2DFF86FC3EE832FD8B3675" blockId="0.[917,1475,1797,1927]" lastBlockId="1.[151,790,155,833]" lastPageId="1" lastPageNumber="655" pageId="0" pageNumber="654">
In this double-blind, randomized trial (known as “VAX004”), the volunteers were healthy, 18–62 years old, did not use intravenous drugs, and were either men who have sex with men (MSM) or women at high risk for heterosexual transmission of HIV-1. Men were eligible if they had had any anal intercourse during the preceding 12 months but were excluded if they had had a continuously monogamous sexual relationship with an HIV-1–uninfected male partner for 12 months. Women were eligible if they had had sexual intercourse with an HIV-1–infected male during the preceding 30 days or met at least 1 of the following criteria: had smoked crack cocaine during the preceding 12 months, had exchanged sex for drugs or money during the preceding 12 months, or had 5 male sex partners during the preceding 12 months. A computer-generated block randomization list, stratifie by the 61 sites that participated in the study, was designed to satisfy a 2:1 vaccinee to placebo recipient ratio. The eligibility criteria for and screening and enrollmentofthesevolunteershave been described in detail elsewhere [
<bibRefCitation id="EFD2E8E65E2CFF86FE53ED80FDDA3782" author="Harro CD &amp; Judson FN &amp; Gorse GJ" box="[504,533,671,694]" journalOrPublisher="J Acquir Immune Defi Syndr" pageId="1" pageNumber="655" pagination="1385 - 92" part="37" refString="19. Harro CD, Judson FN, Gorse GJ, et al. Recruitment and baseline epidemiologic profil of participants in the firs phase 3 HIV vaccine efficac trial. J Acquir Immune Defi Syndr 2004; 37: 1385 - 92." title="Recruitment and baseline epidemiologic profil of participants in the firs phase 3 HIV vaccine efficac trial" type="journal article" year="2004">19</bibRefCitation>
]. Volunteers who met the eligibility criteria, which included a negative test for HIV-1, were to be enrolled within 30 days of screening. The actual screening interval ranged from 1 to 51 days (median, 15 days), and 99% were enrolled within the required 30 days.
</paragraph>
<paragraph id="8BFC95175E2DFF87FE9CE85BFD1A3260" blockId="0.[311,871,1517,1924]" box="[311,725,1859,1876]" pageId="0" pageNumber="654">
<!--emphasis removed-->
<docJournal id="0EDEAEA65E2DFF87FE9CE85BFD8A3260" box="[311,581,1859,1876]" pageId="0" pageNumber="654">The Journal of Infectious Diseases</docJournal>
2005; 
<docVolume id="FCA5D20B5E2DFF87FD2EE85CFD513260" box="[645,670,1859,1876]" pageId="0" pageNumber="654">191</docVolume>
:654–65

</paragraph>
<paragraph id="8BFC95175E2DFF87FEE6E844FDE632B0" blockId="0.[311,871,1517,1924]" pageId="0" pageNumber="654">2005 by the Infectious Diseases Society of America. All rights reserved. 0022-1899/2005/19105-0003$15.00</paragraph>
</footnote>
<paragraph id="8BFC95175E2CFF86FF3CEC6CFE3F36BD" blockId="1.[151,791,883,1186]" box="[151,496,883,905]" pageId="1" pageNumber="655">
<heading id="D0B4227B5E2CFF86FF3CEC6CFE3F36BD" bold="true" box="[151,496,883,905]" fontSize="9" level="2" pageId="1" pageNumber="655" reason="6">
<!--emphasis removed-->Vaccine and Placebo Preparations
</heading>
</paragraph>
<paragraph id="8BFC95175E2CFF86FF3CEC85FE2F3196" blockId="1.[151,791,883,1186]" pageId="1" pageNumber="655">The study vaccine contained 2 rgp120 HIV-1 envelope antigens (300 mg each of MN and GNE8 rgp120/HIV-1) (AIDSVAX B/ B; VaxGen) that had been derived from 2 different subtype B strains and that were adsorbed onto 600 mg of alum. GNE8 gp120 was cloned directly from peripheral-blood mononuclear cells and had the CCR5 phenotype; the GNE8 gp120 DNA sequence was deposited in GenBank (accession no. AY771703). Placebo consisted of alum only.</paragraph>
<paragraph id="8BFC95175E2CFF86FF3CEBCAFEA231DF" blockId="1.[151,790,1237,1712]" box="[151,365,1237,1259]" pageId="1" pageNumber="655">
<heading id="D0B4227B5E2CFF86FF3CEBCAFEA231DF" bold="true" box="[151,365,1237,1259]" fontSize="9" level="2" pageId="1" pageNumber="655" reason="6">
<!--emphasis removed-->Ethics Considerations
</heading>
</paragraph>
<paragraph id="8BFC95175E2CFF86FF3CEBE4FDE23384" blockId="1.[151,790,1237,1712]" pageId="1" pageNumber="655">
The present study was conducted in accordance with the Declaration of Helsinki and local institutional review board requirements and with approval from appropriate regulatory authorities. Written, informed consent was obtained from all volunteers. Before enrollment in the study, a thorough discussion of possible issues and risks associated with participation was conducted with each potential volunteer [
<bibRefCitation id="EFD2E8E65E2CFF86FDC1EAD5FD4630D5" author="Francis DP &amp; Heyward WL &amp; Popovic V" box="[618,649,1482,1505]" journalOrPublisher="AIDS" pageId="1" pageNumber="655" pagination="147 - 56" part="17" refString="20. Francis DP, Heyward WL, Popovic V, et al. Candidate HIV / AIDS vaccines: lessons learned from the world's firs phase III efficac trials. AIDS 2003; 17: 147 - 56." title="Candidate HIV / AIDS vaccines: lessons learned from the world's firs phase III efficac trials" type="journal article" year="2003">20</bibRefCitation>
]. At each visit that included screening, trained counselors provided comprehensive education and pre- or post-HIV test and risk-reduction counseling, according to a comprehensive manual. Safety was monitored every 6 months by an independent data and safety monitoring board, which performed 1 interim efficac analysis 40 months after initiation of the study.
</paragraph>
<paragraph id="8BFC95175E2CFF86FF3CE9FCFE3133CC" blockId="1.[151,790,1762,1927]" box="[151,510,1762,1785]" pageId="1" pageNumber="655">
<heading id="D0B4227B5E2CFF86FF3CE9FCFE3133CC" bold="true" box="[151,510,1762,1785]" fontSize="9" level="2" pageId="1" pageNumber="655" reason="6">
<!--emphasis removed-->Vaccination and Study Assessments
</heading>
</paragraph>
<paragraph id="8BFC95175E2CFF86FF3CE815FC68362A" blockId="1.[151,790,1762,1927]" lastBlockId="1.[837,1478,155,798]" pageId="1" pageNumber="655">Vaccine or placebo was administered by intramuscularinjection at months 0, 1, 6, 12, 18, 24, and 30, with a fina follow-up visit at month 36. At each visit, adverse events and possible social harms were assessed; blood was obtained for assessment of HIV-1 status and immunogenicity. HIV-1 status was determined by detection of HIV-1 antibodies, using a standard HIV- 1 ELISA and confi matory immunoblot. The date of HIV-1 infection was estimated as follows: if HIV-1 RNA was undetectable in serum by a highly sensitive and specifi nucleicacid– based amplificatio test (NAT; Procleix HIV-1 Discriminatory Assay) at the date of the last seronegative test, then the date of HIV-1 infection was estimated as the midpoint of the dates of the last negative and firs positive ELISA/immunoblot test results. Otherwise, the infection date was estimated as the date of the earliest sample with detectable HIV-1 RNA. For volunteers who became infected during the study, plasma HIV-1 RNA load and CD4+ lymphocyte counts were assessed at!1 month and at months 1, 2, 4, 8, 12, 16, 20, and 24 afterdiagnosis of infection. Self-reported risk behaviors, including sexual activity and alcohol and drug use, and occurrence of sexually transmitted diseases were assessed by use of standard interviewer-administeredquestionnairesatbaselineandevery6months thereafter.</paragraph>
<paragraph id="8BFC95175E2CFF86FCEEEC4FFB853652" blockId="1.[837,1476,848,1048]" box="[837,1098,848,871]" pageId="1" pageNumber="655">
<heading id="D0B4227B5E2CFF86FCEEEC4FFB853652" bold="true" box="[837,1098,848,871]" fontSize="9" level="2" pageId="1" pageNumber="655" reason="6">
<!--emphasis removed-->Sequencing of Viral gp120
</heading>
</paragraph>
<paragraph id="8BFC95175E2CFF86FCEEEC67FAC43123" blockId="1.[837,1476,848,1048]" pageId="1" pageNumber="655">HIV-1 RNA was isolated from the earliest postinfection plasma sample; full-length gp120 genes were amplifie and cloned. Three full-length gp120 sequences were recovered from each of 336 of 368 infected volunteers. With the exception of 1 subtype C virus, all isolates were subtype B.</paragraph>
<paragraph id="8BFC95175E2CFF86FCEEEB54FB2C3155" blockId="1.[837,1476,1099,1505]" box="[837,1251,1099,1121]" pageId="1" pageNumber="655">
<heading id="D0B4227B5E2CFF86FCEEEB54FB2C3155" bold="true" box="[837,1251,1099,1121]" fontSize="9" level="2" pageId="1" pageNumber="655" reason="6">
<!--emphasis removed-->Immune Responses to the rgp120 Vaccine
</heading>
</paragraph>
<paragraph id="8BFC95175E2CFF86FCEEEB6EFB2A30D5" blockId="1.[837,1476,1099,1505]" pageId="1" pageNumber="655">
A cytopathicity bioassay was used to determine 50% neutralizing titers for HIV-1MN infection of MT-4 cells. Binding antibodies were measured in 5 indirect ELISAs with anMN/GNE8 gp120 mixture and GNE8 V2, MN V2, GNE8 V3, and MN V3 peptides as the antigens. Two competitive ELISAs were used to measure antibody blocking of the binding of MN or GNE8 gp120 to recombinant soluble CD4 [
<bibRefCitation id="EFD2E8E65E2CFF86FB11EA5EFB193062" author="Peterson ML &amp; Good JW &amp; Zaharias EM" box="[1210,1238,1345,1366]" journalOrPublisher="Alexandria, VA: Foundation for Retrovirology and Human Health" pageId="1" pageNumber="655" refString="21. Peterson ML, Good JW, Zaharias EM, et al. Development of a novel assay to measure antigen-specifi immune responses to multivalent vaccines for HIV- 1 [abstract 769]. In: Program and abstracts of the 7 th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2000." title="Development of a novel assay to measure antigen-specifi immune responses to multivalent vaccines for HIV- 1 [abstract 769]" type="book" volumeTitle="Program and abstracts of the 7 th Conference on Retroviruses and Opportunistic Infections (San Francisco)" year="2000">21</bibRefCitation>
, 
<bibRefCitation id="EFD2E8E65E2CFF86FB49EA20FACF3062" author="Gilbert PB &amp; Peterson ML &amp; Follmann D" box="[1250,1280,1343,1366]" journalOrPublisher="J Infect Dis" pageId="1" pageNumber="655" pagination="666 - 77" part="191" refString="22. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV- 1 infection in a phase 3 HIV- 1 preventive vaccine trial. J Infect Dis 2005: 191: 666 - 77 (in this issue)." title="Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV- 1 infection in a phase 3 HIV- 1 preventive vaccine trial" type="journal article" year="2005">22</bibRefCitation>
]. The 8 assays were performed on samples obtained 2 weeks after the last immunization before HIV-1 infection for infected vaccinees and on samples obtained 2 weeks after each immunization for a 5% random sample of uninfected vaccinees.
</paragraph>
<paragraph id="8BFC95175E2CFF86FCEEE90CFBCA331E" blockId="1.[837,1475,1555,1927]" box="[837,1029,1555,1578]" pageId="1" pageNumber="655">
<heading id="D0B4227B5E2CFF86FCEEE90CFBCA331E" bold="true" box="[837,1029,1555,1578]" fontSize="9" level="2" pageId="1" pageNumber="655" reason="6">
<!--emphasis removed-->Statistical Analysis
</heading>
</paragraph>
<paragraph id="8BFC95175E2CFF86FCEEE925FB7C32B3" blockId="1.[837,1475,1555,1927]" pageId="1" pageNumber="655">
<!--emphasis removed-->Primary end-point analysis.
Vaccine efficac (VE) was define as (1 the relative risk of infection) 100 and was estimated by use of a Cox proportional hazards model, with time to HIV infection grouped over six 6-month intervals and with the Efron method used for correction for ties [
<bibRefCitation id="EFD2E8E65E2CFF86FAB5E9DBFAF233EF" author="Allison PD." box="[1310,1341,1732,1755]" journalOrPublisher="Cary, NC: SAS Institute" pageId="1" pageNumber="655" refString="23. Allison PD. Survival analysis using the SAS system: a practical guide. Cary, NC: SAS Institute, 1995." title="Survival analysis using the SAS system: a practical guide" type="book" year="1995">23</bibRefCitation>
]. The sample size of the trial was selected as that which would provide, by a 2-sided log-rank test, 90% power to reject the null hypothesis—VE 30% if the true VE 60%. The Lan-DeMets implementation of the O’Brien-Fleming stopping boundary was used for 1 interim efficac analysis.
</paragraph>
<paragraph id="8BFC95175E2FFF85FF1AEF85FE53349D" blockId="2.[151,791,154,1927]" pageId="2" pageNumber="656">
<!--emphasis removed-->Secondary end-point analyses.
A generalized-estimatingequations model, which was based on all viral loads from samples obtained before initiation of antiretroviral therapy (ART), was used to estimate the mean difference between the vaccine and placebo arms in pre-ART viral load at each of the 9 postinfection visits. The time between detection of HIV infection and initiation of ART was compared between the 2 study arms by use of a log-rank test.
</paragraph>
<paragraph id="8BFC95175E2FFF85FF1AEEA9FDA8335D" blockId="2.[151,791,154,1927]" pageId="2" pageNumber="656">
<!--emphasis removed-->Exploratory analyses.
Tests for interaction in Cox proportional hazards models were used to evaluate whether VE differed by age (30 or 1 30 years), sex, education (less than a college degree or a college or graduate degree), race (white, black, Hispanic, Asian, and other and white vs. nonwhite), and baseline behavioral risk (low, medium, and high) [
<bibRefCitation id="EFD2E8E65E2FFF85FD12ED77FD17374B" author="Bristol DR." box="[697,728,616,639]" journalOrPublisher="J Biopharm Stat" pageId="2" pageNumber="656" pagination="313 - 21" part="7" refString="24. Bristol DR. p-value adjustments for subgroup analyses. J Biopharm Stat 1997; 7: 313 - 21 / 323 - 31." title="p-value adjustments for subgroup analyses" type="journal article" year="1997">24</bibRefCitation>
]. The binary categories for age and education were determinedbefore the unblinded analysis was conducted by collapsing the 5 age categories and the 4 education categories into 2 binary categories with approximately equal sample size. Because there was limited power to evaluate the VE for particular nonwhite subgroups, race was also dichotomized as white and nonwhite, with the latter category including volunteers who designated their race as Hispanic. Volunteers were classifie as having low, medium, or high baseline behavioral risk on the basis of selfreported behaviors during the 6 months before enrollment that were predictive of HIV infection in men pooled over the treatment arms. Behaviors that were statistically significan (
<!--emphasis removed-->P
!.05) in univariate Cox proportional hazards models were further assessed in multivariate models. Nine behaviors were identifie as independent predictors of HIV infection. A behavioral risk score for each volunteer was computed as the total number of these behaviors the person reported at baseline. The score was highly predictive of HIV infection, with anestimatedhazardratio of 1.66 (95% confidenc interval [CI], 1.56 to 1.77) per 1 riskfactor increase (
<!--emphasis removed-->P
!.0 0 0 1). Behavioral risk scores ranged from 0 to 7; 0 was categorized as low, 1–3 was categorized as medium, and 4–7 was categorized as high. The baseline behavioral risk score was based on data for men only, because only 6 HIV-1 infections were observed among the 308 female volunteers and because the important risk factor of insertive anal sex does not apply to women. The results reported below on VE by behavioral risk category did not change appreciably when the risk model was based on data for both men and women.
</paragraph>
<paragraph id="8BFC95175E2FFF85FF1AE967FA8B35E0" blockId="2.[151,791,154,1927]" lastBlockId="2.[837,1474,155,212]" pageId="2" pageNumber="656">
To account for multiple comparisons in subgroup analyses, a rerandomization procedure(with10,000permutations)wasused to testtheomnibusnullhypothesisthat 
<!--emphasis removed-->VE
p 0 forallsubgroups versus the alternative hypothesis that 
<!--emphasis removed-->VE
(0 for at least 1 subgroup. A bootstrap resampling procedure was used to compute adjusted 
<!--emphasis removed-->P
values [
<bibRefCitation id="EFD2E8E65E2FFF85FEE5E834FEA33276" author="Pollard KS &amp; van der Laan MJ." box="[334,364,1835,1858]" journalOrPublisher="J Statist Plann Inference" pageId="2" pageNumber="656" pagination="85 - 100" part="125" refString="25. Pollard KS, van der Laan MJ. Choice of a null distribution in resampling-based multiple testing. J Statist Plann Inference 2004; 125: 85 - 100." title="Choice of a null distribution in resampling-based multiple testing" type="journal article" year="2004">25</bibRefCitation>
]. The estimate and 95% CI of the VE value within each subgroup was also computed by use of a Cox proportional hazards model. A Cox proportional hazards modelwas used to estimate VE values for particular HIV-1 genotypes and to test whether VE differed by viral genotype [
<bibRefCitation id="EFD2E8E65E2FFF85FAB0EFA2FAF635E0" author="Lunn M &amp; McNeil D." box="[1307,1337,189,212]" journalOrPublisher="Biometrics" pageId="2" pageNumber="656" pagination="524 - 32" part="51" refString="26. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995; 51: 524 - 32." title="Applying Cox regression to competing risks" type="journal article" year="1995">26</bibRefCitation>
].
</paragraph>
<paragraph id="8BFC95175E2FFF85FCEEEE19FC70342F" blockId="2.[837,959,262,283]" box="[837,959,262,283]" pageId="2" pageNumber="656">
<heading id="D0B4227B5E2FFF85FCEEEE19FC70342F" allCaps="true" box="[837,959,262,283]" fontSize="9" level="3" pageId="2" pageNumber="656" reason="3">RESULTS</heading>
</paragraph>
<paragraph id="8BFC95175E2FFF85FCEEEE58FA853468" blockId="2.[837,1354,326,349]" box="[837,1354,326,349]" pageId="2" pageNumber="656">
<!--emphasis removed-->Demographics, Risk Behavior, and Conduct of Study
</paragraph>
<paragraph id="8BFC95175E2FFF85FCEEEE6BFB6A311B" blockId="2.[837,1476,371,1927]" pageId="2" pageNumber="656">
Between June 1998 and October 1999, 7185 volunteers were screened for study eligibility criteria (
<figureCitation id="137889925E2FFF85FB6CEE88FAD73499" box="[1223,1304,407,429]" captionStart="Figure 1" captionStartId="3.[366,427,1364,1386]" captionTargetBox="[296,1332,165,1320]" captionTargetId="figure@3.[295,1333,165,1321]" captionTargetPageId="3" captionText="Figure 1. Flow of study participants in the present trial (VAX004). rgp, recombinant glycoprotein." httpUri="https://zenodo.org/record/1145714/files/figure.png" pageId="2" pageNumber="656">figu e 1</figureCitation>
). Of these, 5417 eligible volunteers (5108 men and 309 women) were enrolled and were randomized to receive either vaccine or placebo. Of the 1768 volunteers not enrolled, 966 did not return after the initial screening visit, 328 met the study eligibility criteria but chose not to enroll, and 474 were excluded; the major reasons for exclusion were HIV-1 infection (161), serious underlying disease (148), and not meeting risk-behavior criteria (141). Despite being HIV-1 antibody negative at screening, 14 (11 vaccinees and 3 placebo recipients) volunteers had HIV-1infection detected at baseline (month 0) and were excluded from all efficac, but not safety, analyses. Of these, 12 were positive by NAT at month 0, although they were antibody negative; 1 was positive by NAT and intermediate by immunoblot; and 1 was positive by NAT and antibody positive. The vaccineandplacebo arms were similar in terms of demographiccharacteristics(
<tableCitation id="C6C1A0AC5E2FFF85FA3AECB1FC9E36DC" captionStart="Table 1" captionStartId="4.[265,318,154,175]" captionTargetBox="[265,1362,217,810]" captionText="Table 1. Baseline demographic characteristics and risk of HIV-1 infection." httpUri="http://table.plazi.org/id/DF3CC59F5E29FF83FEA2EF85FBC7359B" pageId="2" pageNumber="656" tableUuid="DF3CC59F5E29FF83FEA2EF85FBC7359B">table 1</tableCitation>
). The study population was predominantly male (94%),white (83%), young (median age, 36 years), and well educated (61% had a college or graduate degree).
</paragraph>
<paragraph id="8BFC95175E2FFF85FCF5EB23FB3D335D" blockId="2.[837,1476,371,1927]" pageId="2" pageNumber="656">
Self-reported risk behaviors, including sexual activity and alcohol and drug use, and rates of sexually transmitted diseases were similar in the vaccine and placebo arms at baseline and during follow-up (
<tableCitation id="C6C1A0AC5E2FFF85FBA8EBB8FB853188" box="[1027,1098,1191,1213]" captionStart="Table 1" captionStartId="4.[265,318,154,175]" captionTargetBox="[265,1362,217,810]" captionText="Table 1. Baseline demographic characteristics and risk of HIV-1 infection." httpUri="http://table.plazi.org/id/DF3CC59F5E29FF83FEA2EF85FBC7359B" pageId="2" pageNumber="656" tableUuid="DF3CC59F5E29FF83FEA2EF85FBC7359B">table 1</tableCitation>
and 
<figureCitation id="137889925E2FFF85FB2BEBB8FB1E3189" box="[1152,1233,1191,1213]" captionStart="Figure 2" captionStartId="5.[295,356,895,917]" captionTargetBox="[159,1466,164,852]" captionTargetId="figure@5.[159,1467,164,852]" captionTargetPageId="5" captionText="Figure 2. Self-reported risk behaviors by treatment arm and month of visit. STDs, sexually transmitted diseases." httpUri="https://zenodo.org/record/1145716/files/figure.png" pageId="2" pageNumber="656">figu e 2</figureCitation>
); they were also similar when stratifie by race (
<figureCitation id="137889925E2FFF85FB90EBD4FB4231D5" box="[1083,1165,1227,1249]" captionStart="Figure 3" captionStartId="6.[151,212,281,303]" captionText="Figure 3. Self-reported risk behaviors by race, treatment arm, and month of visit. STDs, sexually transmitted diseases." pageId="2" pageNumber="656">figu e 3</figureCitation>
) and by behavioral risk group (
<figureCitation id="137889925E2FFF85FCE7EBF0FC6E3031" box="[844,929,1263,1285]" captionStart="Figure 4" captionStartId="6.[837,898,1875,1897]" captionText="Figure 4. Self-reported risk behaviors by behavioral risk group,treatment arm, and month of visit. STDs, sexually transmitted diseases." pageId="2" pageNumber="656">figu e 4</figureCitation>
). For the 9 behaviors reported at baseline that were predictive of HIV-1 infection, borderline statisticallysignifican differences between the vaccine and placebo arms were observed for unprotected receptive anal sex with an HIV-1–uninfected partner reported at month 6 (i.e., occurring during the interval between baseline and the month 6 visit) and unprotected receptive anal sex with an HIV-1–infected partner reported at month 18. Most behaviors, except amphetamine use and unprotected receptive anal sex with an HIV-1–uninfected partner, decreased over time, with the major decrease occurring between baseline and month 6.
</paragraph>
<paragraph id="8BFC95175E2FFF85FCF5E969FABC32B3" blockId="2.[837,1476,371,1927]" pageId="2" pageNumber="656">
The rate of compliance with study vaccinations and the rate of loss to follow-up were well balanced between the vaccine and placebo arms (
<figureCitation id="137889925E2FFF85FBA2E9A1FB9533E7" box="[1033,1114,1726,1748]" captionStart="Figure 1" captionStartId="3.[366,427,1364,1386]" captionTargetBox="[296,1332,165,1320]" captionTargetId="figure@3.[295,1333,165,1321]" captionTargetPageId="3" captionText="Figure 1. Flow of study participants in the present trial (VAX004). rgp, recombinant glycoprotein." httpUri="https://zenodo.org/record/1145714/files/figure.png" pageId="2" pageNumber="656">figu e 1</figureCitation>
and table 2), although, in the high behavioral risk subgroup, the dropout rate was higher in the placebo arm (24%) than in the vaccine arm (13%) (
<!--emphasis removed-->P
p.0 52, Fisher’s exact test). There were no statistically significan differences in the 9 baseline risk behaviors between the vaccinees and placebo recipients who dropped out of the study.
</paragraph>
<paragraph id="8BFC95175E2FFF84FF3CE8DCFEE0309F" blockId="2.[151,754,1987,2006]" lastBlockId="3.[151,792,1430,1800]" lastPageId="3" lastPageNumber="657" pageId="2" pageNumber="656">
656 • 
<!--emphasis removed-->JID 2005:191 (1 March)
• rgp120 HIV Vaccine Study Group 
<heading id="D0B4227B5E2EFF84FF3CEA89FEE0309F" bold="true" box="[151,303,1430,1451]" fontSize="9" level="2" pageId="3" pageNumber="657" reason="6">
<!--emphasis removed-->Adverse Events
</heading>
</paragraph>
<caption id="DF3CC59F5E2EFF84FEC5EA4BFB21305E" box="[366,1262,1364,1386]" httpUri="https://zenodo.org/record/1145714/files/figure.png" pageId="3" pageNumber="657" targetBox="[296,1332,165,1320]" targetPageId="3">
<paragraph id="8BFC95175E2EFF84FEC5EA4BFE08305D" blockId="3.[366,455,1364,1386]" box="[366,455,1364,1386]" pageId="3" pageNumber="657">
<heading id="D0B4227B5E2EFF84FEC5EA4BFE08305D" bold="true" box="[366,455,1364,1386]" centered="true" fontSize="9" level="1" pageId="3" pageNumber="657" reason="2">
<!--emphasis removed-->Figure 1.
</heading>
</paragraph>
<paragraph id="8BFC95175E2EFF84FE4CEA4BFB21305E" blockId="3.[487,1262,1364,1386]" box="[487,1262,1364,1386]" pageId="3" pageNumber="657">Flow of study participants in the present trial (VAX004). rgp, recombinant glycoprotein.</paragraph>
</caption>
<paragraph id="8BFC95175E2EFF84FF3CEAA4FE2E323C" blockId="3.[151,792,1430,1800]" pageId="3" pageNumber="657">The vaccine was generally well tolerated. The most common adverse events were mild or moderate reactogenicitysymptoms that occurred during the firs 3 days after a vaccination. Rates of local symptoms at the injection site were higher in the vaccinees; local edema, induration, or a subcutaneous nodule reported on at least 1 of the 14 days after any of the vaccinations was reported by 36%, 29%, and 21% of the vaccinees and by 17%, 15%, and 12% of the placebo recipients, respectively. There were no other major differences in the frequency and type of reported adverse events.</paragraph>
<paragraph id="8BFC95175E2EFF84FF3CE835FE5A320B" blockId="3.[151,789,1833,1927]" box="[151,405,1833,1855]" pageId="3" pageNumber="657">
<heading id="D0B4227B5E2EFF84FF3CE835FE5A320B" bold="true" box="[151,405,1833,1855]" fontSize="9" level="2" pageId="3" pageNumber="657" reason="6">
<!--emphasis removed-->Rates of Infection and VE
</heading>
</paragraph>
<paragraph id="8BFC95175E2EFF84FF3CE850FB89336D" blockId="3.[151,789,1833,1927]" lastBlockId="3.[837,1475,1431,1626]" pageId="3" pageNumber="657">
Overall, 368 (6.8%) volunteers became HIV-1 infected during the study, giving an annual incidence rate of 2.6% (2.7% in men and 0.8% in women). No reduction of infection in vaccine recipients was observed (VE, 6% [95% CI, 
<bibRefCitation id="EFD2E8E65E2EFF84FAA3EAA5FAEF30FB" author="Francis DP &amp; Gregory T &amp; McElrath MJ" box="[1288,1312,1466,1487]" journalOrPublisher="AIDS Res Hum Retroviruses" pageId="3" pageNumber="657" pagination="325 - 31" part="14" refString="17. Francis DP, Gregory T, McElrath MJ, et al. Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 1998; 14 (Suppl 3): S 325 - 31." title="Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3" type="journal article" year="1998">17</bibRefCitation>
to 
<bibRefCitation id="EFD2E8E65E2EFF84FAE9EAA6FA9130E4" author="Bristol DR." box="[1346,1374,1465,1488]" journalOrPublisher="J Biopharm Stat" pageId="3" pageNumber="657" pagination="313 - 21" part="7" refString="24. Bristol DR. p-value adjustments for subgroup analyses. J Biopharm Stat 1997; 7: 313 - 21 / 323 - 31." title="p-value adjustments for subgroup analyses" type="journal article" year="1997">24</bibRefCitation>
]; 
<!--emphasis removed-->P
p.59) (
<tableCitation id="C6C1A0AC5E2EFF84FCE7EAC3FC5C30C6" box="[844,915,1500,1522]" captionStart="Table 3" captionStartId="8.[252,305,154,175]" captionTargetBox="[252,1375,217,1134]" captionText="Table 3. Attack rates of HIV-1 infection and vaccine efficacy (VE) against HIV-1 infection." httpUri="http://table.plazi.org/id/DF3CC59F5E25FF8FFF57EF85FB5D359B" pageId="3" pageNumber="657" tableUuid="DF3CC59F5E25FF8FFF57EF85FB5D359B">table 3</tableCitation>
). Kaplan-Meier curves of the time-to-infection showed approximately constant rates of HIV-1 infection; the rates were similar in the vaccine and placebo arms during the 36 months of follow-up (figu e 5 
<!--emphasis removed-->A
).
</paragraph>
<paragraph id="8BFC95175E2EFF84FCEEE983FAC03386" blockId="3.[837,1475,1692,1929]" box="[837,1295,1692,1714]" pageId="3" pageNumber="657">
<!--emphasis removed-->Postinfection Markers of Disease Progression
</paragraph>
<paragraph id="8BFC95175E2EFF84FCEEE9DAFE6B3D17" blockId="3.[837,1475,1692,1929]" lastBlockId="3.[8,766,2055,2099]" pageId="3" pageNumber="657">
Among the volunteers who acquired HIV-1 infection, pre-ART viral loads over the course of the 9 visits were similar in the vaccine and placebo arms (
<!--emphasis removed-->P
p.81). The mean difference (the mean of the vaccine arm minus the mean of the placebo arm) in pre-ART viral load at the visit 2 months after detection was 4.26 4.33 p 0.07 log10 (95% CI, 0.33 to 0.18 log10). The Downloaded from https://academic.oup.com/jid/article-abstract/191/5/654/1234535 by Aerztegemeinschaft fuer Anaesthesie user
</paragraph>
<caption id="DF3CC59F5E29FF83FEA2EF85FBC7359B" ID-Table-UUID="DF3CC59F5E29FF83FEA2EF85FBC7359B" box="[265,1032,153,175]" httpUri="http://table.plazi.org/id/DF3CC59F5E29FF83FEA2EF85FBC7359B" pageId="4" pageNumber="658" targetBox="[265,1362,217,810]" targetIsTable="true" targetPageId="4">
<paragraph id="8BFC95175E29FF83FEA2EF85FE95359A" blockId="4.[265,346,153,175]" box="[265,346,153,175]" pageId="4" pageNumber="658">
<heading id="D0B4227B5E29FF83FEA2EF85FE95359A" bold="true" box="[265,346,153,175]" centered="true" fontSize="9" level="1" pageId="4" pageNumber="658" reason="2">
<!--emphasis removed-->Table 1.
</heading>
</paragraph>
<paragraph id="8BFC95175E29FF83FED1EF86FBC7359B" blockId="4.[378,1032,153,175]" box="[378,1032,153,175]" pageId="4" pageNumber="658">
<!--emphasis removed-->Baseline demographic characteristics and risk of HIV-1 infection.
</paragraph>
</caption>
<paragraph id="8BFC95175E29FF83FD1BEFC6FAF2361D" pageId="4" pageNumber="658">
<table id="F94367B75E290078FEA2EFC6FA9D361E" box="[265,1362,217,810]" gridcols="7" gridrows="18" pageId="4" pageNumber="658">
<tr id="357397555E290078FEA2EFC6FA9D35D8" box="[265,1362,217,236]" gridrow="0" pageId="4" pageNumber="658" rowspan-0="1">
<th id="76A2FE295E290078FDE0EFC6FC8F35D8" box="[587,832,217,236]" colspan="2" colspanRight="1" gridcol="1" gridrow="0" pageId="4" pageNumber="658">Men</th>
<th id="76A2FE295E290078FCCBEFC6FBF235D8" box="[864,1085,217,236]" colspan="2" colspanRight="1" gridcol="3" gridrow="0" pageId="4" pageNumber="658">Women</th>
<th id="76A2FE295E290078FBF7EFC6FA9D35D8" box="[1116,1362,217,236]" colspan="2" colspanRight="1" gridcol="5" gridrow="0" pageId="4" pageNumber="658">All</th>
</tr>
<tr id="357397555E290078FEA2EE1FFA9D3427" box="[265,1362,256,275]" gridrow="1" pageId="4" pageNumber="658" rowspan-0="1">
<td id="76A2FE295E290078FDE0EE1FFD793427" box="[587,694,256,275]" gridcol="1" gridrow="1" pageId="4" pageNumber="658">Vaccine</td>
<td id="76A2FE295E290078FD7EEE1FFC8F3427" box="[725,832,256,275]" gridcol="2" gridrow="1" pageId="4" pageNumber="658">Placebo</td>
<td id="76A2FE295E290078FCCBEE1FFC713427" box="[864,958,256,275]" gridcol="3" gridrow="1" pageId="4" pageNumber="658">Vaccine</td>
<td id="76A2FE295E290078FC75EE1FFBF23427" box="[990,1085,256,275]" gridcol="4" gridrow="1" pageId="4" pageNumber="658">Placebo</td>
<td id="76A2FE295E290078FBF7EE1FFB083427" box="[1116,1223,256,275]" gridcol="5" gridrow="1" pageId="4" pageNumber="658">Vaccine</td>
<td id="76A2FE295E290078FB4CEE1FFA9D3427" box="[1255,1362,256,275]" gridcol="6" gridrow="1" pageId="4" pageNumber="658">Placebo</td>
</tr>
<tr id="357397555E290078FEA2EE04FA9D341A" box="[265,1362,283,302]" gridrow="2" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2EE04FDE3341A" box="[265,556,283,302]" gridcol="0" gridrow="2" pageId="4" pageNumber="658">Category, parameter</th>
<td id="76A2FE295E290078FDE0EE04FD79341A" box="[587,694,283,302]" gridcol="1" gridrow="2" pageId="4" pageNumber="658">
(
<!--emphasis removed-->n
p 3391)
</td>
<td id="76A2FE295E290078FD7EEE04FC8F341A" box="[725,832,283,302]" gridcol="2" gridrow="2" pageId="4" pageNumber="658">
(
<!--emphasis removed-->n
p 1704)
</td>
<td id="76A2FE295E290078FCCBEE04FC71341A" box="[864,958,283,302]" gridcol="3" gridrow="2" pageId="4" pageNumber="658">
(
<!--emphasis removed-->n
p 207)
</td>
<td id="76A2FE295E290078FC75EE04FBF2341A" box="[990,1085,283,302]" gridcol="4" gridrow="2" pageId="4" pageNumber="658">
(
<!--emphasis removed-->n
p 101)
</td>
<td id="76A2FE295E290078FBF7EE04FB08341A" box="[1116,1223,283,302]" gridcol="5" gridrow="2" pageId="4" pageNumber="658">
(
<!--emphasis removed-->n
p 3598)
</td>
<td id="76A2FE295E290078FB4CEE04FA9D341A" box="[1255,1362,283,302]" gridcol="6" gridrow="2" pageId="4" pageNumber="658">
(
<!--emphasis removed-->n
p 1805)
</td>
</tr>
<tr id="357397555E290078FEA2EE5CFA9D3462" box="[265,1362,323,342]" gridrow="3" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2EE5CFA9D3462" box="[265,1362,323,342]" colspan="7" colspanRight="6" gridcol="0" gridrow="3" pageId="4" pageNumber="658">Age, years</th>
</tr>
<tr id="357397555E290078FEA2EE7FFA9D3447" box="[265,1362,352,371]" gridrow="4" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2EE7FFDE33447" box="[265,556,352,371]" gridcol="0" gridrow="4" pageId="4" pageNumber="658">Median</th>
<td id="76A2FE295E290078FDE0EE7FFD793447" box="[587,694,352,371]" gridcol="1" gridrow="4" pageId="4" pageNumber="658">36</td>
<td id="76A2FE295E290078FD7EEE7FFC8F3447" box="[725,832,352,371]" gridcol="2" gridrow="4" pageId="4" pageNumber="658">35</td>
<td id="76A2FE295E290078FCCBEE7FFC713447" box="[864,958,352,371]" gridcol="3" gridrow="4" pageId="4" pageNumber="658">37</td>
<td id="76A2FE295E290078FC75EE7FFBF23447" box="[990,1085,352,371]" gridcol="4" gridrow="4" pageId="4" pageNumber="658">38</td>
<td id="76A2FE295E290078FBF7EE7FFB083447" box="[1116,1223,352,371]" gridcol="5" gridrow="4" pageId="4" pageNumber="658">36</td>
<td id="76A2FE295E290078FB4CEE7FFA9D3447" box="[1255,1362,352,371]" gridcol="6" gridrow="4" pageId="4" pageNumber="658">35</td>
</tr>
<tr id="357397555E290078FEA2EE62FA9D34A5" box="[265,1362,381,401]" gridrow="5" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2EE62FDE334A5" box="[265,556,381,401]" gridcol="0" gridrow="5" pageId="4" pageNumber="658">Range</th>
<td id="76A2FE295E290078FDE0EE62FD7934A5" box="[587,694,381,401]" gridcol="1" gridrow="5" pageId="4" pageNumber="658">18–62</td>
<td id="76A2FE295E290078FD7EEE62FC8F34A5" box="[725,832,381,401]" gridcol="2" gridrow="5" pageId="4" pageNumber="658">18–62</td>
<td id="76A2FE295E290078FCCBEE62FC7134A5" box="[864,958,381,401]" gridcol="3" gridrow="5" pageId="4" pageNumber="658">18–55</td>
<td id="76A2FE295E290078FC75EE62FBF234A5" box="[990,1085,381,401]" gridcol="4" gridrow="5" pageId="4" pageNumber="658">20–55</td>
<td id="76A2FE295E290078FBF7EE62FB0834A5" box="[1116,1223,381,401]" gridcol="5" gridrow="5" pageId="4" pageNumber="658">18–62</td>
<td id="76A2FE295E290078FB4CEE62FA9D34A5" box="[1255,1362,381,401]" gridcol="6" gridrow="5" pageId="4" pageNumber="658">18–62</td>
</tr>
<tr id="357397555E290078FEA2EE84FA9D349A" box="[265,1362,411,430]" gridrow="6" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2EE84FA9D349A" box="[265,1362,411,430]" colspan="7" colspanRight="6" gridcol="0" gridrow="6" pageId="4" pageNumber="658">Race</th>
</tr>
<tr id="357397555E290078FEA2EEA7FA9D34FF" box="[265,1362,440,459]" gridrow="7" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2EEA7FDE334FF" box="[265,556,440,459]" gridcol="0" gridrow="7" pageId="4" pageNumber="658">White (non-Hispanic)</th>
<td id="76A2FE295E290078FDE0EEA7FD7934FF" box="[587,694,440,459]" gridcol="1" gridrow="7" pageId="4" pageNumber="658">2930 (86)</td>
<td id="76A2FE295E290078FD7EEEA7FC8F34FF" box="[725,832,440,459]" gridcol="2" gridrow="7" pageId="4" pageNumber="658">1468 (86)</td>
<td id="76A2FE295E290078FCCBEEA7FC7134FF" box="[864,958,440,459]" gridcol="3" gridrow="7" pageId="4" pageNumber="658">64 (31)</td>
<td id="76A2FE295E290078FC75EEA7FBF234FF" box="[990,1085,440,459]" gridcol="4" gridrow="7" pageId="4" pageNumber="658">27 (27)</td>
<td id="76A2FE295E290078FBF7EEA7FB0834FF" box="[1116,1223,440,459]" gridcol="5" gridrow="7" pageId="4" pageNumber="658">2994 (83)</td>
<td id="76A2FE295E290078FB4CEEA7FA9D34FF" box="[1255,1362,440,459]" gridcol="6" gridrow="7" pageId="4" pageNumber="658">1495 (83)</td>
</tr>
<tr id="357397555E290078FEA2EECAFA9D34DC" box="[265,1362,469,488]" gridrow="8" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2EECAFA9D34DC" box="[265,1362,469,488]" colspan="7" colspanRight="6" gridcol="0" gridrow="8" pageId="4" pageNumber="658">Nonwhite</th>
</tr>
<tr id="357397555E290078FEA2EEEDFA9D3731" box="[265,1362,498,517]" gridrow="9" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2EEEDFDE33731" box="[265,556,498,517]" gridcol="0" gridrow="9" pageId="4" pageNumber="658">Hispanic</th>
<td id="76A2FE295E290078FDE0EEEDFD793731" box="[587,694,498,517]" gridcol="1" gridrow="9" pageId="4" pageNumber="658">211 (6)</td>
<td id="76A2FE295E290078FD7EEEEDFC8F3731" box="[725,832,498,517]" gridcol="2" gridrow="9" pageId="4" pageNumber="658">114 (7)</td>
<td id="76A2FE295E290078FCCBEEEDFC713731" box="[864,958,498,517]" gridcol="3" gridrow="9" pageId="4" pageNumber="658">28 (14)</td>
<td id="76A2FE295E290078FC75EEEDFBF23731" box="[990,1085,498,517]" gridcol="4" gridrow="9" pageId="4" pageNumber="658">14 (14)</td>
<td id="76A2FE295E290078FBF7EEEDFB083731" box="[1116,1223,498,517]" gridcol="5" gridrow="9" pageId="4" pageNumber="658">239 (7)</td>
<td id="76A2FE295E290078FB4CEEEDFA9D3731" box="[1255,1362,498,517]" gridcol="6" gridrow="9" pageId="4" pageNumber="658">128 (7)</td>
</tr>
<tr id="357397555E290078FEA2ED10FA9D3717" box="[265,1362,527,547]" gridrow="10" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2ED10FDE33717" box="[265,556,527,547]" gridcol="0" gridrow="10" pageId="4" pageNumber="658">Black (non-Hispanic)</th>
<td id="76A2FE295E290078FDE0ED10FD793717" box="[587,694,527,547]" gridcol="1" gridrow="10" pageId="4" pageNumber="658">121 (4)</td>
<td id="76A2FE295E290078FD7EED10FC8F3717" box="[725,832,527,547]" gridcol="2" gridrow="10" pageId="4" pageNumber="658">59 (3)</td>
<td id="76A2FE295E290078FCCBED10FC713717" box="[864,958,527,547]" gridcol="3" gridrow="10" pageId="4" pageNumber="658">112 (54)</td>
<td id="76A2FE295E290078FC75ED10FBF23717" box="[990,1085,527,547]" gridcol="4" gridrow="10" pageId="4" pageNumber="658">57 (56)</td>
<td id="76A2FE295E290078FBF7ED10FB083717" box="[1116,1223,527,547]" gridcol="5" gridrow="10" pageId="4" pageNumber="658">233 (6)</td>
<td id="76A2FE295E290078FB4CED10FA9D3717" box="[1255,1362,527,547]" gridcol="6" gridrow="10" pageId="4" pageNumber="658">116 (6)</td>
</tr>
<tr id="357397555E290078FEA2ED33FA9D3774" box="[265,1362,556,576]" gridrow="11" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2ED33FDE33774" box="[265,556,556,576]" gridcol="0" gridrow="11" pageId="4" pageNumber="658">Asian</th>
<td id="76A2FE295E290078FDE0ED33FD793774" box="[587,694,556,576]" gridcol="1" gridrow="11" pageId="4" pageNumber="658">56 (2)</td>
<td id="76A2FE295E290078FD7EED33FC8F3774" box="[725,832,556,576]" gridcol="2" gridrow="11" pageId="4" pageNumber="658">21 (1)</td>
<td id="76A2FE295E290078FCCBED33FC713774" box="[864,958,556,576]" gridcol="3" gridrow="11" pageId="4" pageNumber="658">0</td>
<td id="76A2FE295E290078FC75ED33FBF23774" box="[990,1085,556,576]" gridcol="4" gridrow="11" pageId="4" pageNumber="658">0</td>
<td id="76A2FE295E290078FBF7ED33FB083774" box="[1116,1223,556,576]" gridcol="5" gridrow="11" pageId="4" pageNumber="658">56 (2)</td>
<td id="76A2FE295E290078FB4CED33FA9D3774" box="[1255,1362,556,576]" gridcol="6" gridrow="11" pageId="4" pageNumber="658">21 (1)</td>
</tr>
<tr id="357397555E290078FEA2ED55FA9D374E" box="[265,1362,586,634]" gridrow="12" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2ED55FDE3374E" box="[265,556,586,634]" gridcol="0" gridrow="12" pageId="4" pageNumber="658">Other Education level a</th>
<td id="76A2FE295E290078FDE0ED55FD79374E" box="[587,694,586,634]" gridcol="1" gridrow="12" pageId="4" pageNumber="658">73 (2)</td>
<td id="76A2FE295E290078FD7EED55FC8F374E" box="[725,832,586,634]" gridcol="2" gridrow="12" pageId="4" pageNumber="658">42 (3)</td>
<td id="76A2FE295E290078FCCBED55FC71374E" box="[864,958,586,634]" gridcol="3" gridrow="12" pageId="4" pageNumber="658">3 (1)</td>
<td id="76A2FE295E290078FC75ED55FBF2374E" box="[990,1085,586,634]" gridcol="4" gridrow="12" pageId="4" pageNumber="658">3 (3)</td>
<td id="76A2FE295E290078FBF7ED55FB08374E" box="[1116,1223,586,634]" gridcol="5" gridrow="12" pageId="4" pageNumber="658">76 (2)</td>
<td id="76A2FE295E290078FB4CED55FA9D374E" box="[1255,1362,586,634]" gridcol="6" gridrow="12" pageId="4" pageNumber="658">45 (2)</td>
</tr>
<tr id="357397555E290078FEA2ED9BFA9D37AC" box="[265,1362,644,664]" gridrow="13" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2ED9BFDE337AC" box="[265,556,644,664]" gridcol="0" gridrow="13" pageId="4" pageNumber="658">Less than a college degree</th>
<td id="76A2FE295E290078FDE0ED9BFD7937AC" box="[587,694,644,664]" gridcol="1" gridrow="13" pageId="4" pageNumber="658">1238 (37)</td>
<td id="76A2FE295E290078FD7EED9BFC8F37AC" box="[725,832,644,664]" gridcol="2" gridrow="13" pageId="4" pageNumber="658">627 (37)</td>
<td id="76A2FE295E290078FCCBED9BFC7137AC" box="[864,958,644,664]" gridcol="3" gridrow="13" pageId="4" pageNumber="658">171 (83)</td>
<td id="76A2FE295E290078FC75ED9BFBF237AC" box="[990,1085,644,664]" gridcol="4" gridrow="13" pageId="4" pageNumber="658">86 (85)</td>
<td id="76A2FE295E290078FBF7ED9BFB0837AC" box="[1116,1223,644,664]" gridcol="5" gridrow="13" pageId="4" pageNumber="658">1409 (39)</td>
<td id="76A2FE295E290078FB4CED9BFA9D37AC" box="[1255,1362,644,664]" gridcol="6" gridrow="13" pageId="4" pageNumber="658">713 (40)</td>
</tr>
<tr id="357397555E290078FEA2EDBEFA9D37E6" box="[265,1362,673,722]" gridrow="14" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2EDBEFDE337E6" box="[265,556,673,722]" gridcol="0" gridrow="14" pageId="4" pageNumber="658">College or graduate degree Baseline behavioral risk score b</th>
<td id="76A2FE295E290078FDE0EDBEFD7937E6" box="[587,694,673,722]" gridcol="1" gridrow="14" pageId="4" pageNumber="658">2152 (63)</td>
<td id="76A2FE295E290078FD7EEDBEFC8F37E6" box="[725,832,673,722]" gridcol="2" gridrow="14" pageId="4" pageNumber="658">1077 (63)</td>
<td id="76A2FE295E290078FCCBEDBEFC7137E6" box="[864,958,673,722]" gridcol="3" gridrow="14" pageId="4" pageNumber="658">36 (17)</td>
<td id="76A2FE295E290078FC75EDBEFBF237E6" box="[990,1085,673,722]" gridcol="4" gridrow="14" pageId="4" pageNumber="658">15 (15)</td>
<td id="76A2FE295E290078FBF7EDBEFB0837E6" box="[1116,1223,673,722]" gridcol="5" gridrow="14" pageId="4" pageNumber="658">2188 (61)</td>
<td id="76A2FE295E290078FB4CEDBEFA9D37E6" box="[1255,1362,673,722]" gridcol="6" gridrow="14" pageId="4" pageNumber="658">1092 (60)</td>
</tr>
<tr id="357397555E290078FEA2EDC3FA9D37DB" box="[265,1362,732,751]" gridrow="15" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2EDC3FDE337DB" box="[265,556,732,751]" gridcol="0" gridrow="15" pageId="4" pageNumber="658">Low risk</th>
<td id="76A2FE295E290078FDE0EDC3FD7937DB" box="[587,694,732,751]" gridcol="1" gridrow="15" pageId="4" pageNumber="658">1077 (32)</td>
<td id="76A2FE295E290078FD7EEDC3FC8F37DB" box="[725,832,732,751]" gridcol="2" gridrow="15" pageId="4" pageNumber="658">538 (32)</td>
<td id="76A2FE295E290078FCCBEDC3FC7137DB" box="[864,958,732,751]" gridcol="3" gridrow="15" pageId="4" pageNumber="658">134 (65)</td>
<td id="76A2FE295E290078FC75EDC3FBF237DB" box="[990,1085,732,751]" gridcol="4" gridrow="15" pageId="4" pageNumber="658">71 (70)</td>
<td id="76A2FE295E290078FBF7EDC3FB0837DB" box="[1116,1223,732,751]" gridcol="5" gridrow="15" pageId="4" pageNumber="658">1211 (34)</td>
<td id="76A2FE295E290078FB4CEDC3FA9D37DB" box="[1255,1362,732,751]" gridcol="6" gridrow="15" pageId="4" pageNumber="658">609 (34)</td>
</tr>
<tr id="357397555E290078FEA2EDE6FA9D3638" box="[265,1362,761,780]" gridrow="16" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2EDE6FDE33638" box="[265,556,761,780]" gridcol="0" gridrow="16" pageId="4" pageNumber="658">Medium risk</th>
<td id="76A2FE295E290078FDE0EDE6FD793638" box="[587,694,761,780]" gridcol="1" gridrow="16" pageId="4" pageNumber="658">2156 (64)</td>
<td id="76A2FE295E290078FD7EEDE6FC8F3638" box="[725,832,761,780]" gridcol="2" gridrow="16" pageId="4" pageNumber="658">1077 (63)</td>
<td id="76A2FE295E290078FCCBEDE6FC713638" box="[864,958,761,780]" gridcol="3" gridrow="16" pageId="4" pageNumber="658">73 (35)</td>
<td id="76A2FE295E290078FC75EDE6FBF23638" box="[990,1085,761,780]" gridcol="4" gridrow="16" pageId="4" pageNumber="658">30 (30)</td>
<td id="76A2FE295E290078FBF7EDE6FB083638" box="[1116,1223,761,780]" gridcol="5" gridrow="16" pageId="4" pageNumber="658">2229 (62)</td>
<td id="76A2FE295E290078FB4CEDE6FA9D3638" box="[1255,1362,761,780]" gridcol="6" gridrow="16" pageId="4" pageNumber="658">1107 (61)</td>
</tr>
<tr id="357397555E290078FEA2EC09FA9D361E" box="[265,1362,790,810]" gridrow="17" pageId="4" pageNumber="658">
<th id="76A2FE295E290078FEA2EC09FDE3361E" box="[265,556,790,810]" gridcol="0" gridrow="17" pageId="4" pageNumber="658">High risk</th>
<td id="76A2FE295E290078FDE0EC09FD79361E" box="[587,694,790,810]" gridcol="1" gridrow="17" pageId="4" pageNumber="658">158 (5)</td>
<td id="76A2FE295E290078FD7EEC09FC8F361E" box="[725,832,790,810]" gridcol="2" gridrow="17" pageId="4" pageNumber="658">89 (5)</td>
<td id="76A2FE295E290078FCCBEC09FC71361E" box="[864,958,790,810]" gridcol="3" gridrow="17" pageId="4" pageNumber="658">0</td>
<td id="76A2FE295E290078FC75EC09FBF2361E" box="[990,1085,790,810]" gridcol="4" gridrow="17" pageId="4" pageNumber="658">0</td>
<td id="76A2FE295E290078FBF7EC09FB08361E" box="[1116,1223,790,810]" gridcol="5" gridrow="17" pageId="4" pageNumber="658">158 (4)</td>
<td id="76A2FE295E290078FB4CEC09FA9D361E" box="[1255,1362,790,810]" gridcol="6" gridrow="17" pageId="4" pageNumber="658">89 (5)</td>
</tr>
</table>
</paragraph>
<tableNote id="76A594995E29FF83FEB7EC5AFB0A36DE" pageId="4" pageNumber="658" targetBox="[265,1362,217,810]" targetPageId="4">
<paragraph id="8BFC95175E29FF83FEB7EC5AFC8E3662" blockId="4.[265,1362,836,1002]" box="[284,833,836,854]" pageId="4" pageNumber="658">
<!--emphasis removed-->NOTE.
Data are no. (%) of volunteers, unless otherwise noted.
</paragraph>
<paragraph id="8BFC95175E29FF83FEB7EC44FD573646" blockId="4.[265,1362,836,1002]" box="[284,664,859,882]" pageId="4" pageNumber="658">a One volunteer missing education data.</paragraph>
<paragraph id="8BFC95175E29FF83FE02EC7DFA9E36BE" blockId="4.[265,1362,836,1002]" pageId="4" pageNumber="658">was b Risk defined the total of risk factors reported from the following: (1) unprotected receptive anal with score was as no. sex an</paragraph>
<paragraph id="8BFC95175E29FF83FEA2EC8EFA9E3696" blockId="4.[265,1362,836,1002]" box="[265,1361,912,930]" pageId="4" pageNumber="658">HIV-1–infected male partner; (2) unprotected insertive anal sex with an HIV-1–infected male partner; (3) unprotected receptive anal</paragraph>
<paragraph id="8BFC95175E29FF83FEA2ECB6FA9D368E" blockId="4.[265,1362,836,1002]" box="[265,1362,936,954]" pageId="4" pageNumber="658">sex with an HIV-1–uninfected male partner; (4) 5 acts of unprotected receptive anal sex with a male partner of unknown HIV-1</paragraph>
<paragraph id="8BFC95175E29FF83FEA2ECDEFA9E36E5" blockId="4.[265,1362,836,1002]" box="[265,1361,960,978]" pageId="4" pageNumber="658">status; (5) 10 sex partners; (6) anal herpes; (7) hepatitis A; (8) use of poppers; and (9) use of amphetamines. Behavioral risk scores</paragraph>
<paragraph id="8BFC95175E29FF83FEA2ECC6FB0A36DE" blockId="4.[265,1362,836,1002]" box="[265,1221,985,1002]" pageId="4" pageNumber="658">ranged from 0 to 7; 0 was categorized as low, 1–3 was categorized as medium, and 4–7 was categorized as high.</paragraph>
</tableNote>
<paragraph id="8BFC95175E29FF83FF3CEB36FE683192" blockId="4.[151,790,1064,1190]" pageId="4" pageNumber="658">
rate of initiation of ART was similar in the vaccine (99/225 [
<bibRefCitation id="EFD2E8E65E29FF83FF35EB55FF733155" author="Assmann SF &amp; Pocock SJ &amp; Enos LE" box="[158,188,1098,1121]" journalOrPublisher="Lancet" pageId="4" pageNumber="658" pagination="1064 - 9" part="355" refString="44. Assmann SF, Pocock SJ, Enos LE, et al. Subgroup analysis and other (mis) uses of baseline data in clinical trials. Lancet 2000; 355: 1064 - 9." title="Subgroup analysis and other (mis) uses of baseline data in clinical trials" type="journal article" year="2000">44</bibRefCitation>
%]) and placebo (53/122 [
<bibRefCitation id="EFD2E8E65E29FF83FE7BEB55FE223155" author="Dawson GJ &amp; Schlauder GG &amp; Pilot-Matias TJ" box="[464,493,1098,1121]" journalOrPublisher="J Med Virol" pageId="4" pageNumber="658" pagination="97 - 103" part="50" refString="43. Dawson GJ, Schlauder GG, Pilot-Matias TJ, et al. Prevalence studies of GB virus - C infection using reverse transcriptase - polymerase chain reaction. J Med Virol 1996; 50: 97 - 103." title="Prevalence studies of GB virus - C infection using reverse transcriptase - polymerase chain reaction" type="journal article" year="1996">43</bibRefCitation>
%]) arms (
<!--emphasis removed-->P
p.61, log-rank test). No significan effects of vaccination on any postinfection end points were observed.
</paragraph>
<paragraph id="8BFC95175E29FF83FF3CEBC2FE0231C6" blockId="4.[151,791,1244,1927]" box="[151,461,1244,1266]" pageId="4" pageNumber="658">
<heading id="D0B4227B5E29FF83FF3CEBC2FE0231C6" bold="true" box="[151,461,1244,1266]" fontSize="9" level="2" pageId="4" pageNumber="658" reason="6">
<!--emphasis removed-->Exploratory Subgroup Analyses
</heading>
</paragraph>
<paragraph id="8BFC95175E29FF83FF3CEA1BFECF33C8" blockId="4.[151,791,1244,1927]" pageId="4" pageNumber="658">
There were no significan interactions with treatment for sex, age, or education level, but interaction tests in Cox proportional hazards models that included both baseline behavioral risk score (low, medium, or high) and race (white or nonwhite) demonstrated that VE significantl differed by behavioral risk level (
<!--emphasis removed-->P
p.0 41) and by race (
<!--emphasis removed-->P
p.0 0 7). There was no evidence that the pattern of increasing VE with risk group was restricted to white or nonwhite volunteers, although power was low for assessment of treatment by race by risk interaction. The rerandomization procedure used to account for multiple testing in the 15 subgroups yielded 
<!--emphasis removed-->P
p.102, indicating a nonsignificant trend toward VE being different from 0 in 1 subgroups. Subgroup-specifi estimates of VE values with unadjusted 95% CIs and unadjusted and multiplicity adjusted 
<!--emphasis removed-->P
values are shown in 
<tableCitation id="C6C1A0AC5E29FF83FF1EE9F8FF3333C8" box="[181,252,1767,1789]" captionStart="Table 3" captionStartId="8.[252,305,154,175]" captionTargetBox="[252,1375,217,1134]" captionText="Table 3. Attack rates of HIV-1 infection and vaccine efficacy (VE) against HIV-1 infection." httpUri="http://table.plazi.org/id/DF3CC59F5E25FF8FFF57EF85FB5D359B" pageId="4" pageNumber="658" tableUuid="DF3CC59F5E25FF8FFF57EF85FB5D359B">table 3</tableCitation>
.
</paragraph>
<paragraph id="8BFC95175E29FF83FF1AE815FB7F308E" blockId="4.[151,791,1244,1927]" lastBlockId="4.[837,1476,1064,1466]" pageId="4" pageNumber="658">Both overall and in subgroups, multivariateanalysesinwhich either baseline covariates (sex, age, race, education level, geographic region, and risk behavior) or risk behavior over time was controlled for yielded covariate adjusted point and CI estimates of VE that were nearly identical to the unadjustedvalues (data not shown). Because only 6 female volunteers acquired HIV-1 infection (4 black placebo recipients, 1 black vaccinee, and 1 Hispanic vaccinee), the above analyses of risk and race were repeated for men only; these analyses gave subgroupspecifi point estimates of VE and 95% CIs that were very similar to those obtained for both sexes combined. Because site of enrollment could confound estimates of VE, the analyses of VE were repeated with stratificatio by site. Generally, the results were very similar to the unstratifie results, except that estimates of VE decreased appreciably for the high behavioral risk subgroup (from 43% to 19%).</paragraph>
<paragraph id="8BFC95175E29FF83FCEEEAEEFAB53332" blockId="4.[837,1475,1520,1927]" box="[837,1402,1520,1543]" pageId="4" pageNumber="658">
<!--emphasis removed-->Antibody Responses, Viral Sequencing, and Selective VE
</paragraph>
<paragraph id="8BFC95175E29FF83FCEEE907FABF338C" blockId="4.[837,1475,1520,1927]" pageId="4" pageNumber="658">
All vaccinees assessed demonstrated HIV-1–specifi antibody responses [
<bibRefCitation id="EFD2E8E65E29FF83FC1CE926FC193364" author="Gilbert PB &amp; Peterson ML &amp; Follmann D" box="[951,982,1593,1616]" journalOrPublisher="J Infect Dis" pageId="4" pageNumber="658" pagination="666 - 77" part="191" refString="22. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV- 1 infection in a phase 3 HIV- 1 preventive vaccine trial. J Infect Dis 2005: 191: 666 - 77 (in this issue)." title="Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV- 1 infection in a phase 3 HIV- 1 preventive vaccine trial" type="journal article" year="2005">22</bibRefCitation>
]. The vaccinees with higher peak levels of MN CD4–blocking, GNE8 CD4–blocking, or MN-neutralizing responses tended to have a lower rate of HIV-1 infection; these analyses are described and interpreted elsewhere [
<bibRefCitation id="EFD2E8E65E29FF83FAEDE9BEFAAA338C" author="Gilbert PB &amp; Peterson ML &amp; Follmann D" box="[1350,1381,1697,1720]" journalOrPublisher="J Infect Dis" pageId="4" pageNumber="658" pagination="666 - 77" part="191" refString="22. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV- 1 infection in a phase 3 HIV- 1 preventive vaccine trial. J Infect Dis 2005: 191: 666 - 77 (in this issue)." title="Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV- 1 infection in a phase 3 HIV- 1 preventive vaccine trial" type="journal article" year="2005">22</bibRefCitation>
].
</paragraph>
<paragraph id="8BFC95175E29FF82FCF5E9DAFD3631FE" blockId="4.[837,1475,1520,1927]" lastBlockId="5.[151,789,962,1226]" lastPageId="5" lastPageNumber="659" pageId="4" pageNumber="658">
The subtype B consensus sequence at the tip of the gp120 V3 domain, GPGRAF, which is present in both the MN and GNE8 vaccine antigens, was selected as the main region for detection of the effects of vaccine on virus population dynamics. Overall, there was no evidence of selective efficac on the basis of virus type. VE was estimated as 0% for viruses with 658 • 
<!--emphasis removed-->JID 2005:191 (1 March)
• rgp120 HIV Vaccine Study Group the GPGRAF sequence and 19% forviruseswithouttheGPGRAF sequence. In exploratory analyses, there was no evidence of differential efficac in any behavioral risk group between viruses with and those without the GPGRAF sequence. A nonsignifican trend was found for nonwhite volunteers, with an estimated VE of 73% (95% CI, 35% to 88%) for viruses with the GPGRAF sequence versus an estimated VE of 24% (95% CI, 59% to 63%) for viruses without the GPGRAF sequence (
<!--emphasis removed-->P
p.077).
</paragraph>
<caption id="DF3CC59F5E28FF82FE8CEC60FAFA36A1" box="[295,1333,895,917]" httpUri="https://zenodo.org/record/1145716/files/figure.png" pageId="5" pageNumber="659" targetBox="[159,1466,164,852]" targetPageId="5">
<paragraph id="8BFC95175E28FF82FE8CEC60FE4F36A0" blockId="5.[295,384,895,917]" box="[295,384,895,917]" pageId="5" pageNumber="659">
<heading id="D0B4227B5E28FF82FE8CEC60FE4F36A0" bold="true" box="[295,384,895,917]" centered="true" fontSize="9" level="1" pageId="5" pageNumber="659" reason="2">
<!--emphasis removed-->Figure 2.
</heading>
</paragraph>
<paragraph id="8BFC95175E28FF82FE0BEC60FAFA36A1" blockId="5.[416,1333,895,917]" box="[416,1333,895,917]" pageId="5" pageNumber="659">Self-reported risk behaviors by treatment arm and month of visit. STDs, sexually transmitted diseases.</paragraph>
</caption>
<paragraph id="8BFC95175E28FF82FF3CEBEFFE893031" blockId="5.[151,326,1264,1285]" box="[151,326,1264,1285]" pageId="5" pageNumber="659">
<heading id="D0B4227B5E28FF82FF3CEBEFFE893031" allCaps="true" box="[151,326,1264,1285]" fontSize="9" level="3" pageId="5" pageNumber="659" reason="3">DISCUSSION</heading>
</paragraph>
<paragraph id="8BFC95175E28FF82FF3CEA39FEA33347" blockId="5.[151,790,1318,1927]" pageId="5" pageNumber="659">
VAX004 was the firs phase 3 placebo-controlled efficac study of a vaccine to prevent HIV-1 infection [
<bibRefCitation id="EFD2E8E65E28FF82FD95EA57FD92306B" author="Francis DP &amp; Heyward WL &amp; Popovic V" box="[574,605,1352,1375]" journalOrPublisher="AIDS" pageId="5" pageNumber="659" pagination="147 - 56" part="17" refString="20. Francis DP, Heyward WL, Popovic V, et al. Candidate HIV / AIDS vaccines: lessons learned from the world's firs phase III efficac trials. AIDS 2003; 17: 147 - 56." title="Candidate HIV / AIDS vaccines: lessons learned from the world's firs phase III efficac trials" type="journal article" year="2003">20</bibRefCitation>
]. More than 5000 MSMs were enrolled, in whom the predominant site of infection was rectal. A relatively small number (308) of women at high risk for heterosexual transmission of HIV-1 were also enrolled. Because only 6 women acquired HIV-1 infection during follow-up, compared with 362 men, the study had very little power to assess VE in women. Every analysis of VE gave very similar results, regardless of whether both sexes or only men were evaluated.
</paragraph>
<paragraph id="8BFC95175E28FF82FF1AE960FB1036CF" blockId="5.[151,790,1318,1927]" lastBlockId="5.[837,1475,962,1927]" pageId="5" pageNumber="659">
Despite producing neutralizing and CD4-blocking antibody responses in all vaccinees assessed for immunogenicity [
<bibRefCitation id="EFD2E8E65E28FF82FD40E9BEFCC5338C" author="Gilbert PB &amp; Peterson ML &amp; Follmann D" box="[747,778,1697,1720]" journalOrPublisher="J Infect Dis" pageId="5" pageNumber="659" pagination="666 - 77" part="191" refString="22. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV- 1 infection in a phase 3 HIV- 1 preventive vaccine trial. J Infect Dis 2005: 191: 666 - 77 (in this issue)." title="Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV- 1 infection in a phase 3 HIV- 1 preventive vaccine trial" type="journal article" year="2005">22</bibRefCitation>
], the vaccine was ineffective in preventing HIV-1 infection or in modifying postinfection markers of disease progression. This failure to protect likely derived from the lack of induction of antibodies capable of neutralizing genetically diverse primary HIV-1 isolates. Additionally, results from a phase 3 trial of a B/E rgp120 vaccine in Thailand showed no evidence of efficac, although the presumed mode of transmission in that study differed in that it was intravenous [
<bibRefCitation id="EFD2E8E65E28FF82FB1EECFBFB1B36CF" author="Choopanya K &amp; Tappero JW &amp; Pitisuttithum P" box="[1205,1236,996,1019]" journalOrPublisher="(Bangkok, Thailand). Bangkok, Thailand: Clung Wicha Press" pageId="5" pageNumber="659" pagination="2004" refString="27. Choopanya K, Tappero JW, Pitisuttithum P, et al. Preliminary results of a phase III HIV vaccine efficac trial among injecting drug users in Thailand [abstract ThOrA 1427]. In: Program and abstracts of the XV International AIDS Conference 2004 (Bangkok, Thailand). Bangkok, Thailand: Clung Wicha Press, 2004." title="Preliminary results of a phase III HIV vaccine efficac trial among injecting drug users in Thailand [abstract ThOrA 1427]" type="book chapter" volumeTitle="Program and abstracts of the XV International AIDS Conference" year="2004">27</bibRefCitation>
].
</paragraph>
<paragraph id="8BFC95175E28FF82FCF5EB17FBF33000" blockId="5.[837,1475,962,1927]" pageId="5" pageNumber="659">
The rgp120 vaccine used in the present trial appeared to be safe; other than the rate of local reactogenicity, no other rates of adverse events were meaningfully increased in vaccinees versus placebo recipients. Furthermore, although it has been hypothesized that a more rapid disease progression due to “immune enhancement” is a possible risk for vaccinees [
<bibRefCitation id="EFD2E8E65E28FF82FADAEBA9FA4131FF" author="Morens DM." box="[1393,1422,1206,1227]" journalOrPublisher="Clin Infect Dis" pageId="5" pageNumber="659" pagination="500 - 12" part="19" refString="28. Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994; 19: 500 - 12." title="Antibody-dependent enhancement of infection and the pathogenesis of viral disease" type="journal article" year="1994">28</bibRefCitation>
, 
<bibRefCitation id="EFD2E8E65E28FF82FA30EBAAFA7731F8" author="Burke DS." box="[1435,1464,1205,1228]" journalOrPublisher="Perspect Biol Med" pageId="5" pageNumber="659" pagination="511 - 30" part="35" refString="29. Burke DS. Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk? Perspect Biol Med 1992; 35: 511 - 30." title="Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk" type="journal article" year="1992">29</bibRefCitation>
], pre-ART viral loads and time to initiation of ART in the 368 volunteers who acquired HIV-1 infection provided no evidence of such a phenomenon.
</paragraph>
<paragraph id="8BFC95175E28FF82FCF5EA5EFAFF33CF" blockId="5.[837,1475,962,1927]" pageId="5" pageNumber="659">
The finding of the present study should reassure those who have been worried about the difficultie of conducting a phase 3 trial of an HIV-1 vaccine [
<bibRefCitation id="EFD2E8E65E28FF82FBC0EA9AFB4B30A8" author="King RT. FDA" box="[1131,1156,1413,1436]" journalOrPublisher="Wall Street Journal. 3 June" pageId="5" pageNumber="659" pagination="1" refString="30. King RT. FDA allows large-scale trial of AIDS vaccine. Wall Street Journal. 3 June 1998: 1." title="allows large-scale trial of AIDS vaccine" type="book chapter" year="1998">30</bibRefCitation>
– 
<bibRefCitation id="EFD2E8E65E28FF82FB39EA9AFB6430A8" author="Bloom BR." box="[1170,1195,1413,1436]" journalOrPublisher="Science" pageId="5" pageNumber="659" pagination="186 - 8" part="279" refString="32. Bloom BR. The highest attainable standard: ethical issues in AIDS vaccines. Science 1998; 279: 186 - 8." title="The highest attainable standard: ethical issues in AIDS vaccines" type="journal article" year="1998">32</bibRefCitation>
]—concerns with regard to recruiting, retaining, and reducing the pool of participants for future trials [
<bibRefCitation id="EFD2E8E65E28FF82FC65EAD4FC2230D6" author="King RT. FDA" box="[974,1005,1483,1506]" journalOrPublisher="Wall Street Journal. 3 June" pageId="5" pageNumber="659" pagination="1" refString="30. King RT. FDA allows large-scale trial of AIDS vaccine. Wall Street Journal. 3 June 1998: 1." title="allows large-scale trial of AIDS vaccine" type="book chapter" year="1998">30</bibRefCitation>
]; the potential for increased high-risk behavior by participants [
<bibRefCitation id="EFD2E8E65E28FF82FBBEEAF1FBFC3331" author="Chesney MA &amp; Chambers D &amp; Kahn JO." box="[1045,1075,1518,1541]" journalOrPublisher="J Acquir Immune Defi Syndr Hum Retrovirol" pageId="5" pageNumber="659" pagination="266 - 71" part="16" refString="31. Chesney MA, Chambers D, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defi Syndr Hum Retrovirol 1997; 16: 266 - 71." title="Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note" type="journal article" year="1997">31</bibRefCitation>
]; and conducting such a trial ethically should be allayed [
<bibRefCitation id="EFD2E8E65E28FF82FBADE90EFBEA331C" author="Bloom BR." box="[1030,1061,1553,1576]" journalOrPublisher="Science" pageId="5" pageNumber="659" pagination="186 - 8" part="279" refString="32. Bloom BR. The highest attainable standard: ethical issues in AIDS vaccines. Science 1998; 279: 186 - 8." title="The highest attainable standard: ethical issues in AIDS vaccines" type="journal article" year="1998">32</bibRefCitation>
]. Also, this trial was conducted with the understanding that it is possible to inflic social harm on individuals who volunteer for HIV-vaccine trials. To minimize the risk of social harm, advice and training were given to staff and volunteers; in the end, minimal harm occurred [
<bibRefCitation id="EFD2E8E65E28FF82FAD2E981FA573381" author="Francis DP &amp; Heyward WL &amp; Popovic V" box="[1401,1432,1694,1717]" journalOrPublisher="AIDS" pageId="5" pageNumber="659" pagination="147 - 56" part="17" refString="20. Francis DP, Heyward WL, Popovic V, et al. Candidate HIV / AIDS vaccines: lessons learned from the world's firs phase III efficac trials. AIDS 2003; 17: 147 - 56." title="Candidate HIV / AIDS vaccines: lessons learned from the world's firs phase III efficac trials" type="journal article" year="2003">20</bibRefCitation>
]. In addition, at least with this rgp120 vaccine, the chance of falsepositive serologic test results was minimal [
<bibRefCitation id="EFD2E8E65E28FF82FAADE9FBFAEA33CF" author="Ackers M-L &amp; Parekh B &amp; Evans TG" box="[1286,1317,1764,1787]" journalOrPublisher="J Infect Dis" pageId="5" pageNumber="659" pagination="879 - 86" part="187" refString="33. Ackers M-L, Parekh B, Evans TG, et al. Human immunodeficienc virus (HIV) seropositivity among uninfected HIV vaccine recipients. J Infect Dis 2003; 187: 879 - 86." title="Human immunodeficienc virus (HIV) seropositivity among uninfected HIV vaccine recipients" type="journal article" year="2003">33</bibRefCitation>
].
</paragraph>
<paragraph id="8BFC95175E28FF81FCF5E817FE473602" blockId="5.[837,1475,962,1927]" lastBlockId="6.[151,790,386,1927]" lastPageId="6" lastPageNumber="660" pageId="5" pageNumber="659">The finding with regard to risk-reduction counseling are less reassuring. Volunteers received comprehensive counseling by trained counselors at each study visit. Self-reported baseline risk behavior was a good predictor of subsequent infection, with infection rates at least 10-fold greater in the high-risk subgroup than in the low-risk subgroup, and overall self-reported risk behavior decreased over the course of the trial, although amphetamine use remained constant andunprotected receptive anal sex with an HIV-1–uninfected partner increased slightly. Despite the intensive counseling, the HIV-1 infection rate in the study population (which predominantly consisted of well-educated MSM) remained high and was steady during the 3 years of follow-up. In the absence of more-effectivecounseling, an effective HIV-1 vaccine, or other preventivemethods, the HIV-1 epidemic may continue unchecked and might, in some populations, approximate the current prevalence in sub- Saharan African adults.</paragraph>
<caption id="DF3CC59F5E2BFF81FF3CEE06FDA83478" pageId="6" pageNumber="660">
<paragraph id="8BFC95175E2BFF81FF3CEE06FDA83478" blockId="6.[151,790,281,332]" pageId="6" pageNumber="660">
<!--emphasis removed-->Figure 3.
Self-reported risk behaviors by race, treatment arm, and month of visit. STDs, sexually transmitted diseases.
</paragraph>
</caption>
<paragraph id="8BFC95175E2BFF81FF1AEC5CFE2D3097" blockId="6.[151,790,386,1927]" pageId="6" pageNumber="660">
On the basis of interaction tests, VE estimates differed significantl by behavioral risk levelandrace.Thisresultmotivated exploratory subgroup analyses, which indicated possible effi cacy of the vaccine in certain subgroups, such as in the high behavioral risk subgroup (VE, 43%) andinnonwhitevolunteers (VE, 47%). However, the largest of these subgroups (the nonwhite volunteers) comprised only 17% of the study population, and the VE estimates for these 2 subgroups were not signifi cantly different from 0% after adjustment for the multiplicity of tests performed. Because there was evidence of effect modificatio and because the high behavioral risk and nonwhite subgroups each had a substantial number of infections (58 and 59, respectively), we here discuss 4 possible explanations for the finding of the exploratory subgroup analyses. There is precedent for the possibility that VE can differ by demographic factors: a similar recombinant glycoprotein vaccine has been reported to confer protection against genital herpes infection in women but not in men [
<bibRefCitation id="EFD2E8E65E2BFF81FE13EA93FE183097" author="Stanberry LR &amp; Spruance SL &amp; Cunningham AL" box="[440,471,1420,1443]" journalOrPublisher="N Engl J Med" pageId="6" pageNumber="660" pagination="1652 - 61" part="347" refString="34. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-d - adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347: 1652 - 61." title="Glycoprotein-d - adjuvant vaccine to prevent genital herpes" type="journal article" year="2002">34</bibRefCitation>
].
</paragraph>
<paragraph id="8BFC95175E2BFF81FF1AEAAFFB8334F0" blockId="6.[151,790,386,1927]" lastBlockId="6.[837,1476,154,1695]" pageId="6" pageNumber="660">The firs possible explanation is that the variation in VE estimates across subgroups could simply be attributable to statistical variation and, therefore, not reflec any underlying pattern in the true VE values. Second, a findin of VE within a subgroup could have been caused by greater exposure to HIV- 1 in the placebo arm because of possible imbalances in risky behavior or other host or virologic factors. However, our multivariate analyses, which took baseline attributes into account, suggested that imbalances between the 2 treatment arms (if there were any) did not account for observed VE, and risk behaviors over time were similar in the vaccine and placebo arms. Within the racial subgroups and within the behavioral low- and medium-risk subgroups, the rate of loss to followup was well balanced between the treatment arms, and the behavioral risk factors of volunteers who were lost to followup were well balanced. Within the high behavioral risk subgroup, placebo recipients had a higher dropout rate than did vaccinees. Also, for volunteers who dropped out in this subgroup, placebo recipients reported higher rates of unprotect- ed receptive anal sex with an HIV-1–uninfected partner (81%) than did vaccine recipients (43%). However, neither of these differences would explain the higher observed VE in the high behavioral risk subgroup.</paragraph>
<paragraph id="8BFC95175E2BFF81FCF5EECEFB573674" blockId="6.[837,1476,154,1695]" pageId="6" pageNumber="660">
Third, the findin of an apparently higher VE in the high behavioral risk subgroup could be the result of synergybetween the vaccine-induced immune response and a natural “priming” of the immune response by frequent exposure to HIV-1without infection, which has been proposed as a possible explanation for the phenomenon of highly exposed yet persistently uninfected sex workers [
<bibRefCitation id="EFD2E8E65E2BFF81FBBEED80FBEB3782" author="Fowke KR &amp; Nagelkerke NJD &amp; Kimani J" box="[1045,1060,671,694]" journalOrPublisher="Lancet" pageId="6" pageNumber="660" pagination="1347 - 51" part="348" refString="4. Fowke KR, Nagelkerke NJD, Kimani J, et al. Resistance to HIV- 1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996; 348: 1347 - 51." title="Resistance to HIV- 1 infection among persistently seronegative prostitutes in Nairobi, Kenya" type="journal article" year="1996">4</bibRefCitation>
– 
<bibRefCitation id="EFD2E8E65E2BFF81FB98ED80FB8E3782" author="Jennes W &amp; Vuylsteke B &amp; Borget M-Y" box="[1075,1089,671,694]" journalOrPublisher="J Infect Dis" pageId="6" pageNumber="660" pagination="1053 - 63" part="187" refString="6. Jennes W, Vuylsteke B, Borget M-Y, et al. HIV-specifi T helper responses and frequency of exposure among HIV-exposed seronegative female sex workers in Abidjan, Coˆte d'Ivoire. J Infect Dis 2003; 187: 1053 - 63." title="HIV-specifi T helper responses and frequency of exposure among HIV-exposed seronegative female sex workers in Abidjan, Coˆte d'Ivoire" type="journal article" year="2003">6</bibRefCitation>
]. Although there was no evidence of increased antibody responses in the high behavioral risk subgroup in the present study [
<bibRefCitation id="EFD2E8E65E2BFF81FBCEEDFBFB4B37CF" author="Gilbert PB &amp; Peterson ML &amp; Follmann D" box="[1125,1156,740,763]" journalOrPublisher="J Infect Dis" pageId="6" pageNumber="660" pagination="666 - 77" part="191" refString="22. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV- 1 infection in a phase 3 HIV- 1 preventive vaccine trial. J Infect Dis 2005: 191: 666 - 77 (in this issue)." title="Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV- 1 infection in a phase 3 HIV- 1 preventive vaccine trial" type="journal article" year="2005">22</bibRefCitation>
], there may have been priming of cellular or humoral immune responses undetected by any of the assays carried out to date.
</paragraph>
<paragraph id="8BFC95175E2BFF81FCF5EC52FA4D3348" blockId="6.[837,1476,154,1695]" pageId="6" pageNumber="660">
Fourth, biological differences, such as differences in immune responses or in genetic markers of resistance to HIV-1 infection [
<bibRefCitation id="EFD2E8E65E2BFF81FCE0EC8EFC95369C" author="Fowke KR &amp; Nagelkerke NJD &amp; Kimani J" box="[843,858,913,936]" journalOrPublisher="Lancet" pageId="6" pageNumber="660" pagination="1347 - 51" part="348" refString="4. Fowke KR, Nagelkerke NJD, Kimani J, et al. Resistance to HIV- 1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996; 348: 1347 - 51." title="Resistance to HIV- 1 infection among persistently seronegative prostitutes in Nairobi, Kenya" type="journal article" year="1996">4</bibRefCitation>
– 
<bibRefCitation id="EFD2E8E65E2BFF81FCC1EC8EFCB7369C" author="Liu R &amp; Paxton WA &amp; Choe S" box="[874,888,913,936]" journalOrPublisher="Cell" pageId="6" pageNumber="660" pagination="367 - 77" part="86" refString="9. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV- 1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV- 1 infection. Cell 1996; 86: 367 - 77." title="Homozygous defect in HIV- 1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV- 1 infection" type="journal article" year="1996">9</bibRefCitation>
], could explain why the vaccine appeared to be effective only in nonwhite volunteers. Differences in immune responses by sex and race have been reported [
<bibRefCitation id="EFD2E8E65E2BFF81FB7AECC8FB2236D9" author="Whitacre CC &amp; Reingold SC &amp; O'Looney PA" box="[1233,1261,983,1005]" journalOrPublisher="Science" pageId="6" pageNumber="660" pagination="1277 - 8" part="283" refString="35. Whitacre CC, Reingold SC, O'Looney PA, et al. Biomedicine: a gender gap in autoimmunity. Science 1999; 283: 1277 - 8." title="Biomedicine: a gender gap in autoimmunity" type="journal article" year="1999">35</bibRefCitation>
, 
<bibRefCitation id="EFD2E8E65E2BFF81FB57ECC9FAD636D9" author="Sugimoto K &amp; Stadanlick J &amp; Ikeda F" box="[1276,1305,982,1005]" journalOrPublisher="Hepatology" pageId="6" pageNumber="660" pagination="590 - 9" part="37" refString="36. Sugimoto K, Stadanlick J, Ikeda F, et al. Influenc of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 2003; 37: 590 - 9." title="Influenc of ethnicity in the outcome of hepatitis C virus infection and cellular immune response" type="journal article" year="2003">36</bibRefCitation>
]. In the present study, lower vaccine-induced antibody responses correlated with higher infection rates in all racial subgroups [
<bibRefCitation id="EFD2E8E65E2BFF81FAFEEB04FABB3106" author="Gilbert PB &amp; Peterson ML &amp; Follmann D" box="[1365,1396,1051,1074]" journalOrPublisher="J Infect Dis" pageId="6" pageNumber="660" pagination="666 - 77" part="191" refString="22. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV- 1 infection in a phase 3 HIV- 1 preventive vaccine trial. J Infect Dis 2005: 191: 666 - 77 (in this issue)." title="Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV- 1 infection in a phase 3 HIV- 1 preventive vaccine trial" type="journal article" year="2005">22</bibRefCitation>
]. Given that the overall VE estimate (6%) was near 0%, this result cannot be interpreted to imply that higher antibody responses were the cause of protection. Although it may be implausible to group Asian and black volunteers on the basis of genetic similarities, possible differences in exposure among racial subgroups to environmental factors or other infecting pathogens that could increase [
<bibRefCitation id="EFD2E8E65E2BFF81FBA5EA11FBE53017" author="Schacker T &amp; Zeh J &amp; Hu HL &amp; Hill J &amp; Corey L." box="[1038,1066,1294,1315]" journalOrPublisher="J Infect Dis" pageId="6" pageNumber="660" pagination="1616 - 22" part="178" refString="37. Schacker T, Zeh J, Hu HL, Hill J, Corey L. Frequency of symptomatic and asymptomatic HSV- 2 reactivations among HIV-infected men. J Infect Dis 1998; 178: 1616 - 22." title="Frequency of symptomatic and asymptomatic HSV- 2 reactivations among HIV-infected men" type="journal article" year="1998">37</bibRefCitation>
, 
<bibRefCitation id="EFD2E8E65E2BFF81FB9EEA13FB9F3017" author="Wald A &amp; Link K." box="[1077,1104,1292,1315]" journalOrPublisher="J Infect Dis" pageId="6" pageNumber="660" pagination="45 - 52" part="185" refString="38. Wald A, Link K. Risk of human immunodeficienc virus infection in herpes simplex virus type 2 - seropositive persons: a meta-analysis. J Infect Dis 2002; 185: 45 - 52." title="Risk of human immunodeficienc virus infection in herpes simplex virus type 2 - seropositive persons: a meta-analysis" type="journal article" year="2002">38</bibRefCitation>
] or decrease susceptibility [
<bibRefCitation id="EFD2E8E65E2BFF81FACBEA13FAB53017" author="Xiang J &amp; Wunschmann S &amp; Diekema DJ" box="[1376,1402,1292,1315]" journalOrPublisher="N Engl J Med" pageId="6" pageNumber="660" pagination="707 - 14" part="345" refString="39. Xiang J, Wunschmann S, Diekema DJ, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001; 345: 707 - 14." title="Effect of coinfection with GB virus C on survival among patients with HIV infection" type="journal article" year="2001">39</bibRefCitation>
– 
<bibRefCitation id="EFD2E8E65E2BFF81FA23EA13FA6D3017" author="Dawson GJ &amp; Schlauder GG &amp; Pilot-Matias TJ" box="[1416,1442,1292,1315]" journalOrPublisher="J Med Virol" pageId="6" pageNumber="660" pagination="97 - 103" part="50" refString="43. Dawson GJ, Schlauder GG, Pilot-Matias TJ, et al. Prevalence studies of GB virus - C infection using reverse transcriptase - polymerase chain reaction. J Med Virol 1996; 50: 97 - 103." title="Prevalence studies of GB virus - C infection using reverse transcriptase - polymerase chain reaction" type="journal article" year="1996">43</bibRefCitation>
] to HIV-1 infection might help to account for differingVEestimates. For example, some studies have demonstrated that coinfection with GB virus C (GBV-C)—a flavivi us whose prevalence varies widely and appears to correlate with injection drug use, highrisk sexual activity, and certain geographic areas—has an apparently beneficia effect on progression of HIV-1 disease [
<bibRefCitation id="EFD2E8E65E2BFF81FA09EAC2FA7130C6" author="Pomerantz RJ &amp; Nunnari G. HIV" box="[1442,1470,1501,1522]" journalOrPublisher="N Engl J Med" pageId="6" pageNumber="660" pagination="963 - 5" part="350" refString="42. Pomerantz RJ, Nunnari G. HIV and GB virus C: can two viruses be better than one? N Engl J Med 2004; 350: 963 - 5." title="and GB virus C: can two viruses be better than one" type="journal article" year="2004">42</bibRefCitation>
, 
<bibRefCitation id="EFD2E8E65E2BFF81FCEEEAE1FCAD3321" author="Dawson GJ &amp; Schlauder GG &amp; Pilot-Matias TJ" box="[837,866,1534,1557]" journalOrPublisher="J Med Virol" pageId="6" pageNumber="660" pagination="97 - 103" part="50" refString="43. Dawson GJ, Schlauder GG, Pilot-Matias TJ, et al. Prevalence studies of GB virus - C infection using reverse transcriptase - polymerase chain reaction. J Med Virol 1996; 50: 97 - 103." title="Prevalence studies of GB virus - C infection using reverse transcriptase - polymerase chain reaction" type="journal article" year="1996">43</bibRefCitation>
]. Proposed mechanisms include GBV-C–mediated reduction in expression of CCR5, induction of anti–HIV-1 cytokines, and enhancement of natural immunity[
<bibRefCitation id="EFD2E8E65E2BFF81FB02E95CFB0C336E" author="Dawson GJ &amp; Schlauder GG &amp; Pilot-Matias TJ" box="[1193,1219,1603,1626]" journalOrPublisher="J Med Virol" pageId="6" pageNumber="660" pagination="97 - 103" part="50" refString="43. Dawson GJ, Schlauder GG, Pilot-Matias TJ, et al. Prevalence studies of GB virus - C infection using reverse transcriptase - polymerase chain reaction. J Med Virol 1996; 50: 97 - 103." title="Prevalence studies of GB virus - C infection using reverse transcriptase - polymerase chain reaction" type="journal article" year="1996">43</bibRefCitation>
], anyofwhichcouldwork synergistically with a vaccine-induced antibody response.
</paragraph>
<paragraph id="8BFC95175E2BFF81FCF5E996FE6B3D17" blockId="6.[837,1476,154,1695]" lastBlockId="6.[8,766,2055,2099]" pageId="6" pageNumber="660">
What conclusions can be drawn from the present phase 3 660 • 
<!--emphasis removed-->JID 2005:191 (1 March)
• rgp120 HIV Vaccine Study Group Downloaded from https://academic.oup.com/jid/article-abstract/191/5/654/1234535 by Aerztegemeinschaft fuer Anaesthesie user
</paragraph>
<caption id="DF3CC59F5E2BFF81FCEEE84CFA5032B2" pageId="6" pageNumber="660">
<paragraph id="8BFC95175E2BFF81FCEEE84CFA5032B2" blockId="6.[837,1475,1875,1926]" pageId="6" pageNumber="660">
<!--emphasis removed-->Figure 4.
Self-reported risk behaviors by behavioral risk group, treatment arm, and month of visit. STDs, sexually transmitted diseases.
</paragraph>
</caption>
<paragraph id="8BFC95175E2AFF80FF3CEF85FF27359A" blockId="7.[151,232,153,175]" box="[151,232,153,175]" pageId="7" pageNumber="661">
<heading id="D0B4227B5E2AFF80FF3CEF85FF27359A" bold="true" box="[151,232,153,175]" centered="true" fontSize="9" level="1" pageId="7" pageNumber="661" reason="2">
<!--emphasis removed-->Table 2.
</heading>
</paragraph>
<paragraph id="8BFC95175E2AFF80FEA3EF85FD08359B" blockId="7.[264,711,153,175]" box="[264,711,153,175]" pageId="7" pageNumber="661">
<heading id="D0B4227B5E2AFF80FEA3EF85FD08359B" bold="true" box="[264,711,153,175]" centered="true" fontSize="9" level="1" pageId="7" pageNumber="661" reason="2">
<!--emphasis removed-->Rates of immunization and study completion.
</heading>
</paragraph>
<table id="F94367B75E2A0078FF3CEFC6FA0B3781" box="[151,1476,217,693]" gridcols="7" gridrows="14" pageId="7" pageNumber="661">
<paragraph id="8BFC95175E2AFF80FC8FEFC6FA0B341A" pageId="7" pageNumber="661">
<table id="F94367B75E2A0078FF3CEFC6FA0B341A" box="[151,1476,217,302]" gridcols="7" gridrows="3" pageId="7" pageNumber="661">
<tr id="357397555E2A0078FF3CEFC6FA0B35D8" box="[151,1476,217,236]" gridrow="0" pageId="7" pageNumber="661" rowspan-0="1">
<th id="76A2FE295E2A0078FD14EFC6FC7B35D8" box="[703,948,217,236]" colspan="2" colspanRight="1" gridcol="1" gridrow="0" pageId="7" pageNumber="661">Men</th>
<th id="76A2FE295E2A0078FC78EFC6FB7F35D8" box="[979,1200,217,236]" colspan="2" colspanRight="1" gridcol="3" gridrow="0" pageId="7" pageNumber="661">Women</th>
<th id="76A2FE295E2A0078FB64EFC6FA0B35D8" box="[1231,1476,217,236]" colspan="2" colspanRight="1" gridcol="5" gridrow="0" pageId="7" pageNumber="661">All</th>
</tr>
<tr id="357397555E2A0078FF3CEE1FFA0B3427" box="[151,1476,256,275]" gridrow="1" pageId="7" pageNumber="661" rowspan-0="1">
<td id="76A2FE295E2A0078FD14EE1FFCE53427" box="[703,810,256,275]" gridcol="1" gridrow="1" pageId="7" pageNumber="661">Vaccine</td>
<td id="76A2FE295E2A0078FCE2EE1FFC7B3427" box="[841,948,256,275]" gridcol="2" gridrow="1" pageId="7" pageNumber="661">Placebo</td>
<td id="76A2FE295E2A0078FC78EE1FFBFE3427" box="[979,1073,256,275]" gridcol="3" gridrow="1" pageId="7" pageNumber="661">Vaccine</td>
<td id="76A2FE295E2A0078FBFAEE1FFB7F3427" box="[1105,1200,256,275]" gridcol="4" gridrow="1" pageId="7" pageNumber="661">Placebo</td>
<td id="76A2FE295E2A0078FB64EE1FFAF63427" box="[1231,1337,256,275]" gridcol="5" gridrow="1" pageId="7" pageNumber="661">Vaccine</td>
<td id="76A2FE295E2A0078FAF3EE1FFA0B3427" box="[1368,1476,256,275]" gridcol="6" gridrow="1" pageId="7" pageNumber="661">Placebo</td>
</tr>
<tr id="357397555E2A0078FF3CEE04FA0B341A" box="[151,1476,283,302]" gridrow="2" pageId="7" pageNumber="661">
<th id="76A2FE295E2A0078FF3CEE04FF22341A" box="[151,237,283,302]" gridcol="0" gridrow="2" pageId="7" pageNumber="661">Category</th>
<td id="76A2FE295E2A0078FD14EE04FCE5341A" box="[703,810,283,302]" gridcol="1" gridrow="2" pageId="7" pageNumber="661">
(
<!--emphasis removed-->n
p 3391)
</td>
<td id="76A2FE295E2A0078FCE2EE04FC7B341A" box="[841,948,283,302]" gridcol="2" gridrow="2" pageId="7" pageNumber="661">
(
<!--emphasis removed-->n
p 1704)
</td>
<td id="76A2FE295E2A0078FC78EE04FBFE341A" box="[979,1073,283,302]" gridcol="3" gridrow="2" pageId="7" pageNumber="661">
(
<!--emphasis removed-->n
p 207)
</td>
<td id="76A2FE295E2A0078FBFAEE04FB7F341A" box="[1105,1200,283,302]" gridcol="4" gridrow="2" pageId="7" pageNumber="661">
(
<!--emphasis removed-->n
p 101)
</td>
<td id="76A2FE295E2A0078FB64EE04FAF6341A" box="[1231,1337,283,302]" gridcol="5" gridrow="2" pageId="7" pageNumber="661">
(
<!--emphasis removed-->n
p 3598)
</td>
<td id="76A2FE295E2A0078FAF3EE04FA0B341A" box="[1368,1476,283,302]" gridcol="6" gridrow="2" pageId="7" pageNumber="661">
(
<!--emphasis removed-->n
p 1805)
</td>
</tr>
</table>
</paragraph>
<paragraph id="8BFC95175E2AFF80FF3CEE5CFA7A3781" pageId="7" pageNumber="661">
<tr id="357397555E2A0078FF3CEE21FA0B3462" box="[151,1476,318,342]" gridrow="3" pageId="7" pageNumber="661">
<th id="76A2FE295E2A0078FF3CEE21FA0B3462" box="[151,1476,318,342]" colspan="7" colspanRight="6" gridcol="0" gridrow="3" pageId="7" pageNumber="661">Dose no.a</th>
</tr>
<tr id="357397555E2A0078FF3CEE7FFA0B3447" box="[151,1476,352,371]" gridrow="4" pageId="7" pageNumber="661">
<th id="76A2FE295E2A0078FF3CEE7FFD6E3447" box="[151,673,352,371]" gridcol="0" gridrow="4" pageId="7" pageNumber="661">Dose 1 (month 0)</th>
<td id="76A2FE295E2A0078FD14EE7FFCE53447" box="[703,810,352,371]" gridcol="1" gridrow="4" pageId="7" pageNumber="661">3391 (100)</td>
<td id="76A2FE295E2A0078FCE2EE7FFC7B3447" box="[841,948,352,371]" gridcol="2" gridrow="4" pageId="7" pageNumber="661">1704 (100)</td>
<td id="76A2FE295E2A0078FC78EE7FFBFE3447" box="[979,1073,352,371]" gridcol="3" gridrow="4" pageId="7" pageNumber="661">207 (100)</td>
<td id="76A2FE295E2A0078FBFAEE7FFB7F3447" box="[1105,1200,352,371]" gridcol="4" gridrow="4" pageId="7" pageNumber="661">101 (100)</td>
<td id="76A2FE295E2A0078FB64EE7FFAF63447" box="[1231,1337,352,371]" gridcol="5" gridrow="4" pageId="7" pageNumber="661">3598 (100)</td>
<td id="76A2FE295E2A0078FAF3EE7FFA0B3447" box="[1368,1476,352,371]" gridcol="6" gridrow="4" pageId="7" pageNumber="661">1805 (100)</td>
</tr>
<tr id="357397555E2A0078FF3CEE62FA0B34A5" box="[151,1476,381,401]" gridrow="5" pageId="7" pageNumber="661">
<th id="76A2FE295E2A0078FF3CEE62FD6E34A5" box="[151,673,381,401]" gridcol="0" gridrow="5" pageId="7" pageNumber="661">Dose 2 (month 1)</th>
<td id="76A2FE295E2A0078FD14EE62FCE534A5" box="[703,810,381,401]" gridcol="1" gridrow="5" pageId="7" pageNumber="661">3344 (99)</td>
<td id="76A2FE295E2A0078FCE2EE62FC7B34A5" box="[841,948,381,401]" gridcol="2" gridrow="5" pageId="7" pageNumber="661">1681 (99)</td>
<td id="76A2FE295E2A0078FC78EE62FBFE34A5" box="[979,1073,381,401]" gridcol="3" gridrow="5" pageId="7" pageNumber="661">196 (95)</td>
<td id="76A2FE295E2A0078FBFAEE62FB7F34A5" box="[1105,1200,381,401]" gridcol="4" gridrow="5" pageId="7" pageNumber="661">99 (98)</td>
<td id="76A2FE295E2A0078FB64EE62FAF634A5" box="[1231,1337,381,401]" gridcol="5" gridrow="5" pageId="7" pageNumber="661">3540 (99)</td>
<td id="76A2FE295E2A0078FAF3EE62FA0B34A5" box="[1368,1476,381,401]" gridcol="6" gridrow="5" pageId="7" pageNumber="661">1780 (99)</td>
</tr>
<tr id="357397555E2A0078FF3CEE85FA0B349A" box="[151,1476,410,430]" gridrow="6" pageId="7" pageNumber="661">
<th id="76A2FE295E2A0078FF3CEE85FD6E349A" box="[151,673,410,430]" gridcol="0" gridrow="6" pageId="7" pageNumber="661">Dose 3 (month 6)</th>
<td id="76A2FE295E2A0078FD14EE85FCE5349A" box="[703,810,410,430]" gridcol="1" gridrow="6" pageId="7" pageNumber="661">3202 (96)</td>
<td id="76A2FE295E2A0078FCE2EE85FC7B349A" box="[841,948,410,430]" gridcol="2" gridrow="6" pageId="7" pageNumber="661">1609 (96)</td>
<td id="76A2FE295E2A0078FC78EE85FBFE349A" box="[979,1073,410,430]" gridcol="3" gridrow="6" pageId="7" pageNumber="661">180 (87)</td>
<td id="76A2FE295E2A0078FBFAEE85FB7F349A" box="[1105,1200,410,430]" gridcol="4" gridrow="6" pageId="7" pageNumber="661">95 (94)</td>
<td id="76A2FE295E2A0078FB64EE85FAF6349A" box="[1231,1337,410,430]" gridcol="5" gridrow="6" pageId="7" pageNumber="661">3382 (95)</td>
<td id="76A2FE295E2A0078FAF3EE85FA0B349A" box="[1368,1476,410,430]" gridcol="6" gridrow="6" pageId="7" pageNumber="661">1704 (96)</td>
</tr>
<tr id="357397555E2A0078FF3CEEA7FA0B34FF" box="[151,1476,440,459]" gridrow="7" pageId="7" pageNumber="661">
<th id="76A2FE295E2A0078FF3CEEA7FD6E34FF" box="[151,673,440,459]" gridcol="0" gridrow="7" pageId="7" pageNumber="661">Dose 4 (month 12)</th>
<td id="76A2FE295E2A0078FD14EEA7FCE534FF" box="[703,810,440,459]" gridcol="1" gridrow="7" pageId="7" pageNumber="661">3051 (92)</td>
<td id="76A2FE295E2A0078FCE2EEA7FC7B34FF" box="[841,948,440,459]" gridcol="2" gridrow="7" pageId="7" pageNumber="661">1511 (92)</td>
<td id="76A2FE295E2A0078FC78EEA7FBFE34FF" box="[979,1073,440,459]" gridcol="3" gridrow="7" pageId="7" pageNumber="661">162 (79)</td>
<td id="76A2FE295E2A0078FBFAEEA7FB7F34FF" box="[1105,1200,440,459]" gridcol="4" gridrow="7" pageId="7" pageNumber="661">86 (87)</td>
<td id="76A2FE295E2A0078FB64EEA7FAF634FF" box="[1231,1337,440,459]" gridcol="5" gridrow="7" pageId="7" pageNumber="661">3213 (91)</td>
<td id="76A2FE295E2A0078FAF3EEA7FA0B34FF" box="[1368,1476,440,459]" gridcol="6" gridrow="7" pageId="7" pageNumber="661">1597 (91)</td>
</tr>
<tr id="357397555E2A0078FF3CEECAFA0B34DC" box="[151,1476,469,488]" gridrow="8" pageId="7" pageNumber="661">
<th id="76A2FE295E2A0078FF3CEECAFD6E34DC" box="[151,673,469,488]" gridcol="0" gridrow="8" pageId="7" pageNumber="661">Dose 5 (month 18)</th>
<td id="76A2FE295E2A0078FD14EECAFCE534DC" box="[703,810,469,488]" gridcol="1" gridrow="8" pageId="7" pageNumber="661">2920 (89)</td>
<td id="76A2FE295E2A0078FCE2EECAFC7B34DC" box="[841,948,469,488]" gridcol="2" gridrow="8" pageId="7" pageNumber="661">1450 (89)</td>
<td id="76A2FE295E2A0078FC78EECAFBFE34DC" box="[979,1073,469,488]" gridcol="3" gridrow="8" pageId="7" pageNumber="661">158 (77)</td>
<td id="76A2FE295E2A0078FBFAEECAFB7F34DC" box="[1105,1200,469,488]" gridcol="4" gridrow="8" pageId="7" pageNumber="661">81 (82)</td>
<td id="76A2FE295E2A0078FB64EECAFAF634DC" box="[1231,1337,469,488]" gridcol="5" gridrow="8" pageId="7" pageNumber="661">3078 (89)</td>
<td id="76A2FE295E2A0078FAF3EECAFA0B34DC" box="[1368,1476,469,488]" gridcol="6" gridrow="8" pageId="7" pageNumber="661">1531 (88)</td>
</tr>
<tr id="357397555E2A0078FF3CEEEDFA0B3732" box="[151,1476,498,518]" gridrow="9" pageId="7" pageNumber="661">
<th id="76A2FE295E2A0078FF3CEEEDFD6E3732" box="[151,673,498,518]" gridcol="0" gridrow="9" pageId="7" pageNumber="661">Dose 6 (month 24)</th>
<td id="76A2FE295E2A0078FD14EEEDFCE53732" box="[703,810,498,518]" gridcol="1" gridrow="9" pageId="7" pageNumber="661">2811 (87)</td>
<td id="76A2FE295E2A0078FCE2EEEDFC7B3732" box="[841,948,498,518]" gridcol="2" gridrow="9" pageId="7" pageNumber="661">1379 (85)</td>
<td id="76A2FE295E2A0078FC78EEEDFBFE3732" box="[979,1073,498,518]" gridcol="3" gridrow="9" pageId="7" pageNumber="661">147 (72)</td>
<td id="76A2FE295E2A0078FBFAEEEDFB7F3732" box="[1105,1200,498,518]" gridcol="4" gridrow="9" pageId="7" pageNumber="661">78 (79)</td>
<td id="76A2FE295E2A0078FB64EEEDFAF63732" box="[1231,1337,498,518]" gridcol="5" gridrow="9" pageId="7" pageNumber="661">2958 (86)</td>
<td id="76A2FE295E2A0078FAF3EEEDFA0B3732" box="[1368,1476,498,518]" gridcol="6" gridrow="9" pageId="7" pageNumber="661">1457 (85)</td>
</tr>
<tr id="357397555E2A0078FF3CED10FA0B3769" box="[151,1476,527,605]" gridrow="10" pageId="7" pageNumber="661">
<th id="76A2FE295E2A0078FF3CED10FD6E3769" box="[151,673,527,605]" gridcol="0" gridrow="10" pageId="7" pageNumber="661">Dose 7 (month 30) Received all scheduled immunizations b Final visit c</th>
<td id="76A2FE295E2A0078FD14ED10FCE53769" box="[703,810,527,605]" gridcol="1" gridrow="10" pageId="7" pageNumber="661">2720 (85) 2851 (84)</td>
<td id="76A2FE295E2A0078FCE2ED10FC7B3769" box="[841,948,527,605]" gridcol="2" gridrow="10" pageId="7" pageNumber="661">1323 (83) 1397 (82)</td>
<td id="76A2FE295E2A0078FC78ED10FBFE3769" box="[979,1073,527,605]" gridcol="3" gridrow="10" pageId="7" pageNumber="661">139 (68) 130 (63)</td>
<td id="76A2FE295E2A0078FBFAED10FB7F3769" box="[1105,1200,527,605]" gridcol="4" gridrow="10" pageId="7" pageNumber="661">74 (76) 75 (74)</td>
<td id="76A2FE295E2A0078FB64ED10FAF63769" box="[1231,1337,527,605]" gridcol="5" gridrow="10" pageId="7" pageNumber="661">2859 (84) 2981 (83)</td>
<td id="76A2FE295E2A0078FAF3ED10FA0B3769" box="[1368,1476,527,605]" gridcol="6" gridrow="10" pageId="7" pageNumber="661">1397 (83) 1472 (82)</td>
</tr>
<tr id="357397555E2A0078FF3CED78FA0B374E" box="[151,1476,615,634]" gridrow="11" pageId="7" pageNumber="661">
<th id="76A2FE295E2A0078FF3CED78FD6E374E" box="[151,673,615,634]" gridcol="0" gridrow="11" pageId="7" pageNumber="661">HIV-1 uninfected at final visit</th>
<td id="76A2FE295E2A0078FD14ED78FCE5374E" box="[703,810,615,634]" gridcol="1" gridrow="11" pageId="7" pageNumber="661">2632 (78)</td>
<td id="76A2FE295E2A0078FCE2ED78FC7B374E" box="[841,948,615,634]" gridcol="2" gridrow="11" pageId="7" pageNumber="661">1292 (76)</td>
<td id="76A2FE295E2A0078FC78ED78FBFE374E" box="[979,1073,615,634]" gridcol="3" gridrow="11" pageId="7" pageNumber="661">151 (73)</td>
<td id="76A2FE295E2A0078FBFAED78FB7F374E" box="[1105,1200,615,634]" gridcol="4" gridrow="11" pageId="7" pageNumber="661">78 (77)</td>
<td id="76A2FE295E2A0078FB64ED78FAF6374E" box="[1231,1337,615,634]" gridcol="5" gridrow="11" pageId="7" pageNumber="661">2783 (77)</td>
<td id="76A2FE295E2A0078FAF3ED78FA0B374E" box="[1368,1476,615,634]" gridcol="6" gridrow="11" pageId="7" pageNumber="661">1370 (76)</td>
</tr>
<tr id="357397555E2A0078FF3CED9BFA0B37AC" box="[151,1476,644,664]" gridrow="12" pageId="7" pageNumber="661">
<th id="76A2FE295E2A0078FF3CED9BFD6E37AC" box="[151,673,644,664]" gridcol="0" gridrow="12" pageId="7" pageNumber="661">HIV-1 infected before or at final visit</th>
<td id="76A2FE295E2A0078FD14ED9BFCE537AC" box="[703,810,644,664]" gridcol="1" gridrow="12" pageId="7" pageNumber="661">239 (7)</td>
<td id="76A2FE295E2A0078FCE2ED9BFC7B37AC" box="[841,948,644,664]" gridcol="2" gridrow="12" pageId="7" pageNumber="661">123 (7)</td>
<td id="76A2FE295E2A0078FC78ED9BFBFE37AC" box="[979,1073,644,664]" gridcol="3" gridrow="12" pageId="7" pageNumber="661">2 (1)</td>
<td id="76A2FE295E2A0078FBFAED9BFB7F37AC" box="[1105,1200,644,664]" gridcol="4" gridrow="12" pageId="7" pageNumber="661">4 (4)</td>
<td id="76A2FE295E2A0078FB64ED9BFAF637AC" box="[1231,1337,644,664]" gridcol="5" gridrow="12" pageId="7" pageNumber="661">241 (7)</td>
<td id="76A2FE295E2A0078FAF3ED9BFA0B37AC" box="[1368,1476,644,664]" gridcol="6" gridrow="12" pageId="7" pageNumber="661">127 (7)</td>
</tr>
<tr id="357397555E2A0078FF3CEDBEFA0B3781" box="[151,1476,673,693]" gridrow="13" pageId="7" pageNumber="661">
<th id="76A2FE295E2A0078FF3CEDBEFD6E3781" box="[151,673,673,693]" gridcol="0" gridrow="13" pageId="7" pageNumber="661">HIV-1 status unknown at final visit (lost to follow-up)</th>
<td id="76A2FE295E2A0078FD14EDBEFCE53781" box="[703,810,673,693]" gridcol="1" gridrow="13" pageId="7" pageNumber="661">520 (15)</td>
<td id="76A2FE295E2A0078FCE2EDBEFC7B3781" box="[841,948,673,693]" gridcol="2" gridrow="13" pageId="7" pageNumber="661">289 (17)</td>
<td id="76A2FE295E2A0078FC78EDBEFBFE3781" box="[979,1073,673,693]" gridcol="3" gridrow="13" pageId="7" pageNumber="661">54 (26)</td>
<td id="76A2FE295E2A0078FBFAEDBEFB7F3781" box="[1105,1200,673,693]" gridcol="4" gridrow="13" pageId="7" pageNumber="661">19 (19)</td>
<td id="76A2FE295E2A0078FB64EDBEFAF63781" box="[1231,1337,673,693]" gridcol="5" gridrow="13" pageId="7" pageNumber="661">574 (16)</td>
<td id="76A2FE295E2A0078FAF3EDBEFA0B3781" box="[1368,1476,673,693]" gridcol="6" gridrow="13" pageId="7" pageNumber="661">308 (17)</td>
</tr>
</paragraph>
</table>
<paragraph id="8BFC95175E2AFF80FF01EDCEFDCF37D5" blockId="7.[151,1475,719,861]" box="[170,512,719,738]" pageId="7" pageNumber="661">
<!--emphasis removed-->NOTE.
Data are no. (%) of volunteers.
</paragraph>
<paragraph id="8BFC95175E2AFF80FF01EDF9FE0D3621" blockId="7.[151,1475,719,861]" pageId="7" pageNumber="661">a Rates of immunization were calculated as the no. vaccinated during each visit divided by the no. who were uninfected (i.e., not diagnosed with HIV-1 infection before or during the indicated visit).</paragraph>
<paragraph id="8BFC95175E2AFF80FF01EC09FE2F3671" blockId="7.[151,1475,719,861]" pageId="7" pageNumber="661">b No. who received either all 7 doses or all doses before infection divided by the no. enrolled. Volunteers, once diagnosed with HIV-1 infection, were not scheduled for further vaccination visits.</paragraph>
<paragraph id="8BFC95175E2AFF80FF01EC59FE0A3669" blockId="7.[151,1475,719,861]" box="[170,453,838,861]" pageId="7" pageNumber="661">c The final visit was at month 36.</paragraph>
<paragraph id="8BFC95175E2AFF80FF3CEC85FE2730CF" blockId="7.[151,790,922,1773]" pageId="7" pageNumber="661">
study about the use rgp120 as a preventive vaccine? The lack of protection demonstrates that monomeric rgp120 is insufficientl immunogenic against fiel HIV-1 isolates and that improved or different rgp120 constructs, or different approaches, will be required. The trends toward efficac observed in the exploratory subgroup analyses, if real [
<bibRefCitation id="EFD2E8E65E2AFF80FE1CEB58FE1B3168" author="Bristol DR." box="[439,468,1095,1116]" journalOrPublisher="J Biopharm Stat" pageId="7" pageNumber="661" pagination="313 - 21" part="7" refString="24. Bristol DR. p-value adjustments for subgroup analyses. J Biopharm Stat 1997; 7: 313 - 21 / 323 - 31." title="p-value adjustments for subgroup analyses" type="journal article" year="1997">24</bibRefCitation>
, 
<bibRefCitation id="EFD2E8E65E2AFF80FE4FEB59FDCE3169" author="Assmann SF &amp; Pocock SJ &amp; Enos LE" box="[484,513,1094,1117]" journalOrPublisher="Lancet" pageId="7" pageNumber="661" pagination="1064 - 9" part="355" refString="44. Assmann SF, Pocock SJ, Enos LE, et al. Subgroup analysis and other (mis) uses of baseline data in clinical trials. Lancet 2000; 355: 1064 - 9." title="Subgroup analysis and other (mis) uses of baseline data in clinical trials" type="journal article" year="2000">44</bibRefCitation>
], raise the possibility that improved rgp120 immunogens can protect in certain circumstances; these trends also may provide clues that can inform the design of new HIV-1 vaccines, whether they are based on rgp120 or other approaches. Improvement of an rgp120vaccine might require additional, more representative, or modifie subtype envelope antigens (e.g., oligomeric vs. monomeric forms); newer adjuvants that enhance innate immunity or promote a Th1-biased response [
<bibRefCitation id="EFD2E8E65E2AFF80FED4EA45FE553045" author="Klinman DM &amp; Kamstrup S &amp; Verthelyi D" box="[383,410,1370,1393]" journalOrPublisher="Springer Semin Immunopathol" pageId="7" pageNumber="661" pagination="173 - 83" part="22" refString="45. Klinman DM, Kamstrup S, Verthelyi D, et al. Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotectiveactivity and safety. Springer Semin Immunopathol 2000; 22: 173 - 83." title="Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotectiveactivity and safety" type="journal article" year="2000">45</bibRefCitation>
– 
<bibRefCitation id="EFD2E8E65E2AFF80FE02EA45FE0B3045" author="Verthelyi D &amp; Kenney RT &amp; Seder RA &amp; Gam AA &amp; Friedag B &amp; Klinman DM." box="[425,452,1370,1393]" journalOrPublisher="J Immunol" pageId="7" pageNumber="661" pagination="1659 - 63" part="168" refString="48. Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 2002; 168: 1659 - 63." title="CpG oligodeoxynucleotides as vaccine adjuvants in primates" type="journal article" year="2002">48</bibRefCitation>
]; or combination with vaccines that promote cellular immunity to HIV-1 [
<bibRefCitation id="EFD2E8E65E2AFF80FDF8EA61FDAE30A7" author="Nathanson N &amp; Mathieson BJ." box="[595,609,1406,1427]" journalOrPublisher="J Infect Dis" pageId="7" pageNumber="661" pagination="579 - 89" part="182" refString="3. Nathanson N, Mathieson BJ. Biological considerations in the development of a human immunodeficienc virus vaccine. J Infect Dis 2000; 182: 579 - 89." title="Biological considerations in the development of a human immunodeficienc virus vaccine" type="journal article" year="2000">3</bibRefCitation>
, 
<bibRefCitation id="EFD2E8E65E2AFF80FDC4EA61FD4630A7" author="Nabel GJ." box="[623,649,1406,1427]" journalOrPublisher="Nature" pageId="7" pageNumber="661" pagination="1002 - 6" part="410" refString="49. Nabel GJ. Challenges and opportunities of development of an AIDS vaccine. Nature 2001; 410: 1002 - 6." title="Challenges and opportunities of development of an AIDS vaccine" type="journal article" year="2001">49</bibRefCitation>
, 
<bibRefCitation id="EFD2E8E65E2AFF80FD3EEA62FD7C30A0" author="Schultz AM &amp; Bradac JA." box="[661,691,1405,1428]" journalOrPublisher="AIDS" pageId="7" pageNumber="661" pagination="147 - 58" part="15" refString="50. Schultz AM, Bradac JA. The HIV vaccine pipeline, from preclinical to phase III. AIDS 2001; 15 (Suppl 5): S 147 - 58." title="The HIV vaccine pipeline, from preclinical to phase III" type="journal article" year="2001">50</bibRefCitation>
]. A phase 3 trial using the latter approach was recently initiated in Thailand; in the trial, immunization with rgp120 is combined with a canarypox vector vaccine [
<bibRefCitation id="EFD2E8E65E2AFF80FE15EAFBFE1330CF" author="Nitayaphan S &amp; Pitisuttithum P &amp; de Souza M" box="[446,476,1508,1531]" journalOrPublisher="Barcelona, Spain: Prous Science" pageId="7" pageNumber="661" pagination="2002" refString="51. Nitayaphan S, Pitisuttithum P, de Souza M, et al. Safety and immunogenicity of live recombinant ALVAC-HIV (vCP 1521) priming with AIDSVAX B / E gp 120 boosting in Thai HIV-negative adults (abstract WePeB 6049). In: Program and abstracts of the XIV International AIDS Conference 2002 (Barcelona, Spain). Barcelona, Spain: Prous Science, 2002." title="Safety and immunogenicity of live recombinant ALVAC-HIV (vCP" type="book chapter" volumeTitle="Program and abstracts of the XIV International AIDS Conference 2002 (Barcelona, Spain)" year="1521">51</bibRefCitation>
].
</paragraph>
<paragraph id="8BFC95175E2AFF80FF1AE917FDA833D9" blockId="7.[151,790,922,1773]" pageId="7" pageNumber="661">To further aid the interpretation of the results of VAX004 and to provide information that is helpful to the HIV-1 vaccine field additional analyses are either ongoing or planned, including analyses of the ability of participant serum to neutralize a spectrum of primary HIV-1 isolates, of T cell responses, of the occurrence of genetic polymorphisms of infecting strains, and of the prevalence of GBV-C coinfection.</paragraph>
<paragraph id="8BFC95175E2AFF80FF3CE809FD1C321F" blockId="7.[151,723,1814,1835]" box="[151,723,1814,1835]" pageId="7" pageNumber="661">THE RGP120 HIV VACCINE STUDY GROUP</paragraph>
<paragraph id="8BFC95175E2AFF80FF3CE850FE6B3D17" blockId="7.[151,790,1870,1927]" lastBlockId="7.[8,766,2055,2099]" pageId="7" pageNumber="661">
<!--emphasis removed-->rgp120 HIV Vaccine Study Group Writing and Analysis Committee members.
The following persons are members of the rgp120 HIV Vaccine Study Group Writing and Analysis Committee, which assumes responsibility for the content of this article: rgp120 HIV Vaccine Investigators are Neil M. Flynn (University of California at Davis Medical Center, Davis), Donald N. Forthal (University of California at Irvine College of Medicine, Irvine), Clayton D. Harro (Johns Hopkins Bloomberg School of Public Health, Baltimore, MD), Franklyn N. Judson (Denver Department of Public Health, Denver, CO), Kenneth H. Mayer (Fenway Community Health Center, Boston, MA, and the Miriam Hospital, Providence, RI), and Michael F. Para (Ohio State University, Columbus); other members of thecommittee, affiliate with the Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center (Seattle, WA), are Peter B. Gilbert, Michael G. Hudgens (present affiliation School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill), Barbara J. Metch, and Steven G. Self; and other members of the committee, affiliate with VaxGen (Brisbane, CA), are Phillip W. Berman (present affiliation Global Solutions for Infectious Diseases, Brisbane, CA), Donald P. Francis (present affiliation Global Solutions for Infectious Diseases, Brisbane,CA),MarcGurwith, William L. Heyward (present affiliation Quattro Clinical Research, Oakland, CA), David V. Jobes, Michael L. Peterson, Vladimir Popovic (present affiliation Janssen Ortho, Toronto, Ontario, Canada), and Faruk M. Sinangil. Potential conflict of interest are as follows: Marc Gurwith, David V. Jobes, Michael L. Peterson, and Faruk M. Sinangil are employees of VaxGen; Phillip W. Berman, Donald P. Francis, William L. Heyward, and Vladimir Popovic are former employees of VaxGen; Downloaded from https://academic.oup.com/jid/article-abstract/191/5/654/1234535 by Aerztegemeinschaft fuer Anaesthesie user
</paragraph>
<caption id="DF3CC59F5E25FF8FFF57EF85FB5D359B" ID-Table-UUID="DF3CC59F5E25FF8FFF57EF85FB5D359B" box="[252,1170,153,175]" httpUri="http://table.plazi.org/id/DF3CC59F5E25FF8FFF57EF85FB5D359B" pageId="8" pageNumber="11" targetBox="[252,1375,217,1134]" targetIsTable="true" targetPageId="8">
<paragraph id="8BFC95175E25FF8FFF57EF85FE83359A" blockId="8.[252,332,153,175]" box="[252,332,153,175]" pageId="8" pageNumber="11">
<heading id="D0B4227B5E25FF8FFF57EF85FE83359A" bold="true" box="[252,332,153,175]" centered="true" fontSize="9" level="1" pageId="8" pageNumber="11" reason="2">
<!--emphasis removed-->Table 3.
</heading>
</paragraph>
<paragraph id="8BFC95175E25FF8FFEC6EF86FB5D359B" blockId="8.[365,1170,153,175]" box="[365,1170,153,175]" pageId="8" pageNumber="11">
<!--emphasis removed-->Attack rates of HIV-1 infection and vaccine efficacy (VE) against HIV-1 infection.
</paragraph>
</caption>
<table id="F94367B75E250078FF57EFC6FA90315A" box="[252,1375,217,1134]" gridcols="9" gridrows="28" pageId="8" pageNumber="11">
<paragraph id="8BFC95175E25FF8FFDDDEFC6FA903433" pageId="8" pageNumber="11">
<tr id="357397555E250078FF57EFC6FA9035D8" box="[252,1375,217,236]" gridrow="0" pageId="8" pageNumber="11" rowspan-0="1" rowspan-3="1" rowspan-4="1" rowspan-5="1" rowspan-6="1" rowspan-8="1">
<th id="76A2FE295E250078FD95EFC6FC4835D8" box="[574,903,217,236]" colspan="2" colspanRight="1" gridcol="1" gridrow="0" pageId="8" pageNumber="11">Rate of HIV-1 infection</th>
<th id="76A2FE295E250078FBC4EFC6FB2235D8" box="[1135,1261,217,236]" gridcol="7" gridrow="0" pageId="8" pageNumber="11">
<!--emphasis removed-->P
</th>
</tr>
<tr id="357397555E250078FF57EFE4FA903420" box="[252,1375,251,276]" gridrow="1" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EFE4FDD03420" box="[252,543,251,276]" gridcol="0" gridrow="1" pageId="8" pageNumber="11">Category, parameter</th>
<td id="76A2FE295E250078FD95EFE4FD1D3420" box="[574,722,251,276]" gridcol="1" gridrow="1" pageId="8" pageNumber="11">Vaccine</td>
<td id="76A2FE295E250078FD59EFE4FC483420" box="[754,903,251,276]" gridcol="2" gridrow="1" pageId="8" pageNumber="11">Placebo</td>
<td id="76A2FE295E250078FC1CEFE4FB803420" box="[951,1103,251,276]" colspan="4" colspanRight="3" gridcol="3" gridrow="1" pageId="8" pageNumber="11">VE (95% CI)</td>
<td id="76A2FE295E250078FBC4EFE4FB223420" box="[1135,1261,251,276]" gridcol="7" gridrow="1" pageId="8" pageNumber="11">Unadjusted a</td>
<td id="76A2FE295E250078FAA9EFE4FA903420" box="[1282,1375,251,276]" gridcol="8" gridrow="1" pageId="8" pageNumber="11">Adjusted b</td>
</tr>
</paragraph>
<paragraph id="8BFC95175E25FF8FFF57EE37FA8B315A" pageId="8" pageNumber="11">
<table id="F94367B75E250078FF57EE37FA8A315A" box="[252,1349,296,1134]" gridcols="9" gridrows="26" pageId="8" pageNumber="11">
<tr id="357397555E250078FF57EE37FA8A3408" box="[252,1349,296,316]" gridrow="2" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EE37FDD03408" box="[252,543,296,316]" gridcol="0" gridrow="2" pageId="8" pageNumber="11">All volunteers</th>
<th id="76A2FE295E250078FD95EE37FD1D3408" box="[574,722,296,316]" gridcol="1" gridrow="0" pageId="8" pageNumber="11">241/3598 (6.7)</th>
<th id="76A2FE295E250078FD59EE37FC483408" box="[754,903,296,316]" gridcol="2" gridrow="0" pageId="8" pageNumber="11">127/1805 (7.0)</th>
<th id="76A2FE295E250078FC1CEE37FC003408" box="[951,975,296,316]" gridcol="3" gridrow="0" pageId="8" pageNumber="11">6</th>
<th id="76A2FE295E250078FC7DEE37FC273408" box="[982,1000,296,316]" gridcol="4" gridrow="0" pageId="8" pageNumber="11">(</th>
<th id="76A2FE295E250078FC45EE37FBD03408" box="[1006,1055,296,316]" gridcol="5" gridrow="0" pageId="8" pageNumber="11">17 to</th>
<th id="76A2FE295E250078FB8DEE37FB803408" box="[1062,1103,296,316]" gridcol="6" gridrow="0" pageId="8" pageNumber="11">24)</th>
<th id="76A2FE295E250078FB3FEE37FB713408" box="[1172,1214,296,316]" gridcol="7" gridrow="0" pageId="8" pageNumber="11">.59</th>
<th id="76A2FE295E250078FAB0EE37FA8A3408" box="[1307,1349,296,316]" gridcol="8" gridrow="0" pageId="8" pageNumber="11">1.5</th>
</tr>
<tr id="357397555E250078FF57EE5AFA8A346D" box="[252,1349,325,345]" gridrow="3" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EE5AFDD0346D" box="[252,543,325,345]" gridcol="0" gridrow="3" pageId="8" pageNumber="11">Men</th>
<td id="76A2FE295E250078FD95EE5AFD1D346D" box="[574,722,325,345]" gridcol="1" gridrow="3" pageId="8" pageNumber="11">239/3391 (7.0)</td>
<td id="76A2FE295E250078FD59EE5AFC48346D" box="[754,903,325,345]" gridcol="2" gridrow="3" pageId="8" pageNumber="11">123/1704 (7.2)</td>
<td id="76A2FE295E250078FC1CEE5AFC00346D" box="[951,975,325,345]" gridcol="3" gridrow="3" pageId="8" pageNumber="11">4</td>
<td id="76A2FE295E250078FC7DEE5AFC27346D" box="[982,1000,325,345]" gridcol="4" gridrow="3" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45EE5AFBD0346D" box="[1006,1055,325,345]" gridcol="5" gridrow="3" pageId="8" pageNumber="11">20 to</td>
<td id="76A2FE295E250078FB8DEE5AFB80346D" box="[1062,1103,325,345]" gridcol="6" gridrow="3" pageId="8" pageNumber="11">23)</td>
<td id="76A2FE295E250078FB3FEE5AFB71346D" box="[1172,1214,325,345]" gridcol="7" gridrow="3" pageId="8" pageNumber="11">.73</td>
<td id="76A2FE295E250078FAB0EE5AFA8A346D" box="[1307,1349,325,345]" gridcol="8" gridrow="3" pageId="8" pageNumber="11">1.5</td>
</tr>
<tr id="357397555E250078FF57EE7CFA8A3442" box="[252,1349,355,374]" gridrow="4" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EE7CFDD03442" box="[252,543,355,374]" gridcol="0" gridrow="4" pageId="8" pageNumber="11">Women</th>
<td id="76A2FE295E250078FD95EE7CFD1D3442" box="[574,722,355,374]" gridcol="1" gridrow="4" pageId="8" pageNumber="11">2/207 (1.0)</td>
<td id="76A2FE295E250078FD59EE7CFC483442" box="[754,903,355,374]" gridcol="2" gridrow="4" pageId="8" pageNumber="11">4/101 (4.0)</td>
<td id="76A2FE295E250078FC1CEE7CFC003442" box="[951,975,355,374]" gridcol="3" gridrow="4" pageId="8" pageNumber="11">74</td>
<td id="76A2FE295E250078FC7DEE7CFC273442" box="[982,1000,355,374]" gridcol="4" gridrow="4" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45EE7CFBD03442" box="[1006,1055,355,374]" gridcol="5" gridrow="4" pageId="8" pageNumber="11">42 to</td>
<td id="76A2FE295E250078FB8DEE7CFB803442" box="[1062,1103,355,374]" gridcol="6" gridrow="4" pageId="8" pageNumber="11">95)</td>
<td id="76A2FE295E250078FB3FEE7CFB713442" box="[1172,1214,355,374]" gridcol="7" gridrow="4" pageId="8" pageNumber="11">.0 93</td>
<td id="76A2FE295E250078FAB0EE7CFA8A3442" box="[1307,1349,355,374]" gridcol="8" gridrow="4" pageId="8" pageNumber="11">.41</td>
</tr>
<tr id="357397555E250078FF57EE9FFA8A34A7" box="[252,1349,384,403]" gridrow="5" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EE9FFA8A34A7" box="[252,1349,384,403]" colspan="9" colspanRight="8" gridcol="0" gridrow="5" pageId="8" pageNumber="11">Race</th>
</tr>
<tr id="357397555E250078FF57EE82FA8A3485" box="[252,1349,413,433]" gridrow="6" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EE82FDD03485" box="[252,543,413,433]" gridcol="0" gridrow="6" pageId="8" pageNumber="11">White (non-Hispanic)</th>
<td id="76A2FE295E250078FD95EE82FD1D3485" box="[574,722,413,433]" gridcol="1" gridrow="6" pageId="8" pageNumber="11">211/2994 (7.0)</td>
<td id="76A2FE295E250078FD59EE82FC483485" box="[754,903,413,433]" gridcol="2" gridrow="6" pageId="8" pageNumber="11">98/1495 (6.6)</td>
<td id="76A2FE295E250078FC1CEE82FC003485" box="[951,975,413,433]" gridcol="3" gridrow="6" pageId="8" pageNumber="11">6</td>
<td id="76A2FE295E250078FC7DEE82FC273485" box="[982,1000,413,433]" gridcol="4" gridrow="6" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45EE82FBD03485" box="[1006,1055,413,433]" gridcol="5" gridrow="6" pageId="8" pageNumber="11">35 to</td>
<td id="76A2FE295E250078FB8DEE82FB803485" box="[1062,1103,413,433]" gridcol="6" gridrow="6" pageId="8" pageNumber="11">16)</td>
<td id="76A2FE295E250078FB3FEE82FB713485" box="[1172,1214,413,433]" gridcol="7" gridrow="6" pageId="8" pageNumber="11">.60</td>
<td id="76A2FE295E250078FAB0EE82FA8A3485" box="[1307,1349,413,433]" gridcol="8" gridrow="6" pageId="8" pageNumber="11">1.5</td>
</tr>
<tr id="357397555E250078FF57EEA5FA8A34FA" box="[252,1349,442,462]" gridrow="7" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EEA5FDD034FA" box="[252,543,442,462]" gridcol="0" gridrow="7" pageId="8" pageNumber="11">Men</th>
<td id="76A2FE295E250078FD95EEA5FD1D34FA" box="[574,722,442,462]" gridcol="1" gridrow="7" pageId="8" pageNumber="11">211/2930 (7.2)</td>
<td id="76A2FE295E250078FD59EEA5FC4834FA" box="[754,903,442,462]" gridcol="2" gridrow="7" pageId="8" pageNumber="11">98/1468 (6.7)</td>
<td id="76A2FE295E250078FC1CEEA5FC0034FA" box="[951,975,442,462]" gridcol="3" gridrow="7" pageId="8" pageNumber="11">6</td>
<td id="76A2FE295E250078FC7DEEA5FC2734FA" box="[982,1000,442,462]" gridcol="4" gridrow="7" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45EEA5FBD034FA" box="[1006,1055,442,462]" gridcol="5" gridrow="7" pageId="8" pageNumber="11">35 to</td>
<td id="76A2FE295E250078FB8DEEA5FB8034FA" box="[1062,1103,442,462]" gridcol="6" gridrow="7" pageId="8" pageNumber="11">16)</td>
<td id="76A2FE295E250078FB3FEEA5FB7134FA" box="[1172,1214,442,462]" gridcol="7" gridrow="7" pageId="8" pageNumber="11">.61</td>
<td id="76A2FE295E250078FAB0EEA5FA8A34FA" box="[1307,1349,442,462]" gridcol="8" gridrow="7" pageId="8" pageNumber="11">…</td>
</tr>
<tr id="357397555E250078FF57EEC7FA8A34DF" box="[252,1349,472,491]" gridrow="8" pageId="8" pageNumber="11" rowspan-3="1" rowspan-4="1" rowspan-6="1">
<th id="76A2FE295E250078FF57EEC7FDD034DF" box="[252,543,472,491]" gridcol="0" gridrow="8" pageId="8" pageNumber="11">Women</th>
<td id="76A2FE295E250078FD95EEC7FD1D34DF" box="[574,722,472,491]" gridcol="1" gridrow="8" pageId="8" pageNumber="11">0/64 (0)</td>
<td id="76A2FE295E250078FD59EEC7FC4834DF" box="[754,903,472,491]" gridcol="2" gridrow="8" pageId="8" pageNumber="11">0/27 (0)</td>
<td id="76A2FE295E250078FC45EEC7FBD034DF" box="[1006,1055,472,491]" gridcol="5" gridrow="8" pageId="8" pageNumber="11">…</td>
<td id="76A2FE295E250078FB3FEEC7FB7134DF" box="[1172,1214,472,491]" gridcol="7" gridrow="8" pageId="8" pageNumber="11">…</td>
<td id="76A2FE295E250078FAB0EEC7FA8A34DF" box="[1307,1349,472,491]" gridcol="8" gridrow="8" pageId="8" pageNumber="11">…</td>
</tr>
<tr id="357397555E250078FF57EEEAFA8A373C" box="[252,1349,501,520]" gridrow="9" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EEEAFDD0373C" box="[252,543,501,520]" gridcol="0" gridrow="9" pageId="8" pageNumber="11">Hispanic</th>
<td id="76A2FE295E250078FD95EEEAFD1D373C" box="[574,722,501,520]" gridcol="1" gridrow="9" pageId="8" pageNumber="11">14/239 (5.9)</td>
<td id="76A2FE295E250078FD59EEEAFC48373C" box="[754,903,501,520]" gridcol="2" gridrow="9" pageId="8" pageNumber="11">9/128 (7.0)</td>
<td id="76A2FE295E250078FC1CEEEAFC00373C" box="[951,975,501,520]" gridcol="3" gridrow="9" pageId="8" pageNumber="11">15</td>
<td id="76A2FE295E250078FC7DEEEAFC27373C" box="[982,1000,501,520]" gridcol="4" gridrow="9" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45EEEAFBD0373C" box="[1006,1055,501,520]" gridcol="5" gridrow="9" pageId="8" pageNumber="11">96 to</td>
<td id="76A2FE295E250078FB8DEEEAFB80373C" box="[1062,1103,501,520]" gridcol="6" gridrow="9" pageId="8" pageNumber="11">63)</td>
<td id="76A2FE295E250078FB3FEEEAFB71373C" box="[1172,1214,501,520]" gridcol="7" gridrow="9" pageId="8" pageNumber="11">.70</td>
<td id="76A2FE295E250078FAB0EEEAFA8A373C" box="[1307,1349,501,520]" gridcol="8" gridrow="9" pageId="8" pageNumber="11">1.5</td>
</tr>
<tr id="357397555E250078FF57ED0DFA8A3711" box="[252,1349,530,549]" gridrow="10" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57ED0DFDD03711" box="[252,543,530,549]" gridcol="0" gridrow="10" pageId="8" pageNumber="11">Men</th>
<td id="76A2FE295E250078FD95ED0DFD1D3711" box="[574,722,530,549]" gridcol="1" gridrow="10" pageId="8" pageNumber="11">13/211 (6.2)</td>
<td id="76A2FE295E250078FD59ED0DFC483711" box="[754,903,530,549]" gridcol="2" gridrow="10" pageId="8" pageNumber="11">9/114 (7.9)</td>
<td id="76A2FE295E250078FC1CED0DFC003711" box="[951,975,530,549]" gridcol="3" gridrow="10" pageId="8" pageNumber="11">20</td>
<td id="76A2FE295E250078FC7DED0DFC273711" box="[982,1000,530,549]" gridcol="4" gridrow="10" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45ED0DFBD03711" box="[1006,1055,530,549]" gridcol="5" gridrow="10" pageId="8" pageNumber="11">88 to</td>
<td id="76A2FE295E250078FB8DED0DFB803711" box="[1062,1103,530,549]" gridcol="6" gridrow="10" pageId="8" pageNumber="11">66)</td>
<td id="76A2FE295E250078FB3FED0DFB713711" box="[1172,1214,530,549]" gridcol="7" gridrow="10" pageId="8" pageNumber="11">.61</td>
<td id="76A2FE295E250078FAB0ED0DFA8A3711" box="[1307,1349,530,549]" gridcol="8" gridrow="10" pageId="8" pageNumber="11">…</td>
</tr>
<tr id="357397555E250078FF57ED30FA8A3777" box="[252,1349,559,579]" gridrow="11" pageId="8" pageNumber="11" rowspan-3="1" rowspan-4="1" rowspan-6="1">
<th id="76A2FE295E250078FF57ED30FDD03777" box="[252,543,559,579]" gridcol="0" gridrow="11" pageId="8" pageNumber="11">Women</th>
<td id="76A2FE295E250078FD95ED30FD1D3777" box="[574,722,559,579]" gridcol="1" gridrow="11" pageId="8" pageNumber="11">1/28 (3.6)</td>
<td id="76A2FE295E250078FD59ED30FC483777" box="[754,903,559,579]" gridcol="2" gridrow="11" pageId="8" pageNumber="11">0/14 (0)</td>
<td id="76A2FE295E250078FC45ED30FBD03777" box="[1006,1055,559,579]" gridcol="5" gridrow="11" pageId="8" pageNumber="11">…</td>
<td id="76A2FE295E250078FB3FED30FB713777" box="[1172,1214,559,579]" gridcol="7" gridrow="11" pageId="8" pageNumber="11">…</td>
<td id="76A2FE295E250078FAB0ED30FA8A3777" box="[1307,1349,559,579]" gridcol="8" gridrow="11" pageId="8" pageNumber="11">…</td>
</tr>
<tr id="357397555E250078FF57ED53FA8A3754" box="[252,1349,588,608]" gridrow="12" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57ED53FDD03754" box="[252,543,588,608]" gridcol="0" gridrow="12" pageId="8" pageNumber="11">Black (non-Hispanic)</th>
<td id="76A2FE295E250078FD95ED53FD1D3754" box="[574,722,588,608]" gridcol="1" gridrow="12" pageId="8" pageNumber="11">6/233 (2.6)</td>
<td id="76A2FE295E250078FD59ED53FC483754" box="[754,903,588,608]" gridcol="2" gridrow="12" pageId="8" pageNumber="11">9/116 (7.8)</td>
<td id="76A2FE295E250078FC1CED53FC003754" box="[951,975,588,608]" gridcol="3" gridrow="12" pageId="8" pageNumber="11">67</td>
<td id="76A2FE295E250078FC7DED53FC273754" box="[982,1000,588,608]" gridcol="4" gridrow="12" pageId="8" pageNumber="11">(6</td>
<td id="76A2FE295E250078FC45ED53FB803754" box="[1006,1103,588,608]" colspan="2" colspanRight="1" gridcol="5" gridrow="12" pageId="8" pageNumber="11">to 88)</td>
<td id="76A2FE295E250078FB3FED53FB713754" box="[1172,1214,588,608]" gridcol="7" gridrow="12" pageId="8" pageNumber="11">.0 28</td>
<td id="76A2FE295E250078FAB0ED53FA8A3754" box="[1307,1349,588,608]" gridcol="8" gridrow="12" pageId="8" pageNumber="11">.24</td>
</tr>
<tr id="357397555E250078FF57ED75FA8A37AE" box="[252,1349,618,666]" gridrow="13" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57ED75FDD037AE" box="[252,543,618,666]" gridcol="0" gridrow="13" pageId="8" pageNumber="11">Men Women c</th>
<td id="76A2FE295E250078FD95ED75FD1D37AE" box="[574,722,618,666]" gridcol="1" gridrow="13" pageId="8" pageNumber="11">5/121 (4.1) 1/112 (0.9)</td>
<td id="76A2FE295E250078FD59ED75FC4837AE" box="[754,903,618,666]" gridcol="2" gridrow="13" pageId="8" pageNumber="11">5/59 (8.5) 4/57 (7.0)</td>
<td id="76A2FE295E250078FC1CED75FC0037AE" box="[951,975,618,666]" gridcol="3" gridrow="13" pageId="8" pageNumber="11">54 87</td>
<td id="76A2FE295E250078FC7DED75FC2737AE" box="[982,1000,618,666]" gridcol="4" gridrow="13" pageId="8" pageNumber="11">((</td>
<td id="76A2FE295E250078FC45ED75FBD037AE" box="[1006,1055,618,666]" gridcol="5" gridrow="13" pageId="8" pageNumber="11">61 to 19 to</td>
<td id="76A2FE295E250078FB8DED75FB8037AE" box="[1062,1103,618,666]" gridcol="6" gridrow="13" pageId="8" pageNumber="11">87) 98)</td>
<td id="76A2FE295E250078FB3FED75FB7137AE" box="[1172,1214,618,666]" gridcol="7" gridrow="13" pageId="8" pageNumber="11">.21.0 33</td>
<td id="76A2FE295E250078FAB0ED75FA8A37AE" box="[1307,1349,618,666]" gridcol="8" gridrow="13" pageId="8" pageNumber="11">… …</td>
</tr>
<tr id="357397555E250078FF57EDBBFA8A378C" box="[252,1349,676,696]" gridrow="14" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EDBBFDD0378C" box="[252,543,676,696]" gridcol="0" gridrow="14" pageId="8" pageNumber="11">Asian (all men)</th>
<td id="76A2FE295E250078FD95EDBBFD1D378C" box="[574,722,676,696]" gridcol="1" gridrow="14" pageId="8" pageNumber="11">3/56 (5.4)</td>
<td id="76A2FE295E250078FD59EDBBFC48378C" box="[754,903,676,696]" gridcol="2" gridrow="14" pageId="8" pageNumber="11">3/21 (14.3)</td>
<td id="76A2FE295E250078FC1CEDBBFC00378C" box="[951,975,676,696]" gridcol="3" gridrow="14" pageId="8" pageNumber="11">66</td>
<td id="76A2FE295E250078FC7DEDBBFC27378C" box="[982,1000,676,696]" gridcol="4" gridrow="14" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45EDBBFBD0378C" box="[1006,1055,676,696]" gridcol="5" gridrow="14" pageId="8" pageNumber="11">70 to</td>
<td id="76A2FE295E250078FB8DEDBBFB80378C" box="[1062,1103,676,696]" gridcol="6" gridrow="14" pageId="8" pageNumber="11">93)</td>
<td id="76A2FE295E250078FB3FEDBBFB71378C" box="[1172,1214,676,696]" gridcol="7" gridrow="14" pageId="8" pageNumber="11">.17</td>
<td id="76A2FE295E250078FAB0EDBBFA8A378C" box="[1307,1349,676,696]" gridcol="8" gridrow="14" pageId="8" pageNumber="11">1.5</td>
</tr>
<tr id="357397555E250078FF57EDDEFA8A37E1" box="[252,1349,705,725]" gridrow="15" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EDDEFDD037E1" box="[252,543,705,725]" gridcol="0" gridrow="15" pageId="8" pageNumber="11">Other</th>
<td id="76A2FE295E250078FD95EDDEFD1D37E1" box="[574,722,705,725]" gridcol="1" gridrow="15" pageId="8" pageNumber="11">7/76 (9.2)</td>
<td id="76A2FE295E250078FD59EDDEFC4837E1" box="[754,903,705,725]" gridcol="2" gridrow="15" pageId="8" pageNumber="11">8/45 (17.8)</td>
<td id="76A2FE295E250078FC1CEDDEFC0037E1" box="[951,975,705,725]" gridcol="3" gridrow="15" pageId="8" pageNumber="11">50</td>
<td id="76A2FE295E250078FC7DEDDEFC2737E1" box="[982,1000,705,725]" gridcol="4" gridrow="15" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45EDDEFBD037E1" box="[1006,1055,705,725]" gridcol="5" gridrow="15" pageId="8" pageNumber="11">39 to</td>
<td id="76A2FE295E250078FB8DEDDEFB8037E1" box="[1062,1103,705,725]" gridcol="6" gridrow="15" pageId="8" pageNumber="11">82)</td>
<td id="76A2FE295E250078FB3FEDDEFB7137E1" box="[1172,1214,705,725]" gridcol="7" gridrow="15" pageId="8" pageNumber="11">.18</td>
<td id="76A2FE295E250078FAB0EDDEFA8A37E1" box="[1307,1349,705,725]" gridcol="8" gridrow="15" pageId="8" pageNumber="11">1.5</td>
</tr>
<tr id="357397555E250078FF57EDC1FA8A37C6" box="[252,1349,734,754]" gridrow="16" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EDC1FDD037C6" box="[252,543,734,754]" gridcol="0" gridrow="16" pageId="8" pageNumber="11">Men</th>
<td id="76A2FE295E250078FD95EDC1FD1D37C6" box="[574,722,734,754]" gridcol="1" gridrow="16" pageId="8" pageNumber="11">7/73 (9.6)</td>
<td id="76A2FE295E250078FD59EDC1FC4837C6" box="[754,903,734,754]" gridcol="2" gridrow="16" pageId="8" pageNumber="11">8/42 (19.0)</td>
<td id="76A2FE295E250078FC1CEDC1FC0037C6" box="[951,975,734,754]" gridcol="3" gridrow="16" pageId="8" pageNumber="11">51</td>
<td id="76A2FE295E250078FC7DEDC1FC2737C6" box="[982,1000,734,754]" gridcol="4" gridrow="16" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45EDC1FBD037C6" box="[1006,1055,734,754]" gridcol="5" gridrow="16" pageId="8" pageNumber="11">34 to</td>
<td id="76A2FE295E250078FB8DEDC1FB8037C6" box="[1062,1103,734,754]" gridcol="6" gridrow="16" pageId="8" pageNumber="11">82)</td>
<td id="76A2FE295E250078FB3FEDC1FB7137C6" box="[1172,1214,734,754]" gridcol="7" gridrow="16" pageId="8" pageNumber="11">.16</td>
<td id="76A2FE295E250078FAB0EDC1FA8A37C6" box="[1307,1349,734,754]" gridcol="8" gridrow="16" pageId="8" pageNumber="11">…</td>
</tr>
<tr id="357397555E250078FF57EDE3FA8A363B" box="[252,1349,764,783]" gridrow="17" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EDE3FDD0363B" box="[252,543,764,783]" gridcol="0" gridrow="17" pageId="8" pageNumber="11">Nonwhite</th>
<td id="76A2FE295E250078FD95EDE3FD1D363B" box="[574,722,764,783]" gridcol="1" gridrow="17" pageId="8" pageNumber="11">30/604 (5.0)</td>
<td id="76A2FE295E250078FD59EDE3FC48363B" box="[754,903,764,783]" gridcol="2" gridrow="17" pageId="8" pageNumber="11">29/310 (9.4)</td>
<td id="76A2FE295E250078FC1CEDE3FC00363B" box="[951,975,764,783]" gridcol="3" gridrow="17" pageId="8" pageNumber="11">47</td>
<td id="76A2FE295E250078FC7DEDE3FB80363B" box="[982,1103,764,783]" colspan="3" colspanRight="2" gridcol="4" gridrow="17" pageId="8" pageNumber="11">(12 to 68)</td>
<td id="76A2FE295E250078FB3FEDE3FB71363B" box="[1172,1214,764,783]" gridcol="7" gridrow="17" pageId="8" pageNumber="11">.0 12</td>
<td id="76A2FE295E250078FAB0EDE3FA8A363B" box="[1307,1349,764,783]" gridcol="8" gridrow="17" pageId="8" pageNumber="11">.13</td>
</tr>
<tr id="357397555E250078FF57EC06FA8A3618" box="[252,1349,793,812]" gridrow="18" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EC06FDD03618" box="[252,543,793,812]" gridcol="0" gridrow="18" pageId="8" pageNumber="11">Men</th>
<td id="76A2FE295E250078FD95EC06FD1D3618" box="[574,722,793,812]" gridcol="1" gridrow="18" pageId="8" pageNumber="11">28/461 (6.1)</td>
<td id="76A2FE295E250078FD59EC06FC483618" box="[754,903,793,812]" gridcol="2" gridrow="18" pageId="8" pageNumber="11">25/236 (10.6)</td>
<td id="76A2FE295E250078FC1CEC06FC003618" box="[951,975,793,812]" gridcol="3" gridrow="18" pageId="8" pageNumber="11">43</td>
<td id="76A2FE295E250078FC7DEC06FC273618" box="[982,1000,793,812]" gridcol="4" gridrow="18" pageId="8" pageNumber="11">(3</td>
<td id="76A2FE295E250078FC45EC06FB803618" box="[1006,1103,793,812]" colspan="2" colspanRight="1" gridcol="5" gridrow="18" pageId="8" pageNumber="11">to 67)</td>
<td id="76A2FE295E250078FB3FEC06FB713618" box="[1172,1214,793,812]" gridcol="7" gridrow="18" pageId="8" pageNumber="11">.0 36</td>
<td id="76A2FE295E250078FAB0EC06FA8A3618" box="[1307,1349,793,812]" gridcol="8" gridrow="18" pageId="8" pageNumber="11">…</td>
</tr>
<tr id="357397555E250078FF57EC29FA8A367E" box="[252,1349,822,842]" gridrow="19" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EC29FDD0367E" box="[252,543,822,842]" gridcol="0" gridrow="19" pageId="8" pageNumber="11">Women</th>
<td id="76A2FE295E250078FD95EC29FD1D367E" box="[574,722,822,842]" gridcol="1" gridrow="19" pageId="8" pageNumber="11">2/143 (1.4)</td>
<td id="76A2FE295E250078FD59EC29FC48367E" box="[754,903,822,842]" gridcol="2" gridrow="19" pageId="8" pageNumber="11">4/74 (5.4)</td>
<td id="76A2FE295E250078FC1CEC29FC00367E" box="[951,975,822,842]" gridcol="3" gridrow="19" pageId="8" pageNumber="11">74</td>
<td id="76A2FE295E250078FC7DEC29FC27367E" box="[982,1000,822,842]" gridcol="4" gridrow="19" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45EC29FBD0367E" box="[1006,1055,822,842]" gridcol="5" gridrow="19" pageId="8" pageNumber="11">43 to</td>
<td id="76A2FE295E250078FB8DEC29FB80367E" box="[1062,1103,822,842]" gridcol="6" gridrow="19" pageId="8" pageNumber="11">95)</td>
<td id="76A2FE295E250078FB3FEC29FB71367E" box="[1172,1214,822,842]" gridcol="7" gridrow="19" pageId="8" pageNumber="11">.10</td>
<td id="76A2FE295E250078FAB0EC29FA8A367E" box="[1307,1349,822,842]" gridcol="8" gridrow="19" pageId="8" pageNumber="11">…</td>
</tr>
<tr id="357397555E250078FF57EC4BFA8A3653" box="[252,1349,852,871]" gridrow="20" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EC4BFA8A3653" box="[252,1349,852,871]" colspan="9" colspanRight="8" gridcol="0" gridrow="20" pageId="8" pageNumber="11">Age</th>
</tr>
<tr id="357397555E250078FF57EC6EFA8A36B0" box="[252,1349,881,900]" gridrow="21" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EC6EFDD036B0" box="[252,543,881,900]" gridcol="0" gridrow="21" pageId="8" pageNumber="11">30 years</th>
<td id="76A2FE295E250078FD95EC6EFD1D36B0" box="[574,722,881,900]" gridcol="1" gridrow="21" pageId="8" pageNumber="11">84/971 (8.7)</td>
<td id="76A2FE295E250078FD59EC6EFC4836B0" box="[754,903,881,900]" gridcol="2" gridrow="21" pageId="8" pageNumber="11">43/504 (8.5)</td>
<td id="76A2FE295E250078FC1CEC6EFC0036B0" box="[951,975,881,900]" gridcol="3" gridrow="21" pageId="8" pageNumber="11">1</td>
<td id="76A2FE295E250078FC7DEC6EFC2736B0" box="[982,1000,881,900]" gridcol="4" gridrow="21" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45EC6EFBD036B0" box="[1006,1055,881,900]" gridcol="5" gridrow="21" pageId="8" pageNumber="11">46 to</td>
<td id="76A2FE295E250078FB8DEC6EFB8036B0" box="[1062,1103,881,900]" gridcol="6" gridrow="21" pageId="8" pageNumber="11">30)</td>
<td id="76A2FE295E250078FB3FEC6EFB7136B0" box="[1172,1214,881,900]" gridcol="7" gridrow="21" pageId="8" pageNumber="11">.95</td>
<td id="76A2FE295E250078FAB0EC6EFA8A36B0" box="[1307,1349,881,900]" gridcol="8" gridrow="21" pageId="8" pageNumber="11">1.5</td>
</tr>
<tr id="357397555E250078FF57EC91FA8A368A" box="[252,1349,910,958]" gridrow="22" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EC91FDD0368A" box="[252,543,910,958]" gridcol="0" gridrow="22" pageId="8" pageNumber="11">1 30 years Education level d</th>
<td id="76A2FE295E250078FD95EC91FD1D368A" box="[574,722,910,958]" gridcol="1" gridrow="22" pageId="8" pageNumber="11">157/2627 (6.0)</td>
<td id="76A2FE295E250078FD59EC91FC48368A" box="[754,903,910,958]" gridcol="2" gridrow="22" pageId="8" pageNumber="11">84/1301 (6.5)</td>
<td id="76A2FE295E250078FC1CEC91FC00368A" box="[951,975,910,958]" gridcol="3" gridrow="22" pageId="8" pageNumber="11">8</td>
<td id="76A2FE295E250078FC7DEC91FC27368A" box="[982,1000,910,958]" gridcol="4" gridrow="22" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45EC91FBD0368A" box="[1006,1055,910,958]" gridcol="5" gridrow="22" pageId="8" pageNumber="11">19 to</td>
<td id="76A2FE295E250078FB8DEC91FB80368A" box="[1062,1103,910,958]" gridcol="6" gridrow="22" pageId="8" pageNumber="11">30)</td>
<td id="76A2FE295E250078FB3FEC91FB71368A" box="[1172,1214,910,958]" gridcol="7" gridrow="22" pageId="8" pageNumber="11">.51</td>
<td id="76A2FE295E250078FAB0EC91FA8A368A" box="[1307,1349,910,958]" gridcol="8" gridrow="22" pageId="8" pageNumber="11">1.5</td>
</tr>
<tr id="357397555E250078FF57ECD7FA8A36E8" box="[252,1349,968,988]" gridrow="23" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57ECD7FDD036E8" box="[252,543,968,988]" gridcol="0" gridrow="23" pageId="8" pageNumber="11">Less than a college degree</th>
<td id="76A2FE295E250078FD95ECD7FD1D36E8" box="[574,722,968,988]" gridcol="1" gridrow="23" pageId="8" pageNumber="11">95/1409 (6.7)</td>
<td id="76A2FE295E250078FD59ECD7FC4836E8" box="[754,903,968,988]" gridcol="2" gridrow="23" pageId="8" pageNumber="11">52/713 (7.3)</td>
<td id="76A2FE295E250078FC1CECD7FC0036E8" box="[951,975,968,988]" gridcol="3" gridrow="23" pageId="8" pageNumber="11">8</td>
<td id="76A2FE295E250078FC7DECD7FC2736E8" box="[982,1000,968,988]" gridcol="4" gridrow="23" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45ECD7FBD036E8" box="[1006,1055,968,988]" gridcol="5" gridrow="23" pageId="8" pageNumber="11">29 to</td>
<td id="76A2FE295E250078FB8DECD7FB8036E8" box="[1062,1103,968,988]" gridcol="6" gridrow="23" pageId="8" pageNumber="11">34)</td>
<td id="76A2FE295E250078FB3FECD7FB7136E8" box="[1172,1214,968,988]" gridcol="7" gridrow="23" pageId="8" pageNumber="11">.63</td>
<td id="76A2FE295E250078FAB0ECD7FA8A36E8" box="[1307,1349,968,988]" gridcol="8" gridrow="23" pageId="8" pageNumber="11">1.5</td>
</tr>
<tr id="357397555E250078FF57ECFAFA8A3122" box="[252,1349,997,1046]" gridrow="24" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57ECFAFDD03122" box="[252,543,997,1046]" gridcol="0" gridrow="24" pageId="8" pageNumber="11">College or graduate degree Baseline behavioral risk score e</th>
<td id="76A2FE295E250078FD95ECFAFD1D3122" box="[574,722,997,1046]" gridcol="1" gridrow="24" pageId="8" pageNumber="11">146/2188 (6.7)</td>
<td id="76A2FE295E250078FD59ECFAFC483122" box="[754,903,997,1046]" gridcol="2" gridrow="24" pageId="8" pageNumber="11">75/1092 (6.9)</td>
<td id="76A2FE295E250078FC1CECFAFC003122" box="[951,975,997,1046]" gridcol="3" gridrow="24" pageId="8" pageNumber="11">4</td>
<td id="76A2FE295E250078FC7DECFAFC273122" box="[982,1000,997,1046]" gridcol="4" gridrow="24" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45ECFAFBD03122" box="[1006,1055,997,1046]" gridcol="5" gridrow="24" pageId="8" pageNumber="11">27 to</td>
<td id="76A2FE295E250078FB8DECFAFB803122" box="[1062,1103,997,1046]" gridcol="6" gridrow="24" pageId="8" pageNumber="11">27)</td>
<td id="76A2FE295E250078FB3FECFAFB713122" box="[1172,1214,997,1046]" gridcol="7" gridrow="24" pageId="8" pageNumber="11">.77</td>
<td id="76A2FE295E250078FAB0ECFAFA8A3122" box="[1307,1349,997,1046]" gridcol="8" gridrow="24" pageId="8" pageNumber="11">1.5</td>
</tr>
<tr id="357397555E250078FF57EB3FFA8A3107" box="[252,1349,1056,1075]" gridrow="25" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EB3FFDD03107" box="[252,543,1056,1075]" gridcol="0" gridrow="25" pageId="8" pageNumber="11">Low risk</th>
<td id="76A2FE295E250078FD95EB3FFD1D3107" box="[574,722,1056,1075]" gridcol="1" gridrow="25" pageId="8" pageNumber="11">32/1211 (2.6)</td>
<td id="76A2FE295E250078FD59EB3FFC483107" box="[754,903,1056,1075]" gridcol="2" gridrow="25" pageId="8" pageNumber="11">11/609 (1.8)</td>
<td id="76A2FE295E250078FC1CEB3FFC003107" box="[951,975,1056,1075]" gridcol="3" gridrow="25" pageId="8" pageNumber="11">48</td>
<td id="76A2FE295E250078FC7DEB3FFC273107" box="[982,1000,1056,1075]" gridcol="4" gridrow="25" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45EB3FFB803107" box="[1006,1103,1056,1075]" colspan="2" colspanRight="1" gridcol="5" gridrow="25" pageId="8" pageNumber="11">193 to 26)</td>
<td id="76A2FE295E250078FB3FEB3FFB713107" box="[1172,1214,1056,1075]" gridcol="7" gridrow="25" pageId="8" pageNumber="11">.26</td>
<td id="76A2FE295E250078FAB0EB3FFA8A3107" box="[1307,1349,1056,1075]" gridcol="8" gridrow="25" pageId="8" pageNumber="11">1.5</td>
</tr>
<tr id="357397555E250078FF57EB22FA8A3165" box="[252,1349,1085,1105]" gridrow="26" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EB22FDD03165" box="[252,543,1085,1105]" gridcol="0" gridrow="26" pageId="8" pageNumber="11">Medium risk</th>
<td id="76A2FE295E250078FD95EB22FD1D3165" box="[574,722,1085,1105]" gridcol="1" gridrow="26" pageId="8" pageNumber="11">177/2229 (7.9)</td>
<td id="76A2FE295E250078FD59EB22FC483165" box="[754,903,1085,1105]" gridcol="2" gridrow="26" pageId="8" pageNumber="11">90/1107 (8.1)</td>
<td id="76A2FE295E250078FC1CEB22FC003165" box="[951,975,1085,1105]" gridcol="3" gridrow="26" pageId="8" pageNumber="11">3</td>
<td id="76A2FE295E250078FC7DEB22FC273165" box="[982,1000,1085,1105]" gridcol="4" gridrow="26" pageId="8" pageNumber="11">(</td>
<td id="76A2FE295E250078FC45EB22FBD03165" box="[1006,1055,1085,1105]" gridcol="5" gridrow="26" pageId="8" pageNumber="11">25 to</td>
<td id="76A2FE295E250078FB8DEB22FB803165" box="[1062,1103,1085,1105]" gridcol="6" gridrow="26" pageId="8" pageNumber="11">25)</td>
<td id="76A2FE295E250078FB3FEB22FB713165" box="[1172,1214,1085,1105]" gridcol="7" gridrow="26" pageId="8" pageNumber="11">.82</td>
<td id="76A2FE295E250078FAB0EB22FA8A3165" box="[1307,1349,1085,1105]" gridcol="8" gridrow="26" pageId="8" pageNumber="11">1.5</td>
</tr>
<tr id="357397555E250078FF57EB45FA8A315A" box="[252,1349,1114,1134]" gridrow="27" pageId="8" pageNumber="11">
<th id="76A2FE295E250078FF57EB45FDD0315A" box="[252,543,1114,1134]" gridcol="0" gridrow="27" pageId="8" pageNumber="11">High risk</th>
<td id="76A2FE295E250078FD95EB45FD1D315A" box="[574,722,1114,1134]" gridcol="1" gridrow="27" pageId="8" pageNumber="11">32/158 (20.3)</td>
<td id="76A2FE295E250078FD59EB45FC48315A" box="[754,903,1114,1134]" gridcol="2" gridrow="27" pageId="8" pageNumber="11">26/89 (29.2)</td>
<td id="76A2FE295E250078FC1CEB45FC00315A" box="[951,975,1114,1134]" gridcol="3" gridrow="27" pageId="8" pageNumber="11">43</td>
<td id="76A2FE295E250078FC7DEB45FC27315A" box="[982,1000,1114,1134]" gridcol="4" gridrow="27" pageId="8" pageNumber="11">(4</td>
<td id="76A2FE295E250078FC45EB45FB80315A" box="[1006,1103,1114,1134]" colspan="2" colspanRight="1" gridcol="5" gridrow="27" pageId="8" pageNumber="11">to 66)</td>
<td id="76A2FE295E250078FB3FEB45FB71315A" box="[1172,1214,1114,1134]" gridcol="7" gridrow="27" pageId="8" pageNumber="11">.0 32</td>
<td id="76A2FE295E250078FAB0EB45FA8A315A" box="[1307,1349,1114,1134]" gridcol="8" gridrow="27" pageId="8" pageNumber="11">.29</td>
</tr>
</table>
</paragraph>
</table>
<tableNote id="76A594995E25FF8FFEA4EB95FBEB3089" pageId="8" pageNumber="11" targetBox="[252,1375,217,1134]" targetPageId="8">
<paragraph id="8BFC95175E25FF8FFEA4EB95FDBF3182" blockId="8.[252,1374,1160,1470]" pageId="8" pageNumber="11">
<!--emphasis removed-->NOTE.
Data are no. of infected volunteers/no. of total volunteers (%) in category. CI, confidence interval. a Two-sided values from log-rank 
<!--emphasis removed-->P
a test.
</paragraph>
<paragraph id="8BFC95175E25FF8FFEA4EBA8FA9131FA" blockId="8.[252,1374,1160,1470]" box="[271,1374,1207,1230]" pageId="8" pageNumber="11">b Two-sided values from nonparametric bootstrap procedure that conducted with 10,000 resampled data Wald statistics</paragraph>
<paragraph id="8BFC95175E25FF8FFED2EBA1FCD531D1" blockId="8.[252,1374,1160,1470]" pageId="8" pageNumber="11">
<!--emphasis removed-->P
a was sets; from univariate Cox proportional hazards models were used [25].
</paragraph>
<paragraph id="8BFC95175E25FF8FFEA4EBF8FA9131CA" blockId="8.[252,1374,1160,1470]" box="[271,1374,1255,1278]" pageId="8" pageNumber="11">c All 5 infected black women were from 1 site. gp120 sequence analysis of the 5 isolates from these women indicated that 3 of the</paragraph>
<paragraph id="8BFC95175E25FF8FFF57EA1AFA913022" blockId="8.[252,1374,1160,1470]" box="[252,1374,1284,1302]" pageId="8" pageNumber="11">isolates (all from placebo recipients) were clustered together in a phylogenetic tree, which suggests at least a phylogenetic linkage.The</paragraph>
<paragraph id="8BFC95175E25FF8FFF57EA02FC473019" blockId="8.[252,1374,1160,1470]" box="[252,904,1309,1326]" pageId="8" pageNumber="11">3 phylogenetically linked infections occurred during 3 separate calendar years.</paragraph>
<paragraph id="8BFC95175E25FF8FFEA4EA30FD433072" blockId="8.[252,1374,1160,1470]" box="[271,652,1327,1350]" pageId="8" pageNumber="11">d One volunteer was missing education data.</paragraph>
<paragraph id="8BFC95175E25FF8FFEA4EA58FA913069" blockId="8.[252,1374,1160,1470]" box="[271,1374,1351,1374]" pageId="8" pageNumber="11">e Risk score was defined as the total no. of risk factors reported from the following: (1) unprotected receptive anal sex with an HIV-</paragraph>
<paragraph id="8BFC95175E25FF8FFF57EA7AFA913042" blockId="8.[252,1374,1160,1470]" box="[252,1374,1380,1398]" pageId="8" pageNumber="11">1–infected male partner; (2) unprotected insertive anal sex with an HIV-1–infected male partner; (3) unprotected receptive anal sex with</paragraph>
<paragraph id="8BFC95175E25FF8FFF57EA62FA9130BA" blockId="8.[252,1374,1160,1470]" box="[252,1374,1404,1422]" pageId="8" pageNumber="11">an HIV-1–uninfected male partner; (4) 5 acts of unprotected receptive anal sex with a male partner of unknown HIV-1 status; (5) 10</paragraph>
<paragraph id="8BFC95175E25FF8FFF57EA8AFA913091" blockId="8.[252,1374,1160,1470]" box="[252,1374,1428,1446]" pageId="8" pageNumber="11">sex partners; (6) anal herpes; (7) hepatitis A; (8) use of poppers; and (9) use of amphetamines. Behavioral risk scores ranged from 0 to</paragraph>
<paragraph id="8BFC95175E25FF8FFF57EAB2FBEB3089" blockId="8.[252,1374,1160,1470]" box="[252,1060,1452,1470]" pageId="8" pageNumber="11">7; 0 was categorized as low, 1–3 was categorized as medium, and 4–7 was categorized as high.</paragraph>
</tableNote>
<paragraph id="8BFC95175E25FF8FFF3CEAEAFEC23364" blockId="8.[151,790,1525,1927]" pageId="8" pageNumber="11">and Peter B. Gilbert, Michael G. Hudgens, Barbara J. Metch, and Steven G. Self have received consulting fees from VaxGen in the past.</paragraph>
<paragraph id="8BFC95175E25FF8FFF1AE942FE6B3D17" blockId="8.[151,790,1525,1927]" lastBlockId="8.[8,766,2055,2099]" pageId="8" pageNumber="11">
<!--emphasis removed-->rgp120 HIV Vaccine Study Group members.
Thefollowing persons are members of the rgp120 HIV Vaccine Study Group: Angeli Adamczyk (ACRC/Arizona Clinical Research Center, Tucson, AZ); Robert L. Baker (Community Medical Research Institute, Indianapolis, IN); David Brand (North Texas Center for AIDS and Clinical Research, Dallas); Stephen J. Brown (AIDS Research Alliance, West Hollywood, CA); Susan Buchbinder (San Francisco Department of Public Health, San Francisco, CA); Brian P. Buggy (Wisconsin AIDS Research Consortium, Milwaukee); Jerry Cade (Wellness Center, Las Vegas, NV); Michael C. Caldwell (Dutchess County Department of Health, Poughkeepsie, NY); Connie Celum (University of Washington/Seattle HPTU, Seattle); Catherine Creticos (Howard Brown Health Center, Chicago, IL); Roel A. Coutinho and Karen Lindenburg (GG&amp;GD/Municipal Health Service Amsterdam, Amsterdam, The Netherlands); Patrick Daly (Nelson- Tebedo Health Resource Center, Dallas, TX); Edwin DeJesus (IDC Research Initiative, Altamonte Springs, FL); Richard Di- Carlo (Louisiana State University Health Sciences Center, New Orleans); Martin Fenstersheib (Crane Center, San Jose, CA); Neil Flynn (University of California at Davis Medical Center, 662 • 
<!--emphasis removed-->JID 2005:191 (1 March)
• rgp120 HIV Vaccine Study Group Downloaded from https://academic.oup.com/jid/article-abstract/191/5/654/1234535 by Aerztegemeinschaft fuer Anaesthesie user
</paragraph>
<paragraph id="8BFC95175E24FF8EFFA3E718FE6B3D17" blockId="9.[8,766,2055,2099]" pageId="9" pageNumber="663">Downloaded from https://academic.oup.com/jid/article-abstract/191/5/654/1234535 by Aerztegemeinschaft fuer Anaesthesie user</paragraph>
<paragraph id="8BFC95175E24FF8EF99CEAAAF9BB30FF" blockId="9.[1591,1652,1461,1483]" box="[1591,1652,1461,1483]" pageId="9" pageNumber="663">
<heading id="D0B4227B5E24FF8EF99CEAAAF9BB30FF" bold="true" box="[1591,1652,1461,1483]" centered="true" fontSize="9" level="1" pageId="9" pageNumber="663" reason="2">
<!--emphasis removed-->Figure
</heading>
</paragraph>
<paragraph id="8BFC95175E27FF8DFF3CEF84FEB63253" blockId="10.[151,790,155,1895]" pageId="10" pageNumber="664">Infectious Diseases, Sacramento); Donald Forthal (University of California at Irvine College of Medicine, Orange); Barbara Gripshover (University Hospitals of Cleveland,Cleveland,OH); Geoffrey J. Gorse and Robert Belshe (Saint Louis University, St. Louis, MO); Howard Grossman (Polaris Medical Group, New York, NY); Clayton D. Harro (Johns Hopkins Bloomberg School of Public Health, Baltimore, MD); Keith Henry (Hennepin County Medical Center, Minneapolis, MN); Ross G. Hewitt (Erie County Medical Center, Buffalo, NY); Robert Hogg (BC Centre for Excellence in HIV/AIDS, Vancouver,British Columbia, Canada); Jeffrey M. Jacobson (Beth Israel Medical Center, New York, NY); Joseph Jemsek (Jemsek Clinic, Huntersville, NC); Franklyn Judson (Denver Department of Public Health, Denver, CO); James O. Kahn (University of California at San Francisco Positive Health Program, San Francisco); Michael C. Keefer (University of Rochester, Rochester, NY); Harold Kessler (Chicago Center for Clinical Research, Chicago, IL); Beryl Koblin (New York Blood Center, New York, NY); Jay Kostman (Philadelphia Fight,Philadelphia,PA);Michelle Lally (The Miriam Hospital, Providence, RI); Ken Logue (CascAids Research, Toronto, Ontario, Canada); Michael Marmor (New York University School of Medicine, New York, NY); Kenneth Mayer (Fenway Community Health, Boston, MA); David McKinsey (Antibiotic Research Associates, Kansas City, MO); Barry M. Miskin (Palm Beach Research Center, West Palm Beach, FL); Javier O. Morales (Clinical Research Puerto Rico, San Juan, Puerto Rico); Mark J. Mulligan (University of Alabama at Birmingham, Birmingham); RobertA.Myers(Body Positive, Phoenix, AZ); Richard Novak (University of Illinois at Chicago, Chicago); Michael Para (Ohio State University,Columbus); Peter Piliero (Albany Medical College, Albany, NY); Ronald Poblete (North Jersey Community Research Initiative, Newark, NJ); Frank Rhame (Abbott Northwestern Hospital, Minneapolis, MN); Sharon Riddler (University of Pittsburgh, Pittsburgh, PA); Ralph W. Richter (Clinical PharmaceuticalTrials, Tulsa, OK); James H. Sampson (Research and Education Group, Portland, OR); Michael Sands (University of Florida at Jacksonville, Jacksonville); Steven Santiago (Care Resource, Coral Gables, FL); Cecilia Shikuma (HawaiiAIDSClinicalTrials Unit, Honolulu); Michael S. Somero (Offic of Michael S. Somero, MD, Palm Springs, CA); Elaine Thomas (University of New Mexico Health Sciences Center, Albuquerque); Melanie Thompson (AIDS Research Consortium of Atlanta, Atlanta, GA); Stephen K. Tyring (University of Texas Medical Branch Center for Clinical Studies, Houston); Jean Vincelette (Hoˆpital Saint-Luc du CHUM, Montreal, Quebec, Canada); Peter S. Vrooman, Jr. (ALL TRIALS Clinical Research, Winston–Salem, NC); and Bienvenido G. Yangco (Infectious Disease Research Institute, Tampa, FL).</paragraph>
<paragraph id="8BFC95175E27FF8DFCEEEF85FBFC3584" blockId="10.[837,1075,154,176]" box="[837,1075,154,176]" pageId="10" pageNumber="664">Acknowledgments</paragraph>
<paragraph id="8BFC95175E27FF8DFCF1EFD6FB4E34D2" blockId="10.[837,1476,201,486]" pageId="10" pageNumber="664">We thank the VAX004 trial participants, for their contribution and dedication to this trial; the study coordinators, in recognition of their hard work and commitment to quality; and the following individuals, for their significan contributions to the trial and its interpretation: Dale Hu, Ann Wang, Alan Greenberg, Elizabeth Li, Tim Mastro, Jim Young, Brad Bartholow, Adrian Hirsh, Marta Ackers, Michael Longhi, Eleanor McLellan, Gina Rossen, Marlene Chernow, John Curd, Nzeera Virani-Ketter, John Jermano, Patti Cronin, Mike Busch, Nathan Winslow, Chip Sheppard, Valerie Smith, Karin Orelind, Lynne Deans, Marc Drucker, Jim Key, Mark McLaughlin, Lisa Brooks, Donna Eastman, Mike Lock, Lavon Riddle, Andrew McCluskey, and Tina Ippolito.</paragraph>
<paragraph id="8BFC95175E27FF8DFCEEED2AFC1D377F" blockId="10.[837,978,565,587]" box="[837,978,565,587]" pageId="10" pageNumber="664">References</paragraph>
<paragraph id="8BFC95175E27FF8DFCE4ED7AFC1E3799" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCE4ED7AFC1E3799" _evidence="authorListStart.regEx.txt" author="Esparza J &amp; Bhamarapravati N." journalOrPublisher="Lancet" pageId="10" pageNumber="664" pagination="2061 - 6" part="355" title="Accelerating the development and future availability of HIV- 1 vaccines: why, when, where, and how" type="journal article" year="2000">
1. 
<author id="53FE7DF25E27FF8DFCC2ED7AFC76374C" box="[873,953,613,632]" fns="I" npo="LF" pageId="10" pageNumber="664">Esparza J</author>
, 
<author id="53FE7DF25E27FF8DFC6AED7AFBAA374C" box="[961,1125,613,632]" fns="I" npo="LF" pageId="10" pageNumber="664">Bhamarapravati N.</author>
<title id="F9477E215E27FF8DFBC2ED7AFA8137A7" jopScore="0.7499792" pageId="10" pageNumber="664">Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how</title>
? 
<journalOrPublisher id="51829FDB5E27FF8DFAF1ED9FFA5E37A7" box="[1370,1425,640,659]" jopScore="3.5499792" pageId="10" pageNumber="664">Lancet</journalOrPublisher>
<!--emphasis removed-->
<year id="FFEBD4445E27FF8DFA3EED9FFA7137A7" box="[1429,1470,640,659]" pageId="10" pageNumber="664">2000</year>

; 
<part id="FFE73F8A5E27FF8DFCC2ED85FC463799" box="[873,905,666,685]" pageId="10" pageNumber="664" type="volume">355</part>
: 
<pagination id="B28A6BE35E27FF8DFC27ED85FC033799" box="[908,972,666,685]" pageId="10" pageNumber="664" type="pagination">2061–6</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8DFCE4EDAAFAF037D6" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCE4EDAAFAF037D6" _evidence="numberAuthorListStart.regEx.txt" author="Spearman P. HIV" journalOrPublisher="Curr HIV Res" pageId="10" pageNumber="664" pagination="101 - 20" part="1" title="vaccine development: lessons from the past and promise for the future" type="journal article" year="2003">
2. 
<author id="53FE7DF25E27FF8DFCC2EDAAFBC837FC" box="[873,1031,693,712]" fns="I" npo="LF" pageId="10" pageNumber="664">Spearman P. HIV</author>
<title id="F9477E215E27FF8DFBBAEDAAFBE137D6" pageId="10" pageNumber="664">vaccine development: lessons from the past and promise for the future</title>
. 
<journalOrPublisher id="51829FDB5E27FF8DFB93EDD0FB7C37D6" box="[1080,1203,719,738]" pageId="10" pageNumber="664">Curr HIV Res</journalOrPublisher>
<year id="FFEBD4445E27FF8DFB11EDD0FB2B37D6" box="[1210,1252,719,738]" pageId="10" pageNumber="664">
<!--emphasis removed-->2003
</year>
; 
<part id="FFE73F8A5E27FF8DFB4CEDD0FB2037D6" box="[1255,1263,719,738]" pageId="10" pageNumber="664" type="volume">1</part>
: 
<pagination id="B28A6BE35E27FF8DFB59EDD0FAF437D6" box="[1266,1339,719,738]" pageId="10" pageNumber="664" type="pagination">101–20</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8DFCE4EDF5FC1E3606" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCE4EDF5FC1E3606" _evidence="authorListStart.regEx.txt" author="Nathanson N &amp; Mathieson BJ." journalOrPublisher="J Infect Dis" pageId="10" pageNumber="664" pagination="579 - 89" part="182" title="Biological considerations in the development of a human immunodeficienc virus vaccine" type="journal article" year="2000">
3. 
<author id="53FE7DF25E27FF8DFCC2EDF5FC2F37C9" box="[873,992,746,765]" fns="I" npo="LF" pageId="10" pageNumber="664">Nathanson N</author>
, 
<author id="53FE7DF25E27FF8DFC46EDF5FBA537C9" box="[1005,1130,746,765]" fns="I" kam="kam" npo="LF" pageId="10" pageNumber="664">Mathieson BJ.</author>
<title id="F9477E215E27FF8DFBDAEDF5FAE3362C" pageId="10" pageNumber="664">Biological considerations in the development of a human immunodeficienc virus vaccine</title>
. 
<journalOrPublisher id="51829FDB5E27FF8DFA99EC1AFA5F362C" box="[1330,1424,773,792]" pageId="10" pageNumber="664">J Infect Dis</journalOrPublisher>
<year id="FFEBD4445E27FF8DFA3FEC1AFA71362C" box="[1428,1470,773,792]" pageId="10" pageNumber="664">
<!--emphasis removed-->2000
</year>
; 
<part id="FFE73F8A5E27FF8DFCC2EC00FC463606" box="[873,905,799,818]" pageId="10" pageNumber="664" type="volume">182</part>
: 
<pagination id="B28A6BE35E27FF8DFC20EC00FC023606" box="[907,973,799,818]" pageId="10" pageNumber="664" type="pagination">579–89</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8DFCE4EC25FB8336B6" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCE4EC25FB8336B6" _evidence="authorListStart.regEx.txt" author="Fowke KR &amp; Nagelkerke NJD &amp; Kimani J" journalOrPublisher="Lancet" pageId="10" pageNumber="664" pagination="1347 - 51" part="348" title="Resistance to HIV- 1 infection among persistently seronegative prostitutes in Nairobi, Kenya" type="journal article" year="1996">
4. 
<bibRef id="52E301E15E27FF8DFCC2EC25FB8336B6" _evidence="authorListStart.regEx.txt" pageId="10" pageNumber="664" type="journal article">
<author id="53FE7DF25E27FF8DFCC2EC25FC0A3679" box="[873,965,826,845]" fns="I" npo="LF" pageId="10" pageNumber="664">Fowke KR</author>
, 
<author id="53FE7DF25E27FF8DFC7BEC25FB913679" box="[976,1118,826,845]" fns="I" npo="LF" pageId="10" pageNumber="664">Nagelkerke NJD</author>
, 
<author id="53FE7DF25E27FF8DFBC2EC25FB763679" box="[1129,1209,826,845]" fns="I" kam="kam" npo="LF" pageId="10" pageNumber="664">Kimani J</author>
, et al. 
<title id="F9477E215E27FF8DFB5EEC25FA0F3653" jopScore="0.71487445" pageId="10" pageNumber="664">Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya</title>
. 
<journalOrPublisher id="51829FDB5E27FF8DFCC2EC70FC6D36B6" box="[873,930,879,898]" jopScore="3.5148745" pageId="10" pageNumber="664">Lancet</journalOrPublisher>
<year id="FFEBD4445E27FF8DFC03EC70FC1D36B6" box="[936,978,879,898]" pageId="10" pageNumber="664">
<!--emphasis removed-->1996
</year>
; 
<part id="FFE73F8A5E27FF8DFC7EEC70FC3836B6" box="[981,1015,879,898]" pageId="10" pageNumber="664" type="volume">348</part>
: 
<pagination id="B28A6BE35E27FF8DFC51EC70FB8736B6" box="[1018,1096,879,898]" pageId="10" pageNumber="664" type="pagination">1347–51</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8DFCE4EC95FAB036E7" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCE4EC95FAB036E7" _evidence="authorListStart.regEx.txt" author="Sharon A &amp; Stranford SA &amp; Skurnick J" journalOrPublisher="Proc Natl Acad Sci USA" pageId="10" pageNumber="664" pagination="1030 - 5" part="96" title="Lack of infection in HIVexposed individuals is associated with a strong CD 8 + cell noncytotoxic anti-HIV response" type="journal article" year="1999">
5. 
<bibRef id="52E301E15E27FF8DFCC2EC95FAB036E7" _evidence="authorListStart.regEx.txt" pageId="10" pageNumber="664" type="journal article">
<author id="53FE7DF25E27FF8DFCC2EC95FC7136A9" box="[873,958,906,925]" fns="I" npo="LF" pageId="10" pageNumber="664">Sharon A</author>
, 
<author id="53FE7DF25E27FF8DFC63EC95FBF336A9" box="[968,1084,906,925]" fns="I" npo="LF" pageId="10" pageNumber="664">Stranford SA</author>
, 
<author id="53FE7DF25E27FF8DFBECEC95FB6B36A9" box="[1095,1188,906,925]" fns="I" npo="LF" pageId="10" pageNumber="664">Skurnick J</author>
, et al. 
<title id="F9477E215E27FF8DFB49EC95FBC436E7" pageId="10" pageNumber="664">Lack of infection in HIVexposed individuals is associated with a strong CD8+ cell noncytotoxic anti-HIV response</title>
. 
<journalOrPublisher id="51829FDB5E27FF8DFBBFECDFFB2736E7" box="[1044,1256,960,979]" pageId="10" pageNumber="664">Proc Natl Acad Sci USA</journalOrPublisher>
<year id="FFEBD4445E27FF8DFB44ECDFFAD636E7" box="[1263,1305,960,979]" pageId="10" pageNumber="664">
<!--emphasis removed-->1999
</year>
; 
<part id="FFE73F8A5E27FF8DFAB6ECDFFAFB36E7" box="[1309,1332,960,979]" pageId="10" pageNumber="664" type="volume">96</part>
: 
<pagination id="B28A6BE35E27FF8DFA9CECDFFAB436E7" box="[1335,1403,960,979]" pageId="10" pageNumber="664" type="pagination">1030–5</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8DFCE4ECC4FA583117" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCE4ECC4FA583117" _evidence="authorListStart.regEx.txt" author="Jennes W &amp; Vuylsteke B &amp; Borget M-Y" journalOrPublisher="J Infect Dis" pageId="10" pageNumber="664" pagination="1053 - 63" part="187" title="HIV-specifi T helper responses and frequency of exposure among HIV-exposed seronegative female sex workers in Abidjan, Coˆte d'Ivoire" type="journal article" year="2003">
6. 
<bibRef id="52E301E15E27FF8DFCC3ECC4FA583117" _evidence="authorListStart.regEx.txt" pageId="10" pageNumber="664" type="journal article">
<author id="53FE7DF25E27FF8DFCC3ECC4FC7836DA" box="[872,951,987,1006]" fns="I" npo="LF" pageId="10" pageNumber="664">Jennes W</author>
, 
<author id="53FE7DF25E27FF8DFC14ECC4FBEF36DA" box="[959,1056,987,1006]" fns="I" npo="LF" pageId="10" pageNumber="664">Vuylsteke B</author>
, 
<author id="53FE7DF25E27FF8DFB83ECC4FB4436DA" box="[1064,1163,987,1006]" fns="I" npo="LF" pageId="10" pageNumber="664">Borget M-Y</author>
, et al. 
<title id="F9477E215E27FF8DFB15ECC4FB483117" jopScore="0.2422526" pageId="10" pageNumber="664">HIV-specifi T helper responses and frequency of exposure among HIV-exposed seronegative female sex workers in Abidjan, Coˆte d’Ivoire</title>
. 
<journalOrPublisher id="51829FDB5E27FF8DFB3BEB0FFB3F3117" box="[1168,1264,1040,1059]" jopScore="1.0517764" pageId="10" pageNumber="664">J Infect Dis</journalOrPublisher>
<year id="FFEBD4445E27FF8DFB5CEB0FFAEF3117" box="[1271,1312,1040,1059]" pageId="10" pageNumber="664">
<!--emphasis removed-->2003
</year>
; 
<part id="FFE73F8A5E27FF8DFA88EB0FFA8C3117" box="[1315,1347,1040,1059]" pageId="10" pageNumber="664" type="volume">187</part>
: 
<pagination id="B28A6BE35E27FF8DFAEDEB0FFA5D3117" box="[1350,1426,1040,1059]" pageId="10" pageNumber="664" type="pagination">1053–63</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8DFCE4EB34FBAE3140" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCE4EB34FBAE3140" _evidence="authorListStart.regEx.txt" author="Quillent C &amp; Oberlin E &amp; Braun J" journalOrPublisher="Lancet" pageId="10" pageNumber="664" pagination="14 - 8" part="351" title="HIV- 1 - resistance phenotype conferred by combination of two separate inherited mutationsofCCR 5 gene" type="journal article" year="1998">
7. 
<bibRef id="52E301E15E27FF8DFCC2EB34FBAE3140" _evidence="authorListStart.regEx.txt" pageId="10" pageNumber="664" type="journal article">
<author id="53FE7DF25E27FF8DFCC2EB34FC05310A" box="[873,970,1067,1086]" fns="I" npo="LF" pageId="10" pageNumber="664">Quillent C</author>
, 
<author id="53FE7DF25E27FF8DFC7CEB34FBFD310A" box="[983,1074,1067,1086]" fns="I" npo="LF" pageId="10" pageNumber="664">Oberlin E</author>
, 
<author id="53FE7DF25E27FF8DFB94EB34FB48310A" box="[1087,1159,1067,1086]" fns="I" npo="LF" pageId="10" pageNumber="664">Braun J</author>
, et al. 
<title id="F9477E215E27FF8DFB67EB34FC5C3140" jopScore="0.507339" pageId="10" pageNumber="664">HIV-1–resistance phenotype conferred by combination of two separate inherited mutationsofCCR5 gene</title>
. 
<journalOrPublisher id="51829FDB5E27FF8DFC37EB7EFC1A3140" box="[924,981,1121,1140]" jopScore="3.307339" pageId="10" pageNumber="664">Lancet</journalOrPublisher>
<year id="FFEBD4445E27FF8DFC77EB7EFBC93140" box="[988,1030,1121,1140]" pageId="10" pageNumber="664">
<!--emphasis removed-->1998
</year>
; 
<part id="FFE73F8A5E27FF8DFBA2EB7EFBE33140" box="[1033,1068,1121,1140]" pageId="10" pageNumber="664" type="volume">351</part>
: 
<pagination id="B28A6BE35E27FF8DFB84EB7EFB923140" box="[1071,1117,1121,1140]" pageId="10" pageNumber="664" type="pagination">14–8</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8DFCE4EB63FB2731F1" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCE4EB63FB2731F1" _evidence="authorListStart.regEx.txt" author="Samson M &amp; Libert F &amp; Doranz BJ" journalOrPublisher="Nature" pageId="10" pageNumber="664" pagination="722 - 5" part="382" title="Resistance to HIV- 1 infection in Caucasian individuals bearing mutant alleles of the CCR- 5 chemokine receptor gene" type="journal article" year="1996">
8. 
<bibRef id="52E301E15E27FF8DFCC2EB63FB2731F1" _evidence="authorListStart.regEx.txt" pageId="10" pageNumber="664" type="journal article">
<author id="53FE7DF25E27FF8DFCC2EB63FC0631BB" box="[873,969,1148,1167]" fns="I" npo="LF" pageId="10" pageNumber="664">Samson M</author>
, 
<author id="53FE7DF25E27FF8DFC7FEB63FBD531BB" box="[980,1050,1148,1167]" fns="I" npo="LF" pageId="10" pageNumber="664">Libert F</author>
, 
<author id="53FE7DF25E27FF8DFB8EEB63FB4C31BB" box="[1061,1155,1148,1167]" fns="I" npo="LF" pageId="10" pageNumber="664">Doranz BJ</author>
, et al. 
<title id="F9477E215E27FF8DFB6BEB63FBC331F1" pageId="10" pageNumber="664">Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene</title>
. 
<journalOrPublisher id="51829FDB5E27FF8DFBBDEBADFB9D31F1" box="[1046,1106,1202,1221]" pageId="10" pageNumber="664">Nature</journalOrPublisher>
<year id="FFEBD4445E27FF8DFBF3EBADFB4D31F1" box="[1112,1154,1202,1221]" pageId="10" pageNumber="664">
<!--emphasis removed-->1996
</year>
; 
<part id="FFE73F8A5E27FF8DFB2EEBADFB6731F1" box="[1157,1192,1202,1221]" pageId="10" pageNumber="664" type="volume">382</part>
: 
<pagination id="B28A6BE35E27FF8DFB00EBADFB2B31F1" box="[1195,1252,1202,1221]" pageId="10" pageNumber="664" type="pagination">722–5</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8DFCE4EBD2FB003022" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCE4EBD2FB003022" _evidence="authorListStart.regEx.txt" author="Liu R &amp; Paxton WA &amp; Choe S" journalOrPublisher="Cell" pageId="10" pageNumber="664" pagination="367 - 77" part="86" title="Homozygous defect in HIV- 1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV- 1 infection" type="journal article" year="1996">
9. 
<bibRef id="52E301E15E27FF8DFCC2EBD2FB003022" _evidence="authorListStart.regEx.txt" pageId="10" pageNumber="664" type="journal article">
<author id="53FE7DF25E27FF8DFCC2EBD2FC5231D4" box="[873,925,1229,1248]" fns="I" npo="LF" pageId="10" pageNumber="664">Liu R</author>
, 
<author id="53FE7DF25E27FF8DFC03EBD2FBC031D4" box="[936,1039,1229,1248]" fns="I" npo="LF" pageId="10" pageNumber="664">Paxton WA</author>
, 
<author id="53FE7DF25E27FF8DFBB1EBD2FB9331D4" box="[1050,1116,1229,1248]" fns="I" npo="LF" pageId="10" pageNumber="664">Choe S</author>
, et al. 
<title id="F9477E215E27FF8DFB30EBD2FBC13022" pageId="10" pageNumber="664">Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection</title>
. 
<journalOrPublisher id="51829FDB5E27FF8DFBBCEA1CFBF63022" box="[1047,1081,1283,1302]" pageId="10" pageNumber="664">Cell</journalOrPublisher>
<year id="FFEBD4445E27FF8DFBEBEA1CFBA53022" box="[1088,1130,1283,1302]" pageId="10" pageNumber="664">
<!--emphasis removed-->1996
</year>
; 
<part id="FFE73F8A5E27FF8DFBC6EA1CFB4C3022" box="[1133,1155,1283,1302]" pageId="10" pageNumber="664" type="volume">86</part>
: 
<pagination id="B28A6BE35E27FF8DFB2DEA1CFB033022" box="[1158,1228,1283,1302]" pageId="10" pageNumber="664" type="pagination">367–77</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8DFCEEEA01FB2A307F" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCEEEA01FB2A307F" _evidence="numberAuthorListStart.regEx.txt" author="Zinkernagel RM." journalOrPublisher="Curr Opin Immunol" pageId="10" pageNumber="664" pagination="462 - 70" part="7" title="Are HIV-specifi CTL responses salutary or pathogenic" type="journal article" year="1995">
10. 
<bibRef id="52E301E15E27FF8DFCC2EA01FB2A307F" _evidence="numberAuthorListStart.regEx.txt" pageId="10" pageNumber="664" type="journal article">
<author id="53FE7DF25E27FF8DFCC2EA01FC313005" box="[873,1022,1310,1329]" fns="I" npo="LF" pageId="10" pageNumber="664">Zinkernagel RM.</author>
<title id="F9477E215E27FF8DFBAFEA01FC59307F" pageId="10" pageNumber="664">Are HIV-specifi CTL responses salutary or pathogenic</title>
? 
<journalOrPublisher id="51829FDB5E27FF8DFC0FEA27FB96307F" box="[932,1113,1336,1355]" pageId="10" pageNumber="664">Curr Opin Immunol</journalOrPublisher>
<year id="FFEBD4445E27FF8DFBCBEA27FB45307F" box="[1120,1162,1336,1355]" pageId="10" pageNumber="664">
<!--emphasis removed-->1995
</year>
; 
<part id="FFE73F8A5E27FF8DFB26EA27FB58307F" box="[1165,1175,1336,1355]" pageId="10" pageNumber="664" type="volume">7</part>
: 
<pagination id="B28A6BE35E27FF8DFB31EA27FB2E307F" box="[1178,1249,1336,1355]" pageId="10" pageNumber="664" type="pagination">462–70</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8DFCEEEA4BFC6230B5" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCEEEA4BFC6230B5" _evidence="authorListStart.regEx.txt" author="McMichael AJ &amp; Hanke T. HIV" journalOrPublisher="Nat Med" pageId="10" pageNumber="664" pagination="874 - 80" part="9" title="vaccines 1983 - 2003" type="journal article" year="2003">
11. 
<bibRef id="52E301E15E27FF8DFCC2EA4BFC6230B5" _evidence="authorListStart.regEx.txt" pageId="10" pageNumber="664" type="journal article">
<author id="53FE7DF25E27FF8DFCC2EA4BFC273053" box="[873,1000,1364,1383]" fns="I" npo="LF" pageId="10" pageNumber="664">McMichael AJ</author>
, 
<author id="53FE7DF25E27FF8DFC59EA4BFBBF3053" box="[1010,1136,1364,1383]" fns="I" npo="LF" pageId="10" pageNumber="664">Hanke T. HIV</author>
<title id="F9477E215E27FF8DFBDCEA4BFAEB3053" box="[1143,1316,1364,1383]" jopScore="0.34602413" pageId="10" pageNumber="664">vaccines 1983–2003</title>
. 
<journalOrPublisher id="51829FDB5E27FF8DFA86EA4BFAB43053" box="[1325,1403,1364,1383]" jopScore="1.3840965" pageId="10" pageNumber="664">Nat Med</journalOrPublisher>
<year id="FFEBD4445E27FF8DFA29EA4BFA633053" box="[1410,1452,1364,1383]" pageId="10" pageNumber="664">
<!--emphasis removed-->2003
</year>
; 
<part id="FFE73F8A5E27FF8DFA1AEA4BFA0D3053" box="[1457,1474,1364,1383]" pageId="10" pageNumber="664" type="volume">9</part>
: 
<pagination id="B28A6BE35E27FF8DFCC2EA71FC6630B5" box="[873,937,1390,1409]" pageId="10" pageNumber="664" type="pagination">874–80</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8DFCEEEA95FB3E30E6" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCEEEA95FB3E30E6" _evidence="authorListStart.regEx.txt" author="Berman PW &amp; Gregory TJ &amp; Riddle L" journalOrPublisher="Nature" pageId="10" pageNumber="664" pagination="622 - 5" part="345" title="Protection of chimpanzeesfrom infection by HIV- 1 after vaccination with recombinant glycoprotein gp 120 but not gp 160" type="journal article" year="1990">
12. 
<bibRef id="52E301E15E27FF8DFCC3EA95FB3E30E6" _evidence="authorListStart.regEx.txt" pageId="10" pageNumber="664" type="journal article">
<author id="53FE7DF25E27FF8DFCC3EA95FC0030A9" box="[872,975,1418,1437]" fns="I" npo="LF" pageId="10" pageNumber="664">Berman PW</author>
, 
<author id="53FE7DF25E27FF8DFC7CEA95FBFA30A9" box="[983,1077,1418,1437]" fns="I" npo="LF" pageId="10" pageNumber="664">Gregory TJ</author>
, 
<author id="53FE7DF25E27FF8DFB95EA95FB4930A9" box="[1086,1158,1418,1437]" fns="I" npo="LF" pageId="10" pageNumber="664">Riddle L</author>
, et al. 
<title id="F9477E215E27FF8DFB11EA95FBD330E6" pageId="10" pageNumber="664">Protection of chimpanzeesfrom infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160</title>
. 
<journalOrPublisher id="51829FDB5E27FF8DFB8EEAA0FB9030E6" box="[1061,1119,1471,1490]" pageId="10" pageNumber="664">Nature</journalOrPublisher>
<year id="FFEBD4445E27FF8DFBCDEAA0FB4030E6" box="[1126,1167,1471,1490]" pageId="10" pageNumber="664">
<!--emphasis removed-->1990
</year>
; 
<part id="FFE73F8A5E27FF8DFB39EAA0FB7C30E6" box="[1170,1203,1471,1490]" pageId="10" pageNumber="664" type="volume">345</part>
: 
<pagination id="B28A6BE35E27FF8DFB1EEAA0FB2130E6" box="[1205,1262,1471,1490]" pageId="10" pageNumber="664" type="pagination">622–5</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8DFCEEEAC5FC3C3317" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCEEEAC5FC3C3317" _evidence="bridged" author="el Amad Z &amp; Murthy KK &amp; Higgins K" journalOrPublisher="AIDS" pageId="10" pageNumber="664" pagination="1313 - 22" part="9" title="Resistance of chimpanzees immunized with recombinant gp 120 SF 2 to challenge byHIV- 1 SF 2" type="journal article" year="1995">
13. 
<author id="53FE7DF25E27FF8DFCC3EAC5FC0630D9" box="[872,969,1498,1517]" fns="I" npo="LF" pageId="10" pageNumber="664">el Amad Z</author>
, 
<author id="53FE7DF25E27FF8DFC7EEAC5FBF330D9" box="[981,1084,1498,1517]" fns="I" npo="LF" pageId="10" pageNumber="664">Murthy KK</author>
, 
<author id="53FE7DF25E27FF8DFBE3EAC5FB6E30D9" box="[1096,1185,1498,1517]" fns="I" npo="LF" pageId="10" pageNumber="664">Higgins K</author>
, et al. 
<title id="F9477E215E27FF8DFB4AEAC5FA42333C" pageId="10" pageNumber="664">Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge byHIV-1SF2</title>
. 
<journalOrPublisher id="51829FDB5E27FF8DFA3BEAEAFA0C333C" box="[1424,1475,1525,1544]" pageId="10" pageNumber="664">AIDS</journalOrPublisher>
<year id="FFEBD4445E27FF8DFCC3E90FFC5E3317" box="[872,913,1552,1571]" pageId="10" pageNumber="664">
<!--emphasis removed-->1995
</year>
; 
<part id="FFE73F8A5E27FF8DFC3FE90FFC513317" box="[916,926,1552,1571]" pageId="10" pageNumber="664" type="volume">9</part>
: 
<pagination id="B28A6BE35E27FF8DFC0AE90FFC203317" box="[929,1007,1552,1571]" pageId="10" pageNumber="664" type="pagination">1313–22</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8DFCEEE934FC5933BA" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCEEE934FC5933BA" _evidence="authorListStart.regEx.txt" author="Berman PW &amp; Murthy KK &amp; Wrin T" journalOrPublisher="J Infect Dis" pageId="10" pageNumber="664" pagination="52 - 9" part="173" title="Protection of MN-rgp 120 - immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficienc virus type 1" type="journal article" year="1996">
14. 
<author id="53FE7DF25E27FF8DFCC3E934FC1B330A" box="[872,980,1579,1598]" fns="I" npo="LF" pageId="10" pageNumber="664">Berman PW</author>
, 
<author id="53FE7DF25E27FF8DFC4AE934FB86330A" box="[993,1097,1579,1598]" fns="I" npo="LF" pageId="10" pageNumber="664">Murthy KK</author>
, 
<author id="53FE7DF25E27FF8DFBFEE934FB58330A" box="[1109,1175,1579,1598]" fns="I" npo="LF" pageId="10" pageNumber="664">Wrin T</author>
, et al. 
<title id="F9477E215E27FF8DFB71E934FACD3340" jopScore="0.33578706" pageId="10" pageNumber="664">Protection of MN-rgp120– immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficienc virus type 1</title>
. 
<journalOrPublisher id="51829FDB5E27FF8DFAA7E97EFAA53340" box="[1292,1386,1633,1652]" jopScore="1.1453109" pageId="10" pageNumber="664">J Infect Dis</journalOrPublisher>
<year id="FFEBD4445E27FF8DFAC4E97EFA573340" box="[1391,1432,1633,1652]" pageId="10" pageNumber="664">
<!--emphasis removed-->1996
</year>
; 
<part id="FFE73F8A5E27FF8DFA37E97EFA0F3340" box="[1436,1472,1633,1652]" pageId="10" pageNumber="664" type="volume">173</part>
: 
<pagination id="B28A6BE35E27FF8DFCC3E964FC5C33BA" box="[872,915,1659,1678]" pageId="10" pageNumber="664" type="pagination">52–9</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8DFCEEE988FB5933CE" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCEEE988FB5933CE" _evidence="authorListStart.regEx.txt" author="Belshe RB &amp; Graham BS &amp; Keefer MC" journalOrPublisher="JAMA" pageId="10" pageNumber="664" pagination="475 - 80" part="272" title="Neutralizing antibodies to HIV- 1 in seronegative volunteers immunized with recombinant gp 120 from the MN strain of HIV- 1. NIAID AIDS Vaccine Clinical Trials Network" type="journal article" year="1994">
15. 
<author id="53FE7DF25E27FF8DFCC2E988FC0C339E" box="[873,963,1687,1706]" fns="I" npo="LF" pageId="10" pageNumber="664">Belshe RB</author>
, 
<author id="53FE7DF25E27FF8DFC65E988FBFA339E" box="[974,1077,1687,1706]" fns="I" npo="LF" pageId="10" pageNumber="664">Graham BS</author>
, 
<author id="53FE7DF25E27FF8DFBEBE988FB6D339E" box="[1088,1186,1687,1706]" fns="I" npo="LF" pageId="10" pageNumber="664">Keefer MC</author>
, et al. 
<title id="F9477E215E27FF8DFB4BE988FC7933CE" jopScore="0.07883836" pageId="10" pageNumber="664">Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network</title>
. 
<journalOrPublisher id="51829FDB5E27FF8DFC6BE9F8FC3A33CE" box="[960,1013,1767,1786]" jopScore="3.0788383" pageId="10" pageNumber="664">JAMA</journalOrPublisher>
<year id="FFEBD4445E27FF8DFC57E9F8FBE933CE" box="[1020,1062,1767,1786]" pageId="10" pageNumber="664">
<!--emphasis removed-->1994
</year>
; 
<part id="FFE73F8A5E27FF8DFB82E9F8FB8433CE" box="[1065,1099,1767,1786]" pageId="10" pageNumber="664" type="volume">272</part>
: 
<pagination id="B28A6BE35E27FF8DFBE5E9F8FB5D33CE" box="[1102,1170,1767,1786]" pageId="10" pageNumber="664" type="pagination">475–80</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8DFCEEE81DFB37327F" blockId="10.[837,1477,613,1894]" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8DFCEEE81DFB37327F" _evidence="authorListStart.regEx.txt" author="Pitisuttithum P &amp; Berman PW &amp; Phonrat B" journalOrPublisher="J Acquir Immune Defi Syndr" pageId="10" pageNumber="664" pagination="1160 - 5" part="37" title="Phase I / II study of a candidate vaccine designed against the B and E subtypes of HIV- 1" type="journal article" year="2004">
16. 
<author id="53FE7DF25E27FF8DFCC2E81DFC213221" box="[873,1006,1794,1813]" fns="I" npo="LF" pageId="10" pageNumber="664">Pitisuttithum P</author>
, 
<author id="53FE7DF25E27FF8DFC51E81DFBA93221" box="[1018,1126,1794,1813]" fns="I" npo="LF" pageId="10" pageNumber="664">Berman PW</author>
, 
<author id="53FE7DF25E27FF8DFBDAE81DFB023221" box="[1137,1229,1794,1813]" fns="I" npo="LF" pageId="10" pageNumber="664">Phonrat B</author>
, et al. 
<title id="F9477E215E27FF8DFAA7E81DFA7D3204" pageId="10" pageNumber="664">Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1</title>
. 
<journalOrPublisher id="51829FDB5E27FF8DFA10E802FBAE327F" pageId="10" pageNumber="664">J Acquir Immune Defi Syndr</journalOrPublisher>
<year id="FFEBD4445E27FF8DFBC2E827FB5C327F" box="[1129,1171,1848,1867]" pageId="10" pageNumber="664">
<!--emphasis removed-->2004
</year>
; 
<part id="FFE73F8A5E27FF8DFB3DE827FB62327F" box="[1174,1197,1848,1867]" pageId="10" pageNumber="664" type="volume">37</part>
: 
<pagination id="B28A6BE35E27FF8DFB04E827FB3B327F" box="[1199,1268,1848,1867]" pageId="10" pageNumber="664" type="pagination">1160–5</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E27FF8CFCEEE84CFDD835F6" blockId="10.[837,1477,613,1894]" lastBlockId="11.[151,791,148,1496]" lastPageId="11" lastPageNumber="14" pageId="10" pageNumber="664">
<bibRef id="52E301E15E27FF8CFCEEE84CFDD835F6" _evidence="authorListStart.regEx.txt" author="Francis DP &amp; Gregory T &amp; McElrath MJ" journalOrPublisher="AIDS Res Hum Retroviruses" lastPageId="11" lastPageNumber="14" pageId="10" pageNumber="664" pagination="325 - 31" part="14" title="Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3" type="journal article" year="1998">
17. 
<author id="53FE7DF25E27FF8DFCC2E84CFC053252" box="[873,970,1875,1894]" fns="I" npo="LF" pageId="10" pageNumber="664">Francis DP</author>
, 
<author id="53FE7DF25E27FF8DFC7EE84CFBFE3252" box="[981,1073,1875,1894]" fns="I" npo="LF" pageId="10" pageNumber="664">Gregory T</author>
, 
<author id="53FE7DF25E27FF8DFB97E84CFB7E3252" box="[1084,1201,1875,1894]" fns="I" npo="LF" pageId="10" pageNumber="664">McElrath MJ</author>
, et al. 
<title id="F9477E215E27FF8CFB5BE84CFD443593" jopScore="0.36606675" lastPageId="11" lastPageNumber="14" pageId="10" pageNumber="664">Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFD38EF8BFEEA35F6" jopScore="0.83481675" pageId="11" pageNumber="14" type="_" typeScore="100">AIDS Res Hum Retroviruses</journalOrPublisher>
<!--emphasis removed-->
<year id="FFEBD4445E26FF8CFE87EFB0FE9935F6" box="[300,342,175,194]" pageId="11" pageNumber="14">1998</year>

; 
<pageNumber id="BBE89EC15E26FF8CFEF2EFB0FEA135F6" ambiguity="1" box="[345,366,175,194]" fuzzyness="0" pageId="11" pageNumber="14" score="3.0" value="14">
<part id="FFE73F8A5E26FF8CFEF2EFB0FEA135F6" box="[345,366,175,194]" pageId="11" pageNumber="14" type="volume">14</part>
</pageNumber>
(Suppl 3):S 
<pagination id="B28A6BE35E26FF8CFE7BEFB0FDDC35F6" box="[464,531,175,194]" pageId="11" pageNumber="14" type="pagination">325–31</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEFD6FDF13425" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEFD6FDF13425" _evidence="authorListStart.regEx.txt" author="Berman PW &amp; Huang W &amp; Riddle L" journalOrPublisher="Virology" pageId="11" pageNumber="14" pagination="1 - 9" part="265" title="Development of bivalent (B / E) vaccines able to neutralize CCR 5 - dependent viruses fromtheUnited States and Thailand" type="journal article" year="1999">
18. 
<author id="53FE7DF25E26FF8CFF17EFD6FEE835E8" box="[188,295,201,220]" fns="I" npo="LF" pageId="11" pageNumber="14">Berman PW</author>
, 
<author id="53FE7DF25E26FF8CFE9AEFD6FE4835E8" box="[305,391,201,220]" fns="I" npo="LF" pageId="11" pageNumber="14">Huang W</author>
, 
<author id="53FE7DF25E26FF8CFE39EFD6FE1135E8" box="[402,478,201,220]" fns="I" npo="LF" pageId="11" pageNumber="14">Riddle L</author>
, et al. 
<title id="F9477E215E26FF8CFDB0EFD6FEA53425" jopScore="0.1653618" pageId="11" pageNumber="14">Development of bivalent (B/ E) vaccines able to neutralize CCR5-dependent viruses fromtheUnited States and Thailand</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFED8EFE1FE733425" box="[371,444,254,273]" jopScore="2.165362" pageId="11" pageNumber="14">Virology</journalOrPublisher>
<year id="FFEBD4445E26FF8CFE68EFE1FE223425" box="[451,493,254,273]" pageId="11" pageNumber="14">
<!--emphasis removed-->1999
</year>
; 
<part id="FFE73F8A5E26FF8CFE5AEFE1FDD83425" box="[497,535,254,273]" pageId="11" pageNumber="14" type="volume">265</part>
: 
<pagination id="B28A6BE35E26FF8CFDB2EFE1FDF53425" box="[537,570,254,273]" pageId="11" pageNumber="14" type="pagination">1–9</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEE06FD173455" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEE06FD173455" _evidence="authorListStart.regEx.txt" author="Harro CD &amp; Judson FN &amp; Gorse GJ" journalOrPublisher="J Acquir Immune Defi Syndr" pageId="11" pageNumber="14" pagination="1385 - 92" part="37" title="Recruitment and baseline epidemiologic profil of participants in the firs phase 3 HIV vaccine efficac trial" type="journal article" year="2004">
19. 
<author id="53FE7DF25E26FF8CFF17EE06FED93418" box="[188,278,281,300]" fns="I" npo="LF" pageId="11" pageNumber="14">Harro CD</author>
, 
<author id="53FE7DF25E26FF8CFE8BEE06FE4F3418" box="[288,384,281,300]" fns="I" npo="LF" pageId="11" pageNumber="14">Judson FN</author>
, 
<author id="53FE7DF25E26FF8CFE21EE06FE143418" box="[394,475,281,300]" fns="I" npo="LF" pageId="11" pageNumber="14">Gorse GJ</author>
, et al. 
<title id="F9477E215E26FF8CFDBDEE06FEE83455" pageId="11" pageNumber="14">Recruitment and baseline epidemiologic profil of participants in the firs phase 3 HIV vaccine efficac trial</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFE9BEE51FDF83455" box="[304,567,334,353]" pageId="11" pageNumber="14">J Acquir Immune Defi Syndr</journalOrPublisher>
<year id="FFEBD4445E26FF8CFD94EE51FDA63455" box="[575,617,334,353]" pageId="11" pageNumber="14">
<!--emphasis removed-->2004
</year>
; 
<part id="FFE73F8A5E26FF8CFDC7EE51FD4D3455" box="[620,642,334,353]" pageId="11" pageNumber="14" type="volume">37</part>
: 
<pagination id="B28A6BE35E26FF8CFD2FEE51FD1B3455" box="[644,724,334,353]" pageId="11" pageNumber="14" type="pagination">1385–92</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEE76FE4F3485" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEE76FE4F3485" _evidence="authorListStart.regEx.txt" author="Francis DP &amp; Heyward WL &amp; Popovic V" journalOrPublisher="AIDS" pageId="11" pageNumber="14" pagination="147 - 56" part="17" title="Candidate HIV / AIDS vaccines: lessons learned from the world's firs phase III efficac trials" type="journal article" year="2003">
20. 
<author id="53FE7DF25E26FF8CFF17EE76FED43448" box="[188,283,361,380]" fns="I" npo="LF" pageId="11" pageNumber="14">Francis DP</author>
, 
<author id="53FE7DF25E26FF8CFE8FEE76FE563448" box="[292,409,361,380]" fns="I" npo="LF" pageId="11" pageNumber="14">Heyward WL</author>
, 
<author id="53FE7DF25E26FF8CFE09EE76FE333448" box="[418,508,361,380]" fns="I" npo="LF" pageId="11" pageNumber="14">Popovic V</author>
, et al. 
<title id="F9477E215E26FF8CFD9FEE76FCDC34A2" pageId="11" pageNumber="14">Candidate HIV/AIDS vaccines: lessons learned from the world’s firs phase III efficac trials</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFF10EE81FF263485" box="[187,233,414,433]" pageId="11" pageNumber="14">AIDS</journalOrPublisher>
<year id="FFEBD4445E26FF8CFF5AEE81FED43485" box="[241,283,414,433]" pageId="11" pageNumber="14">
<!--emphasis removed-->2003
</year>
; 
<part id="FFE73F8A5E26FF8CFEB5EE81FEFC3485" box="[286,307,414,433]" pageId="11" pageNumber="14" type="volume">17</part>
: 
<pagination id="B28A6BE35E26FF8CFE9DEE81FEB23485" box="[310,381,414,433]" pageId="11" pageNumber="14" type="pagination">147–56</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEEA7FEFF3764" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEEA7FEFF3764" _evidence="authorListStart.regEx.txt" author="Peterson ML &amp; Good JW &amp; Zaharias EM" journalOrPublisher="Alexandria, VA: Foundation for Retrovirology and Human Health" pageId="11" pageNumber="14" title="Development of a novel assay to measure antigen-specifi immune responses to multivalent vaccines for HIV- 1 [abstract 769]" type="book" volumeTitle="Program and abstracts of the 7 th Conference on Retroviruses and Opportunistic Infections (San Francisco)" year="2000">
21. 
<author id="53FE7DF25E26FF8CFF10EEA7FEE234FF" box="[187,301,440,459]" fns="I" npo="LF" pageId="11" pageNumber="14">Peterson ML</author>
, 
<author id="53FE7DF25E26FF8CFE93EEA7FE4434FF" box="[312,395,440,459]" fns="I" npo="LF" pageId="11" pageNumber="14">Good JW</author>
, 
<author id="53FE7DF25E26FF8CFE3EEEA7FDC834FF" box="[405,519,440,459]" fns="I" npo="LF" pageId="11" pageNumber="14">Zaharias EM</author>
, et al. 
<title id="F9477E215E26FF8CFDE8EEA7FE283735" jopScore="0.051271923" pageId="11" pageNumber="14">Development of a novel assay to measure antigen-specifi immune responses to multivalent vaccines for HIV-1 [abstract 769]</title>
. In: 
<volumeTitle id="34EFF7275E26FF8CFDB8EEF1FED83702" jopScore="0.24407893" pageId="11" pageNumber="14">Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco)</volumeTitle>
. 
<journalOrPublisher id="51829FDB5E26FF8CFE8BED3CFF383764" jopScore="0.6329464" pageId="11" pageNumber="14">Alexandria, VA: Foundation for Retrovirology and Human Health</journalOrPublisher>
, 
<year id="FFEBD4445E26FF8CFEAAED22FEE43764" box="[257,299,573,592]" pageId="11" pageNumber="14">
<!--emphasis removed-->2000
</year>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CED47FDA6378F" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CED47FDA6378F" _evidence="authorListStart.regEx.txt" author="Gilbert PB &amp; Peterson ML &amp; Follmann D" journalOrPublisher="J Infect Dis" pageId="11" pageNumber="14" pagination="666 - 77" part="191" title="Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV- 1 infection in a phase 3 HIV- 1 preventive vaccine trial" type="journal article" year="2005">
22. 
<author id="53FE7DF25E26FF8CFF10ED47FED6375F" box="[187,281,600,619]" fns="I" npo="LF" pageId="11" pageNumber="14">Gilbert PB</author>
, 
<author id="53FE7DF25E26FF8CFE88ED47FE5C375F" box="[291,403,600,619]" fns="I" npo="LF" pageId="11" pageNumber="14">Peterson ML</author>
, 
<author id="53FE7DF25E26FF8CFE36ED47FDC8375F" box="[413,519,600,619]" fns="I" npo="LF" pageId="11" pageNumber="14">Follmann D</author>
, et al. 
<title id="F9477E215E26FF8CFDE9ED47FF2F378F" jopScore="0.037464477" pageId="11" pageNumber="14">Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFF41EDB7FE81378F" box="[234,334,680,699]" jopScore="0.8469883" pageId="11" pageNumber="14">J Infect Dis</journalOrPublisher>
<!--emphasis removed-->
<year id="FFEBD4445E26FF8CFEFEEDB7FEB0378F" box="[341,383,680,699]" pageId="11" pageNumber="14">2005</year>

: 
<part id="FFE73F8A5E26FF8CFE2AEDB7FE6E378F" box="[385,417,680,699]" pageId="11" pageNumber="14" type="volume">191</part>
: 
<pagination id="B28A6BE35E26FF8CFE0FEDB7FE2A378F" box="[420,485,680,699]" pageId="11" pageNumber="14" type="pagination">666-77</pagination>
(in this issue).
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEDDDFE0A37C4" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEDDDFE0A37C4" _evidence="numberAuthorListStart.regEx.txt" author="Allison PD." journalOrPublisher="Cary, NC: SAS Institute" pageId="11" pageNumber="14" title="Survival analysis using the SAS system: a practical guide" type="book" year="1995">
23. 
<author id="53FE7DF25E26FF8CFF10EDDDFEEE37E1" box="[187,289,706,725]" fns="I" npo="LF" pageId="11" pageNumber="14">Allison PD.</author>
<title id="F9477E215E26FF8CFE8CEDDDFCDD37E1" box="[295,786,706,725]" jopScore="0.06900192" pageId="11" pageNumber="14">Survival analysis using the SAS system: a practical guide</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFF10EDC2FE4237C4" box="[187,397,733,752]" jopScore="2.5800314" pageId="11" pageNumber="14">Cary, NC: SAS Institute</journalOrPublisher>
, 
<!--emphasis removed-->
<year id="FFEBD4445E26FF8CFE3CEDC2FE0E37C4" box="[407,449,733,752]" pageId="11" pageNumber="14">1995</year>

.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEDE8FE623611" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEDE8FE623611" _evidence="numberAuthorListStart.regEx.txt" author="Bristol DR." journalOrPublisher="J Biopharm Stat" pageId="11" pageNumber="14" pagination="313 - 21" part="7" title="p-value adjustments for subgroup analyses" type="journal article" year="1997">
24. 
<author id="53FE7DF25E26FF8CFF10EDE8FEEF363E" box="[187,288,759,778]" fns="I" npo="LF" pageId="11" pageNumber="14">Bristol DR.</author>
<title id="F9477E215E26FF8CFE83EDE8FD6A363E" box="[296,677,759,778]" jopScore="0.017620578" pageId="11" pageNumber="14">p-value adjustments for subgroup analyses</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFD1BEDE8FF133611" jopScore="0.09337816" pageId="11" pageNumber="14">J Biopharm Stat</journalOrPublisher>
<!--emphasis removed-->
<year id="FFEBD4445E26FF8CFF48EC0DFEC23611" box="[227,269,786,805]" pageId="11" pageNumber="14">1997</year>

; 
<part id="FFE73F8A5E26FF8CFEBBEC0DFED53611" box="[272,282,786,805]" pageId="11" pageNumber="14" type="volume">7</part>
: 
<pagination id="B28A6BE35E26FF8CFEB6EC0DFEAF3611" box="[285,352,786,805]" pageId="11" pageNumber="14" type="pagination">313–21</pagination>
/323–31.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEC33FCD8366E" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEC33FCD8366E" _evidence="authorListStart.regEx.txt" author="Pollard KS &amp; van der Laan MJ." journalOrPublisher="J Statist Plann Inference" pageId="11" pageNumber="14" pagination="85 - 100" part="125" title="Choice of a null distribution in resampling-based multiple testing" type="journal article" year="2004">
25. 
<author id="53FE7DF25E26FF8CFF10EC33FED5360B" box="[187,282,812,831]" fns="I" npo="LF" pageId="11" pageNumber="14">Pollard KS</author>
, 
<author id="53FE7DF25E26FF8CFE8EEC33FE71360B" box="[293,446,812,831]" fns="I" npo="LF" pageId="11" pageNumber="14">van der Laan MJ.</author>
<title id="F9477E215E26FF8CFE6FEC33FE65366E" pageId="11" pageNumber="14">Choice of a null distribution in resampling-based multiple testing</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFE1AEC58FDB5366E" box="[433,634,839,858]" pageId="11" pageNumber="14">J Statist Plann Inference</journalOrPublisher>
<year id="FFEBD4445E26FF8CFDD5EC58FD67366E" box="[638,680,839,858]" pageId="11" pageNumber="14">
<!--emphasis removed-->2004
</year>
; 
<part id="FFE73F8A5E26FF8CFD00EC58FD03366E" box="[683,716,839,858]" pageId="11" pageNumber="14" type="volume">125</part>
: 
<pagination id="B28A6BE35E26FF8CFD64EC58FCDC366E" box="[719,787,839,858]" pageId="11" pageNumber="14" type="pagination">85–100</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEC7DFE5F36BB" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEC7DFE5F36BB" _evidence="authorListStart.regEx.txt" author="Lunn M &amp; McNeil D." journalOrPublisher="Biometrics" pageId="11" pageNumber="14" pagination="524 - 32" part="51" title="Applying Cox regression to competing risks" type="journal article" year="1995">
26. 
<bibRef id="52E301E15E26FF8CFF10EC7DFE5F36BB" _evidence="authorListStart.regEx.txt" pageId="11" pageNumber="14" type="journal article">
<author id="53FE7DF25E26FF8CFF10EC7DFECA3641" box="[187,261,866,885]" fns="I" npo="LF" pageId="11" pageNumber="14">Lunn M</author>
, 
<author id="53FE7DF25E26FF8CFEA5EC7DFEA63641" box="[270,361,866,885]" fns="I" npo="LF" pageId="11" pageNumber="14">McNeil D.</author>
<title id="F9477E215E26FF8CFEC4EC7DFD263641" box="[367,745,866,885]" pageId="11" pageNumber="14">Applying Cox regression to competing risks</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFD5BEC7DFF3536BB" pageId="11" pageNumber="14">Biometrics</journalOrPublisher>
<!--emphasis removed-->
<year id="FFEBD4445E26FF8CFEAAEC63FEE436BB" box="[257,299,892,911]" pageId="11" pageNumber="14">1995</year>

; 
<part id="FFE73F8A5E26FF8CFE85EC63FE8C36BB" box="[302,323,892,911]" pageId="11" pageNumber="14" type="volume">51</part>
: 
<pagination id="B28A6BE35E26FF8CFEEDEC63FE4336BB" box="[326,396,892,911]" pageId="11" pageNumber="14" type="pagination">524–32</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEC88FE3C3120" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEC88FE3C3120" _evidence="authorListStart.regEx.txt" author="Choopanya K &amp; Tappero JW &amp; Pitisuttithum P" journalOrPublisher="(Bangkok, Thailand). Bangkok, Thailand: Clung Wicha Press" pageId="11" pageNumber="14" pagination="2004" title="Preliminary results of a phase III HIV vaccine efficac trial among injecting drug users in Thailand [abstract ThOrA 1427]" type="book chapter" volumeTitle="Program and abstracts of the XV International AIDS Conference" year="2004">
27. 
<bibRef id="52E301E15E26FF8CFF10EC88FE3C3120" _evidence="authorListStart.regEx.txt" pageId="11" pageNumber="14" type="book chapter">
<author id="53FE7DF25E26FF8CFF10EC88FEFA369E" box="[187,309,919,938]" fns="I" npo="LF" pageId="11" pageNumber="14">Choopanya K</author>
, 
<author id="53FE7DF25E26FF8CFE94EC88FE67369E" box="[319,424,919,938]" fns="I" npo="LF" pageId="11" pageNumber="14">Tappero JW</author>
, 
<author id="53FE7DF25E26FF8CFE19EC88FDF8369E" box="[434,567,919,938]" fns="I" npo="LF" pageId="11" pageNumber="14">Pitisuttithum P</author>
, et al. 
<title id="F9477E215E26FF8CFDD8EC88FE1E36EB" jopScore="0.03397733" pageId="11" pageNumber="14">Preliminary results of a phase III HIV vaccine efficac trial among injecting drug users in Thailand [abstract ThOrA1427]</title>
. In: 
<volumeTitle id="34EFF7275E26FF8CFE52ECD3FE0236CD" jopScore="0.28379244" pageId="11" pageNumber="14">Program and abstracts of the XV International AIDS Conference</volumeTitle>
<year id="FFEBD4445E26FF8CFE7EECF9FE3136CD" box="[469,510,998,1017]" pageId="11" pageNumber="14">2004</year>
<journalOrPublisher id="51829FDB5E26FF8CFDAEECF9FE743120" jopScore="3.0610995" pageId="11" pageNumber="14">(Bangkok, Thailand). Bangkok, Thailand: Clung Wicha Press</journalOrPublisher>
, 
<pagination id="B28A6BE35E26FF8CFE6FEB1EFE213120" box="[452,494,1025,1044]" pageId="11" pageNumber="14" type="pagination">
<!--emphasis removed-->2004
</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEB04FD1C317D" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEB04FD1C317D" _evidence="numberAuthorListStart.regEx.txt" author="Morens DM." journalOrPublisher="Clin Infect Dis" pageId="11" pageNumber="14" pagination="500 - 12" part="19" title="Antibody-dependent enhancement of infection and the pathogenesis of viral disease" type="journal article" year="1994">
28. 
<bibRef id="52E301E15E26FF8CFF10EB04FD1C317D" _evidence="numberAuthorListStart.regEx.txt" pageId="11" pageNumber="14" type="journal article">
<author id="53FE7DF25E26FF8CFF10EB04FEE2311A" box="[187,301,1051,1070]" fns="I" npo="LF" pageId="11" pageNumber="14">Morens DM.</author>
<title id="F9477E215E26FF8CFE9FEB04FE7D317D" pageId="11" pageNumber="14">Antibody-dependent enhancement of infection and the pathogenesis of viral disease</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFE10EB29FDF2317D" box="[443,573,1078,1097]" pageId="11" pageNumber="14">Clin Infect Dis</journalOrPublisher>
<year id="FFEBD4445E26FF8CFDEFEB29FDA1317D" box="[580,622,1078,1097]" pageId="11" pageNumber="14">
<!--emphasis removed-->1994
</year>
; 
<part id="FFE73F8A5E26FF8CFDDAEB29FD49317D" box="[625,646,1078,1097]" pageId="11" pageNumber="14" type="volume">19</part>
: 
<pagination id="B28A6BE35E26FF8CFD22EB29FD00317D" box="[649,719,1078,1097]" pageId="11" pageNumber="14" type="pagination">500–12</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEB4EFCC2314A" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEB4EFCC2314A" _evidence="numberAuthorListStart.regEx.txt" author="Burke DS." journalOrPublisher="Perspect Biol Med" pageId="11" pageNumber="14" pagination="511 - 30" part="35" title="Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk" type="journal article" year="1992">
29. 
<bibRef id="52E301E15E26FF8CFF10EB4EFCC2314A" _evidence="numberAuthorListStart.regEx.txt" pageId="11" pageNumber="14" type="journal article">
<author id="53FE7DF25E26FF8CFF10EB4EFED83150" box="[187,279,1105,1124]" fns="I" npo="LF" pageId="11" pageNumber="14">Burke DS.</author>
<title id="F9477E215E26FF8CFEB5EB4EFE06314A" pageId="11" pageNumber="14">Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk</title>
? 
<journalOrPublisher id="51829FDB5E26FF8CFE73EB74FDB8314A" box="[472,631,1131,1150]" pageId="11" pageNumber="14">Perspect Biol Med</journalOrPublisher>
<year id="FFEBD4445E26FF8CFDD5EB74FD67314A" box="[638,680,1131,1150]" pageId="11" pageNumber="14">
<!--emphasis removed-->1992
</year>
; 
<part id="FFE73F8A5E26FF8CFD00EB74FD0E314A" box="[683,705,1131,1150]" pageId="11" pageNumber="14" type="volume">35</part>
: 
<pagination id="B28A6BE35E26FF8CFD6FEB74FCC6314A" box="[708,777,1131,1150]" pageId="11" pageNumber="14" type="pagination">511–30</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEB99FE4B3187" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEB99FE4B3187" _evidence="numberAuthorListStart.regEx.txt" author="King RT. FDA" journalOrPublisher="Wall Street Journal. 3 June" pageId="11" pageNumber="14" pagination="1" title="allows large-scale trial of AIDS vaccine" type="book chapter" year="1998">
30. 
<bibRef id="52E301E15E26FF8CFF10EB99FE4B3187" _evidence="numberAuthorListStart.regEx.txt" pageId="11" pageNumber="14" type="book chapter">
<author id="53FE7DF25E26FF8CFF10EB99FEF231AD" box="[187,317,1158,1177]" fns="I" npo="LF" pageId="11" pageNumber="14">King RT. FDA</author>
<title id="F9477E215E26FF8CFEEDEB99FD6631AD" box="[326,681,1158,1177]" jopScore="0.045149986" pageId="11" pageNumber="14">allows large-scale trial of AIDS vaccine</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFD1EEB99FEF03187" jopScore="0.52911144" pageId="11" pageNumber="14">Wall Street Journal. 3 June</journalOrPublisher>
<!--emphasis removed-->
<year id="FFEBD4445E26FF8CFEEDEBBFFEBF3187" box="[326,368,1184,1203]" pageId="11" pageNumber="14">1998</year>

: 
<pagination id="B28A6BE35E26FF8CFEDFEBBFFEB03187" box="[372,383,1184,1203]" pageId="11" pageNumber="14" type="pagination">1</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEBA4FD133037" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEBA4FD133037" _evidence="authorListStart.regEx.txt" author="Chesney MA &amp; Chambers D &amp; Kahn JO." journalOrPublisher="J Acquir Immune Defi Syndr Hum Retrovirol" pageId="11" pageNumber="14" pagination="266 - 71" part="16" title="Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note" type="journal article" year="1997">
31. 
<bibRef id="52E301E15E26FF8CFF10EBA4FD133037" _evidence="authorListStart.regEx.txt" pageId="11" pageNumber="14" type="journal article">
<author id="53FE7DF25E26FF8CFF10EBA4FEE231FA" box="[187,301,1211,1230]" fns="I" npo="LF" pageId="11" pageNumber="14">Chesney MA</author>
, 
<author id="53FE7DF25E26FF8CFE9DEBA4FE6B31FA" box="[310,420,1211,1230]" fns="I" npo="LF" pageId="11" pageNumber="14">Chambers D</author>
, 
<author id="53FE7DF25E26FF8CFE05EBA4FE3031FA" box="[430,511,1211,1230]" fns="I" npo="LF" pageId="11" pageNumber="14">Kahn JO.</author>
<title id="F9477E215E26FF8CFDAFEBA4FCCC31DC" pageId="11" pageNumber="14">Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFCA5EBCAFD8A3037" pageId="11" pageNumber="14">J Acquir Immune Defi Syndr Hum Retrovirol</journalOrPublisher>
<year id="FFEBD4445E26FF8CFDE6EBEFFDB83037" box="[589,631,1264,1283]" pageId="11" pageNumber="14">
<!--emphasis removed-->1997
</year>
; 
<part id="FFE73F8A5E26FF8CFDD1EBEFFD403037" box="[634,655,1264,1283]" pageId="11" pageNumber="14" type="volume">16</part>
: 
<pagination id="B28A6BE35E26FF8CFD39EBEFFD173037" box="[658,728,1264,1283]" pageId="11" pageNumber="14" type="pagination">266–71</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEA14FE2C300C" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEA14FE2C300C" _evidence="numberAuthorListStart.regEx.txt" author="Bloom BR." journalOrPublisher="Science" pageId="11" pageNumber="14" pagination="186 - 8" part="279" title="The highest attainable standard: ethical issues in AIDS vaccines" type="journal article" year="1998">
32. 
<bibRef id="52E301E15E26FF8CFF10EA14FE2C300C" _evidence="numberAuthorListStart.regEx.txt" pageId="11" pageNumber="14" type="journal article">
<author id="53FE7DF25E26FF8CFF10EA14FED0302A" box="[187,287,1291,1310]" fns="I" npo="LF" pageId="11" pageNumber="14">Bloom BR.</author>
<title id="F9477E215E26FF8CFE8CEA14FECB300C" pageId="11" pageNumber="14">The highest attainable standard: ethical issues in AIDS vaccines</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFEA6EA3AFE83300C" box="[269,332,1317,1336]" pageId="11" pageNumber="14">Science</journalOrPublisher>
<year id="FFEBD4445E26FF8CFEF8EA3AFEB2300C" box="[339,381,1317,1336]" pageId="11" pageNumber="14">
<!--emphasis removed-->1998
</year>
; 
<part id="FFE73F8A5E26FF8CFE2AEA3AFE6A300C" box="[385,421,1317,1336]" pageId="11" pageNumber="14" type="volume">279</part>
: 
<pagination id="B28A6BE35E26FF8CFE0CEA3AFE10300C" box="[423,479,1317,1336]" pageId="11" pageNumber="14" type="pagination">186–8</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEA5FFE7030BC" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEA5FFE7030BC" _evidence="authorListStart.regEx.txt" author="Ackers M-L &amp; Parekh B &amp; Evans TG" journalOrPublisher="J Infect Dis" pageId="11" pageNumber="14" pagination="879 - 86" part="187" title="Human immunodeficienc virus (HIV) seropositivity among uninfected HIV vaccine recipients" type="journal article" year="2003">
33. 
<bibRef id="52E301E15E26FF8CFF10EA5FFE7030BC" _evidence="authorListStart.regEx.txt" pageId="11" pageNumber="14" type="journal article">
<author id="53FE7DF25E26FF8CFF10EA5FFEE93067" box="[187,294,1344,1363]" fns="I" npo="LF" pageId="11" pageNumber="14">Ackers M-L</author>
, 
<author id="53FE7DF25E26FF8CFE99EA5FFE4B3067" box="[306,388,1344,1363]" fns="I" kam="kam" npo="LF" pageId="11" pageNumber="14">Parekh B</author>
, 
<author id="53FE7DF25E26FF8CFE3AEA5FFE253067" box="[401,490,1344,1363]" fns="I" npo="LF" pageId="11" pageNumber="14">Evans TG</author>
, et al. 
<title id="F9477E215E26FF8CFD80EA5FFCDC3059" pageId="11" pageNumber="14">Human immunodeficienc virus (HIV) seropositivity among uninfected HIV vaccine recipients</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFF10EA6AFED030BC" box="[187,287,1397,1416]" pageId="11" pageNumber="14">J Infect Dis</journalOrPublisher>
<year id="FFEBD4445E26FF8CFE8DEA6AFE9F30BC" box="[294,336,1397,1416]" pageId="11" pageNumber="14">
<!--emphasis removed-->2003
</year>
; 
<part id="FFE73F8A5E26FF8CFEF8EA6AFEBB30BC" box="[339,372,1397,1416]" pageId="11" pageNumber="14" type="volume">187</part>
: 
<pagination id="B28A6BE35E26FF8CFEDDEA6AFE7430BC" box="[374,443,1397,1416]" pageId="11" pageNumber="14" type="pagination">879–86</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFF3CEA90FEC630EC" blockId="11.[151,791,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFF3CEA90FEC630EC" _evidence="authorListStart.regEx.txt" author="Stanberry LR &amp; Spruance SL &amp; Cunningham AL" journalOrPublisher="N Engl J Med" pageId="11" pageNumber="14" pagination="1652 - 61" part="347" title="Glycoprotein-d - adjuvant vaccine to prevent genital herpes" type="journal article" year="2002">
34. 
<bibRef id="52E301E15E26FF8CFF10EA90FEC630EC" _evidence="authorListStart.regEx.txt" pageId="11" pageNumber="14" type="journal article">
<author id="53FE7DF25E26FF8CFF10EA90FEFE3096" box="[187,305,1423,1442]" fns="I" npo="LF" pageId="11" pageNumber="14">Stanberry LR</author>
, 
<author id="53FE7DF25E26FF8CFE97EA90FE643096" box="[316,427,1423,1442]" fns="I" npo="LF" pageId="11" pageNumber="14">Spruance SL</author>
, 
<author id="53FE7DF25E26FF8CFE1EEA90FD853096" box="[437,586,1423,1442]" fns="I" npo="LF" pageId="11" pageNumber="14">Cunningham AL</author>
, et al. 
<title id="F9477E215E26FF8CFD2CEA90FDFA3089" jopScore="0.09759469" pageId="11" pageNumber="14">Glycoprotein-d– adjuvant vaccine to prevent genital herpes</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFD95EAB5FD773089" box="[574,696,1450,1469]" jopScore="0.60759467" pageId="11" pageNumber="14">N Engl J Med</journalOrPublisher>
<year id="FFEBD4445E26FF8CFD15EAB5FD263089" box="[702,745,1450,1469]" pageId="11" pageNumber="14">
<!--emphasis removed-->2002
</year>
; 
<part id="FFE73F8A5E26FF8CFD47EAB5FCDD3089" box="[748,786,1450,1469]" pageId="11" pageNumber="14" type="volume">347</part>
: 
<pagination id="B28A6BE35E26FF8CFF10EADAFECA30EC" box="[187,261,1477,1496]" pageId="11" pageNumber="14" type="pagination">1652–61</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFEF8BFAC335F6" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFEF8BFAC335F6" _evidence="authorListStart.regEx.txt" author="Whitacre CC &amp; Reingold SC &amp; O'Looney PA" journalOrPublisher="Science" pageId="11" pageNumber="14" pagination="1277 - 8" part="283" title="Biomedicine: a gender gap in autoimmunity" type="journal article" year="1999">
35. 
<bibRef id="52E301E15E26FF8CFCC2EF8BFAC335F6" _evidence="authorListStart.regEx.txt" pageId="11" pageNumber="14" type="journal article">
<author id="53FE7DF25E26FF8CFCC2EF8BFC143593" box="[873,987,148,167]" fns="I" npo="LF" pageId="11" pageNumber="14">Whitacre CC</author>
, 
<author id="53FE7DF25E26FF8CFC4FEF8BFB9F3593" box="[996,1104,148,167]" fns="I" npo="LF" pageId="11" pageNumber="14">Reingold SC</author>
, 
<author id="53FE7DF25E26FF8CFBF2EF8BFB023593" box="[1113,1229,148,167]" fns="I" npo="LF" pageId="11" pageNumber="14">O’Looney PA</author>
, et al. 
<title id="F9477E215E26FF8CFAAFEF8BFBEC35F6" pageId="11" pageNumber="14">Biomedicine: a gender gap in autoimmunity</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFB87EFB0FBA435F6" box="[1068,1131,175,194]" pageId="11" pageNumber="14">Science</journalOrPublisher>
<year id="FFEBD4445E26FF8CFBD9EFB0FB5335F6" box="[1138,1180,175,194]" pageId="11" pageNumber="14">
<!--emphasis removed-->1999
</year>
; 
<part id="FFE73F8A5E26FF8CFB34EFB0FB0D35F6" box="[1183,1218,175,194]" pageId="11" pageNumber="14" type="volume">283</part>
: 
<pagination id="B28A6BE35E26FF8CFB6EEFB0FAC735F6" box="[1221,1288,175,194]" pageId="11" pageNumber="14" type="pagination">1277–8</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFEFD6FB983425" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFEFD6FB983425" _evidence="authorListStart.regEx.txt" author="Sugimoto K &amp; Stadanlick J &amp; Ikeda F" journalOrPublisher="Hepatology" pageId="11" pageNumber="14" pagination="590 - 9" part="37" title="Influenc of ethnicity in the outcome of hepatitis C virus infection and cellular immune response" type="journal article" year="2003">
36. 
<bibRef id="52E301E15E26FF8CFCC2EFD6FB983425" _evidence="authorListStart.regEx.txt" pageId="11" pageNumber="14" type="journal article">
<author id="53FE7DF25E26FF8CFCC2EFD6FC1C35E8" box="[873,979,201,220]" fns="I" npo="LF" pageId="11" pageNumber="14">Sugimoto K</author>
, 
<author id="53FE7DF25E26FF8CFC76EFD6FB8935E8" box="[989,1094,201,220]" fns="I" npo="LF" pageId="11" pageNumber="14">Stadanlick J</author>
, 
<author id="53FE7DF25E26FF8CFBFAEFD6FB5D35E8" box="[1105,1170,201,220]" fns="I" npo="LF" pageId="11" pageNumber="14">Ikeda F</author>
, et al. 
<title id="F9477E215E26FF8CFB65EFD6FA0F35C3" pageId="11" pageNumber="14">Influenc of ethnicity in the outcome of hepatitis C virus infection and cellular immune response</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFCC3EFE1FC043425" box="[872,971,254,273]" pageId="11" pageNumber="14">Hepatology</journalOrPublisher>
<year id="FFEBD4445E26FF8CFC79EFE1FC333425" box="[978,1020,254,273]" pageId="11" pageNumber="14">
<!--emphasis removed-->2003
</year>
; 
<part id="FFE73F8A5E26FF8CFC54EFE1FBDA3425" box="[1023,1045,254,273]" pageId="11" pageNumber="14" type="volume">37</part>
: 
<pagination id="B28A6BE35E26FF8CFBB3EFE1FB9C3425" box="[1048,1107,254,273]" pageId="11" pageNumber="14" type="pagination">590–9</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFEE06FBA63455" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFEE06FBA63455" _evidence="authorListStart.regEx.txt" author="Schacker T &amp; Zeh J &amp; Hu HL &amp; Hill J &amp; Corey L." journalOrPublisher="J Infect Dis" pageId="11" pageNumber="14" pagination="1616 - 22" part="178" title="Frequency of symptomatic and asymptomatic HSV- 2 reactivations among HIV-infected men" type="journal article" year="1998">
37. 
<bibRef id="52E301E15E26FF8CFCC2EE06FBA63455" _evidence="authorListStart.regEx.txt" pageId="11" pageNumber="14" type="journal article">
<author id="53FE7DF25E26FF8CFCC2EE06FC073418" box="[873,968,281,300]" fns="I" npo="LF" pageId="11" pageNumber="14">Schacker T</author>
, 
<author id="53FE7DF25E26FF8CFC7AEE06FBCD3418" box="[977,1026,281,300]" fns="I" npo="LF" pageId="11" pageNumber="14">Zeh J</author>
, 
<author id="53FE7DF25E26FF8CFBA0EE06FB833418" box="[1035,1100,281,300]" fns="I" npo="LF" pageId="11" pageNumber="14">Hu HL</author>
, 
<author id="53FE7DF25E26FF8CFBFEEE06FB4A3418" box="[1109,1157,281,300]" fns="I" npo="LF" pageId="11" pageNumber="14">Hill J</author>
, 
<author id="53FE7DF25E26FF8CFB25EE06FB163418" box="[1166,1241,281,300]" fns="I" npo="LF" pageId="11" pageNumber="14">Corey L.</author>
<title id="F9477E215E26FF8CFB75EE06FA7F3473" pageId="11" pageNumber="14">Frequency of symptomatic and asymptomatic HSV-2 reactivations among HIV-infected men</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFA10EE2BFC713455" pageId="11" pageNumber="14">J Infect Dis</journalOrPublisher>
<year id="FFEBD4445E26FF8CFC6EEE51FC203455" box="[965,1007,334,353]" pageId="11" pageNumber="14">
<!--emphasis removed-->1998
</year>
; 
<part id="FFE73F8A5E26FF8CFC59EE51FBDD3455" box="[1010,1042,334,353]" pageId="11" pageNumber="14" type="volume">178</part>
: 
<pagination id="B28A6BE35E26FF8CFBBEEE51FBAA3455" box="[1045,1125,334,353]" pageId="11" pageNumber="14" type="pagination">1616–22</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFEE76FB8E3485" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFEE76FB8E3485" _evidence="authorListStart.regEx.txt" author="Wald A &amp; Link K." journalOrPublisher="J Infect Dis" pageId="11" pageNumber="14" pagination="45 - 52" part="185" title="Risk of human immunodeficienc virus infection in herpes simplex virus type 2 - seropositive persons: a meta-analysis" type="journal article" year="2002">
38. 
<bibRef id="52E301E15E26FF8CFCC2EE76FB8E3485" _evidence="authorListStart.regEx.txt" pageId="11" pageNumber="14" type="journal article">
<author id="53FE7DF25E26FF8CFCC2EE76FC633448" box="[873,940,361,380]" fns="I" npo="LF" pageId="11" pageNumber="14">Wald A</author>
, 
<author id="53FE7DF25E26FF8CFC1DEE76FC363448" box="[950,1017,361,380]" fns="I" kam="kam" npo="LF" pageId="11" pageNumber="14">Link K.</author>
<title id="F9477E215E26FF8CFC54EE76FA5A34A2" jopScore="0.1908327" pageId="11" pageNumber="14">Risk of human immunodeficienc virus infection in herpes simplex virus type 2–seropositive persons: a meta-analysis</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFA37EE9CFC643485" jopScore="1.0003566" pageId="11" pageNumber="14">J Infect Dis</journalOrPublisher>
<year id="FFEBD4445E26FF8CFC19EE81FC133485" box="[946,988,414,433]" pageId="11" pageNumber="14">
<!--emphasis removed-->2002
</year>
; 
<part id="FFE73F8A5E26FF8CFC74EE81FBCF3485" box="[991,1024,414,433]" pageId="11" pageNumber="14" type="volume">185</part>
: 
<pagination id="B28A6BE35E26FF8CFBA8EE81FBF23485" box="[1027,1085,414,433]" pageId="11" pageNumber="14" type="pagination">45–52</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFEEA7FBFF3735" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFEEA7FBFF3735" _evidence="authorListStart.regEx.txt" author="Xiang J &amp; Wunschmann S &amp; Diekema DJ" journalOrPublisher="N Engl J Med" pageId="11" pageNumber="14" pagination="707 - 14" part="345" title="Effect of coinfection with GB virus C on survival among patients with HIV infection" type="journal article" year="2001">
39. 
<bibRef id="52E301E15E26FF8CFCC2EEA7FBFF3735" _evidence="authorListStart.regEx.txt" pageId="11" pageNumber="14" type="journal article">
<author id="53FE7DF25E26FF8CFCC2EEA7FC6534FF" box="[873,938,440,459]" fns="I" kam="kam" npo="LF" pageId="11" pageNumber="14">Xiang J</author>
, 
<author id="53FE7DF25E26FF8CFC18EEA7FBF234FF" box="[947,1085,440,459]" fns="I" kam="kam" npo="LF" pageId="11" pageNumber="14">Wunschmann S</author>
, 
<author id="53FE7DF25E26FF8CFBEDEEA7FB7F34FF" box="[1094,1200,440,459]" fns="I" npo="LF" pageId="11" pageNumber="14">Diekema DJ</author>
, et al. 
<title id="F9477E215E26FF8CFB41EEA7FAA034D2" pageId="11" pageNumber="14">Effect of coinfection with GB virus C on survival among patients with HIV infection</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFAD3EECCFC403735" pageId="11" pageNumber="14">N Engl J Med</journalOrPublisher>
<year id="FFEBD4445E26FF8CFC3CEEF1FC0E3735" box="[919,961,494,513]" pageId="11" pageNumber="14">
<!--emphasis removed-->2001
</year>
; 
<part id="FFE73F8A5E26FF8CFC6FEEF1FC293735" box="[964,998,494,513]" pageId="11" pageNumber="14" type="volume">345</part>
: 
<pagination id="B28A6BE35E26FF8CFC43EEF1FBE33735" box="[1000,1068,494,513]" pageId="11" pageNumber="14" type="pagination">707–14</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFED17FC6D3764" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFED17FC6D3764" _evidence="authorListStart.regEx.txt" author="George SL &amp; Wunschmann S &amp; McCoy J &amp; Xiang J &amp; Stapleton JT." journalOrPublisher="Curr Infect Dis Rep" pageId="11" pageNumber="14" pagination="550 - 8" part="4" title="Interactions between GB virus type C and HIV" type="journal article" year="2002">
40. 
<bibRef id="52E301E15E26FF8CFCC2ED17FC6D3764" _evidence="authorListStart.regEx.txt" pageId="11" pageNumber="14" type="journal article">
<author id="53FE7DF25E26FF8CFCC2ED17FC0A372F" box="[873,965,520,539]" fns="I" npo="LF" pageId="11" pageNumber="14">George SL</author>
, 
<author id="53FE7DF25E26FF8CFC64ED17FB95372F" box="[975,1114,520,539]" fns="I" kam="kam" npo="LF" pageId="11" pageNumber="14">Wunschmann S</author>
, 
<author id="53FE7DF25E26FF8CFBCFED17FB7C372F" box="[1124,1203,520,539]" fns="I" npo="LF" pageId="11" pageNumber="14">McCoy J</author>
, 
<author id="53FE7DF25E26FF8CFB16ED17FB30372F" box="[1213,1279,520,539]" fns="I" kam="kam" npo="LF" pageId="11" pageNumber="14">Xiang J</author>
, 
<author id="53FE7DF25E26FF8CFAA1ED17FAB5372F" box="[1290,1402,520,539]" fns="I" npo="LF" pageId="11" pageNumber="14">Stapleton JT.</author>
<title id="F9477E215E26FF8CFAD4ED17FB083702" pageId="11" pageNumber="14">Interactions between GB virus type C and HIV</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFB64ED3CFAB43702" box="[1231,1403,547,566]" pageId="11" pageNumber="14">Curr Infect Dis Rep</journalOrPublisher>
<year id="FFEBD4445E26FF8CFA2AED3CFA643702" box="[1409,1451,547,566]" pageId="11" pageNumber="14">
<!--emphasis removed-->2002
</year>
; 
<part id="FFE73F8A5E26FF8CFA1BED3CFA0E3702" box="[1456,1473,547,566]" pageId="11" pageNumber="14" type="volume">4</part>
: 
<pagination id="B28A6BE35E26FF8CFCC3ED22FC513764" box="[872,926,573,592]" pageId="11" pageNumber="14" type="pagination">550–8</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFED47FC633794" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFED47FC633794" _evidence="authorListStart.regEx.txt" author="Williams CF &amp; Klinzman D &amp; Yamashita TE" journalOrPublisher="N Engl J Med" pageId="11" pageNumber="14" pagination="981 - 90" part="350" title="Persistent GB virus C infection and survival in HIV-infected men" type="journal article" year="2004">
41. 
<bibRef id="52E301E15E26FF8CFCC2ED47FC633794" _evidence="authorListStart.regEx.txt" pageId="11" pageNumber="14" type="journal article">
<author id="53FE7DF25E26FF8CFCC2ED47FC1B375F" box="[873,980,600,619]" fns="I" npo="LF" pageId="11" pageNumber="14">Williams CF</author>
, 
<author id="53FE7DF25E26FF8CFC75ED47FB85375F" box="[990,1098,600,619]" fns="I" npo="LF" pageId="11" pageNumber="14">Klinzman D</author>
, 
<author id="53FE7DF25E26FF8CFBFEED47FB01375F" box="[1109,1230,600,619]" fns="I" npo="LF" pageId="11" pageNumber="14">Yamashita TE</author>
, et al. 
<title id="F9477E215E26FF8CFAA3ED47FB2B37B1" pageId="11" pageNumber="14">Persistent GB virus C infection and survival in HIV-infected men</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFB45ED6DFAA937B1" box="[1262,1382,626,645]" pageId="11" pageNumber="14">N Engl J Med</journalOrPublisher>
<year id="FFEBD4445E26FF8CFAC6ED6DFA5837B1" box="[1389,1431,626,645]" pageId="11" pageNumber="14">
<!--emphasis removed-->2004
</year>
; 
<part id="FFE73F8A5E26FF8CFA31ED6DFA7037B1" box="[1434,1471,626,645]" pageId="11" pageNumber="14" type="volume">350</part>
: 
<pagination id="B28A6BE35E26FF8CFCC3ED92FC663794" box="[872,937,653,672]" pageId="11" pageNumber="14" type="pagination">981–90</pagination>
.
</bibRef>
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFEDB7FAC137E1" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFEDB7FAC137E1" _evidence="authorListStart.regEx.txt" author="Pomerantz RJ &amp; Nunnari G. HIV" journalOrPublisher="N Engl J Med" pageId="11" pageNumber="14" pagination="963 - 5" part="350" title="and GB virus C: can two viruses be better than one" type="journal article" year="2004">
42. 
<author id="53FE7DF25E26FF8CFCC3EDB7FC2C378F" box="[872,995,680,699]" fns="I" npo="LF" pageId="11" pageNumber="14">Pomerantz RJ</author>
, 
<author id="53FE7DF25E26FF8CFC44EDB7FB4E378F" box="[1007,1153,680,699]" fns="I" npo="LF" pageId="11" pageNumber="14">Nunnari G. HIV</author>
<title id="F9477E215E26FF8CFB23EDB7FC2137E1" pageId="11" pageNumber="14">and GB virus C: can two viruses be better than one</title>
? 
<journalOrPublisher id="51829FDB5E26FF8CFC56EDDDFBB837E1" box="[1021,1143,706,725]" pageId="11" pageNumber="14">N Engl J Med</journalOrPublisher>
<year id="FFEBD4445E26FF8CFBD5EDDDFB6737E1" box="[1150,1192,706,725]" pageId="11" pageNumber="14">
<!--emphasis removed-->2004
</year>
; 
<part id="FFE73F8A5E26FF8CFB00EDDDFB0137E1" box="[1195,1230,706,725]" pageId="11" pageNumber="14" type="volume">350</part>
: 
<pagination id="B28A6BE35E26FF8CFB7AEDDDFAC537E1" box="[1233,1290,706,725]" pageId="11" pageNumber="14" type="pagination">963–5</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFEDC2FB773611" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFEDC2FB773611" _evidence="authorListStart.regEx.txt" author="Dawson GJ &amp; Schlauder GG &amp; Pilot-Matias TJ" journalOrPublisher="J Med Virol" pageId="11" pageNumber="14" pagination="97 - 103" part="50" title="Prevalence studies of GB virus - C infection using reverse transcriptase - polymerase chain reaction" type="journal article" year="1996">
43. 
<author id="53FE7DF25E26FF8CFCC3EDC2FC0137C4" box="[872,974,733,752]" fns="I" npo="LF" pageId="11" pageNumber="14">Dawson GJ</author>
, 
<author id="53FE7DF25E26FF8CFC72EDC2FB9A37C4" box="[985,1109,733,752]" fns="I" npo="LF" pageId="11" pageNumber="14">Schlauder GG</author>
, 
<author id="53FE7DF25E26FF8CFBCBEDC2FB2837C4" box="[1120,1255,733,752]" fns="I" npo="LF" pageId="11" pageNumber="14">Pilot-Matias TJ</author>
, et al. 
<title id="F9477E215E26FF8CFA8EEDC2FC7F3611" jopScore="0.29084566" pageId="11" pageNumber="14">Prevalence studies of GB virus–C infection using reverse transcriptase–polymerase chain reaction</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFC11EC0DFBEE3611" box="[954,1057,786,805]" jopScore="0.89084566" pageId="11" pageNumber="14">J Med Virol</journalOrPublisher>
<year id="FFEBD4445E26FF8CFB82EC0DFB9C3611" box="[1065,1107,786,805]" pageId="11" pageNumber="14">
<!--emphasis removed-->1996
</year>
; 
<part id="FFE73F8A5E26FF8CFBFDEC0DFBA23611" box="[1110,1133,786,805]" pageId="11" pageNumber="14" type="volume">50</part>
: 
<pagination id="B28A6BE35E26FF8CFBDBEC0DFB7B3611" box="[1136,1204,786,805]" pageId="11" pageNumber="14" type="pagination">97–103</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFEC33FA73366E" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFEC33FA73366E" _evidence="authorListStart.regEx.txt" author="Assmann SF &amp; Pocock SJ &amp; Enos LE" journalOrPublisher="Lancet" pageId="11" pageNumber="14" pagination="1064 - 9" part="355" title="Subgroup analysis and other (mis) uses of baseline data in clinical trials" type="journal article" year="2000">
44. 
<author id="53FE7DF25E26FF8CFCC3EC33FC1B360B" box="[872,980,812,831]" fns="I" npo="LF" pageId="11" pageNumber="14">Assmann SF</author>
, 
<author id="53FE7DF25E26FF8CFC75EC33FBF8360B" box="[990,1079,812,831]" fns="I" npo="LF" pageId="11" pageNumber="14">Pocock SJ</author>
, 
<author id="53FE7DF25E26FF8CFBE9EC33FB43360B" box="[1090,1164,812,831]" fns="I" npo="LF" pageId="11" pageNumber="14">Enos LE</author>
, et al. 
<title id="F9477E215E26FF8CFB61EC33FB16366E" pageId="11" pageNumber="14">Subgroup analysis and other (mis)uses of baseline data in clinical trials</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFB49EC58FAD4366E" box="[1250,1307,839,858]" pageId="11" pageNumber="14">Lancet</journalOrPublisher>
<year id="FFEBD4445E26FF8CFA89EC58FA83366E" box="[1314,1356,839,858]" pageId="11" pageNumber="14">
<!--emphasis removed-->2000
</year>
; 
<part id="FFE73F8A5E26FF8CFAE4EC58FABE366E" box="[1359,1393,839,858]" pageId="11" pageNumber="14" type="volume">355</part>
: 
<pagination id="B28A6BE35E26FF8CFADFEC58FA78366E" box="[1396,1463,839,858]" pageId="11" pageNumber="14" type="pagination">1064–9</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFEC7DFA6C369E" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFEC7DFA6C369E" _evidence="authorListStart.regEx.txt" author="Klinman DM &amp; Kamstrup S &amp; Verthelyi D" journalOrPublisher="Springer Semin Immunopathol" pageId="11" pageNumber="14" pagination="173 - 83" part="22" title="Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotectiveactivity and safety" type="journal article" year="2000">
45. 
<author id="53FE7DF25E26FF8CFCC3EC7DFC113641" box="[872,990,866,885]" fns="I" npo="LF" pageId="11" pageNumber="14">Klinman DM</author>
, 
<author id="53FE7DF25E26FF8CFC43EC7DFB9F3641" box="[1000,1104,866,885]" fns="I" npo="LF" pageId="11" pageNumber="14">Kamstrup S</author>
, 
<author id="53FE7DF25E26FF8CFBF2EC7DFB723641" box="[1113,1213,866,885]" fns="I" npo="LF" pageId="11" pageNumber="14">Verthelyi D</author>
, et al. 
<title id="F9477E215E26FF8CFB5DEC7DFC3B369E" pageId="11" pageNumber="14">Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotectiveactivity and safety</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFC56EC88FAC2369E" box="[1021,1293,919,938]" pageId="11" pageNumber="14">Springer Semin Immunopathol</journalOrPublisher>
<year id="FFEBD4445E26FF8CFAB8EC88FAF2369E" box="[1299,1341,919,938]" pageId="11" pageNumber="14">
<!--emphasis removed-->2000
</year>
; 
<part id="FFE73F8A5E26FF8CFAEAEC88FA96369E" box="[1345,1369,919,938]" pageId="11" pageNumber="14" type="volume">22</part>
: 
<pagination id="B28A6BE35E26FF8CFAF0EC88FA50369E" box="[1371,1439,919,938]" pageId="11" pageNumber="14" type="pagination">173–83</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFECAEFC1F3120" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFECAEFC1F3120" _evidence="authorListStart.regEx.txt" author="Moore A &amp; McCarthy L &amp; Mills KH." journalOrPublisher="Vaccine" pageId="11" pageNumber="14" pagination="2517 - 27" part="17" title="The adjuvant combination monophosphoryl lipid A and QS 21 switches T cell responses induced with a soluble recombinant HIV protein from Th 2 to Th 1" type="journal article" year="1999">
46. 
<author id="53FE7DF25E26FF8CFCC3ECAEFC7536F0" box="[872,954,945,964]" fns="I" npo="LF" pageId="11" pageNumber="14">Moore A</author>
, 
<author id="53FE7DF25E26FF8CFC6EECAEFBFF36F0" box="[965,1072,945,964]" fns="I" npo="LF" pageId="11" pageNumber="14">McCarthy L</author>
, 
<author id="53FE7DF25E26FF8CFB90ECAEFB5D36F0" box="[1083,1170,945,964]" fns="I" npo="LF" pageId="11" pageNumber="14">Mills KH.</author>
<title id="F9477E215E26FF8CFB32ECAEFAF136CD" pageId="11" pageNumber="14">The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFAE3ECF9FA4636CD" box="[1352,1417,998,1017]" pageId="11" pageNumber="14">Vaccine</journalOrPublisher>
<year id="FFEBD4445E26FF8CFA3BECF9FA7536CD" box="[1424,1466,998,1017]" pageId="11" pageNumber="14">
<!--emphasis removed-->1999
</year>
; 
<part id="FFE73F8A5E26FF8CFCC3EB1EFCB33120" box="[872,892,1025,1044]" pageId="11" pageNumber="14" type="volume">17</part>
: 
<pagination id="B28A6BE35E26FF8CFCD5EB1EFC033120" box="[894,972,1025,1044]" pageId="11" pageNumber="14" type="pagination">2517–27</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFEB04FB69314A" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFEB04FB69314A" _evidence="authorListStart.regEx.txt" author="Frank FM &amp; Petray PB &amp; Cazorla SI &amp; Munoz MC &amp; Corral RS &amp; Malchiodi EL." journalOrPublisher="Vaccine" pageId="11" pageNumber="14" pagination="77 - 86" part="22" title="Use of a purifie Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes" type="journal article" year="2003">
47. 
<author id="53FE7DF25E26FF8CFCC3EB04FC0D311A" box="[872,962,1051,1070]" fns="I" npo="LF" pageId="11" pageNumber="14">Frank FM</author>
, 
<author id="53FE7DF25E26FF8CFC66EB04FBEB311A" box="[973,1060,1051,1070]" fns="I" npo="LF" pageId="11" pageNumber="14">Petray PB</author>
, 
<author id="53FE7DF25E26FF8CFB84EB04FB44311A" box="[1071,1163,1051,1070]" fns="I" npo="LF" pageId="11" pageNumber="14">Cazorla SI</author>
, 
<author id="53FE7DF25E26FF8CFB3DEB04FB31311A" box="[1174,1278,1051,1070]" fns="I" npo="LF" pageId="11" pageNumber="14">Munoz MC</author>
, 
<author id="53FE7DF25E26FF8CFAA2EB04FAAE311A" box="[1289,1377,1051,1070]" fns="I" npo="LF" pageId="11" pageNumber="14">Corral RS</author>
, 
<author id="53FE7DF25E26FF8CFAC0EB04FC49317D" fns="I" npo="LF" pageId="11" pageNumber="14">Malchiodi EL.</author>
<title id="F9477E215E26FF8CFC21EB29FC1F314A" pageId="11" pageNumber="14">
Use of a purifie 
<!--emphasis removed-->Trypanosoma cruzi
antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes
</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFC72EB74FBD5314A" box="[985,1050,1131,1150]" pageId="11" pageNumber="14">Vaccine</journalOrPublisher>
<!--emphasis removed-->
<year id="FFEBD4445E26FF8CFB8AEB74FB84314A" box="[1057,1099,1131,1150]" pageId="11" pageNumber="14">2003</year>

; 
<part id="FFE73F8A5E26FF8CFBE5EB74FBAA314A" box="[1102,1125,1131,1150]" pageId="11" pageNumber="14" type="volume">22</part>
: 
<pagination id="B28A6BE35E26FF8CFBC3EB74FB6C314A" box="[1128,1187,1131,1150]" pageId="11" pageNumber="14" type="pagination">77–86</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFEB99FBE031FA" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFEB99FBE031FA" _evidence="authorListStart.regEx.txt" author="Verthelyi D &amp; Kenney RT &amp; Seder RA &amp; Gam AA &amp; Friedag B &amp; Klinman DM." journalOrPublisher="J Immunol" pageId="11" pageNumber="14" pagination="1659 - 63" part="168" title="CpG oligodeoxynucleotides as vaccine adjuvants in primates" type="journal article" year="2002">
48. 
<author id="53FE7DF25E26FF8CFCC3EB99FC0331AD" box="[872,972,1158,1177]" fns="I" npo="LF" pageId="11" pageNumber="14">Verthelyi D</author>
, 
<author id="53FE7DF25E26FF8CFC7EEB99FBFA31AD" box="[981,1077,1158,1177]" fns="I" npo="LF" pageId="11" pageNumber="14">Kenney RT</author>
, 
<author id="53FE7DF25E26FF8CFB95EB99FB5F31AD" box="[1086,1168,1158,1177]" fns="I" npo="LF" pageId="11" pageNumber="14">Seder RA</author>
, 
<author id="53FE7DF25E26FF8CFB32EB99FB2931AD" box="[1177,1254,1158,1177]" fns="I" npo="LF" pageId="11" pageNumber="14">Gam AA</author>
, 
<author id="53FE7DF25E26FF8CFB45EB99FA8D31AD" box="[1262,1346,1158,1177]" fns="I" npo="LF" pageId="11" pageNumber="14">Friedag B</author>
, 
<author id="53FE7DF25E26FF8CFAE0EB99FA0B31AD" box="[1355,1476,1158,1177]" fns="I" npo="LF" pageId="11" pageNumber="14">Klinman DM.</author>
<title id="F9477E215E26FF8CFCC3EBBFFABE3187" box="[872,1393,1184,1203]" pageId="11" pageNumber="14">CpG oligodeoxynucleotides as vaccine adjuvants in primates</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFAD2EBBFFC4B31FA" pageId="11" pageNumber="14">J Immunol</journalOrPublisher>
<year id="FFEBD4445E26FF8CFC20EBA4FC7A31FA" box="[907,949,1211,1230]" pageId="11" pageNumber="14">
<!--emphasis removed-->2002
</year>
; 
<part id="FFE73F8A5E26FF8CFC13EBA4FC1631FA" box="[952,985,1211,1230]" pageId="11" pageNumber="14" type="volume">168</part>
: 
<pagination id="B28A6BE35E26FF8CFC77EBA4FBE431FA" box="[988,1067,1211,1230]" pageId="11" pageNumber="14" type="pagination">1659–63</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFEBCAFB5F3037" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFEBCAFB5F3037" _evidence="numberAuthorListStart.regEx.txt" author="Nabel GJ." journalOrPublisher="Nature" pageId="11" pageNumber="14" pagination="1002 - 6" part="410" title="Challenges and opportunities of development of an AIDS vaccine" type="journal article" year="2001">
49. 
<author id="53FE7DF25E26FF8CFCC3EBCAFC7031DC" box="[872,959,1237,1256]" fns="I" npo="LF" pageId="11" pageNumber="14">Nabel GJ.</author>
<title id="F9477E215E26FF8CFC6DEBCAFC653037" pageId="11" pageNumber="14">Challenges and opportunities of development of an AIDS vaccine</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFC18EBEFFC203037" box="[947,1007,1264,1283]" pageId="11" pageNumber="14">Nature</journalOrPublisher>
<year id="FFEBD4445E26FF8CFC5DEBEFFBEF3037" box="[1014,1056,1264,1283]" pageId="11" pageNumber="14">
<!--emphasis removed-->2001
</year>
; 
<part id="FFE73F8A5E26FF8CFB88EBEFFB893037" box="[1059,1094,1264,1283]" pageId="11" pageNumber="14" type="volume">410</part>
: 
<pagination id="B28A6BE35E26FF8CFBE2EBEFFB443037" box="[1097,1163,1264,1283]" pageId="11" pageNumber="14" type="pagination">1002–6</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFEA14FB2D300C" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFEA14FB2D300C" _evidence="authorListStart.regEx.txt" author="Schultz AM &amp; Bradac JA." journalOrPublisher="AIDS" pageId="11" pageNumber="14" pagination="147 - 58" part="15" title="The HIV vaccine pipeline, from preclinical to phase III" type="journal article" year="2001">
50. 
<author id="53FE7DF25E26FF8CFCC3EA14FC1F302A" box="[872,976,1291,1310]" fns="I" npo="LF" pageId="11" pageNumber="14">Schultz AM</author>
, 
<author id="53FE7DF25E26FF8CFC71EA14FBF9302A" box="[986,1078,1291,1310]" fns="I" npo="LF" pageId="11" pageNumber="14">Bradac JA.</author>
<title id="F9477E215E26FF8CFB90EA14FC77300C" jopScore="0.08168082" pageId="11" pageNumber="14">The HIV vaccine pipeline, from preclinical to phase III</title>
. 
<journalOrPublisher id="51829FDB5E26FF8CFC6AEA3AFC20300C" box="[961,1007,1317,1336]" jopScore="0.12019281" pageId="11" pageNumber="14" type="_" typeScore="100">AIDS</journalOrPublisher>
<!--emphasis removed-->
<year id="FFEBD4445E26FF8CFC5CEA3AFBEE300C" box="[1015,1057,1317,1336]" pageId="11" pageNumber="14">2001</year>

; 
<part id="FFE73F8A5E26FF8CFB8FEA3AFBF6300C" box="[1060,1081,1317,1336]" pageId="11" pageNumber="14" type="volume">15</part>
(Suppl 5):S 
<pagination id="B28A6BE35E26FF8CFB30EA3AFB11300C" box="[1179,1246,1317,1336]" pageId="11" pageNumber="14" type="pagination">147–58</pagination>
.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFCEFEA5FFC5830EC" blockId="11.[836,1477,148,1496]" pageId="11" pageNumber="14">
<bibRef id="52E301E15E26FF8CFCEFEA5FFC5830EC" _evidence="authorListStart.regEx.txt" author="Nitayaphan S &amp; Pitisuttithum P &amp; de Souza M" journalOrPublisher="Barcelona, Spain: Prous Science" pageId="11" pageNumber="14" pagination="2002" title="Safety and immunogenicity of live recombinant ALVAC-HIV (vCP" type="book chapter" volumeTitle="Program and abstracts of the XIV International AIDS Conference 2002 (Barcelona, Spain)" year="1521">
51. 
<author id="53FE7DF25E26FF8CFCC3EA5FFC2F3067" box="[872,992,1344,1363]" fns="I" npo="LF" pageId="11" pageNumber="14">Nitayaphan S</author>
, 
<author id="53FE7DF25E26FF8CFC40EA5FFBBF3067" box="[1003,1136,1344,1363]" fns="I" npo="LF" pageId="11" pageNumber="14">Pitisuttithum P</author>
, 
<author id="53FE7DF25E26FF8CFBD0EA5FFB283067" box="[1147,1255,1344,1363]" fns="I" npo="LF" pageId="11" pageNumber="14">de Souza M</author>
, et al. 
<title id="F9477E215E26FF8CFA8FEA5FFAD43059" jopScore="0.3348465" pageId="11" pageNumber="14" type="_" typeScore="100">Safety and immunogenicity of live recombinant ALVAC-HIV (vCP</title>
<year id="FFEBD4445E26FF8CFAB0EA45FA8B3059" box="[1307,1348,1370,1389]" pageId="11" pageNumber="14">1521</year>
) priming with AIDSVAX B/E gp120 boosting in Thai HIV-negative adults (abstract WePeB6049). In: 
<volumeRef id="7EF797605E26FF8CFC56EA90FA703089" pageId="11" pageNumber="14">
<volumeTitle id="34EFF7275E26FF8CFC56EA90FB6D3089" jopScore="0.6662069" pageId="11" pageNumber="14">Program and abstracts of the XIV International AIDS Conference 2002 (Barcelona, Spain)</volumeTitle>
. 
<journalOrPublisher id="51829FDB5E26FF8CFB07EAB5FA703089" box="[1196,1471,1450,1469]" jopScore="2.6643808" pageId="11" pageNumber="14">Barcelona, Spain: Prous Science</journalOrPublisher>
</volumeRef>
, 
<!--emphasis removed-->
<pagination id="B28A6BE35E26FF8CFCC3EADAFC5D30EC" box="[872,914,1477,1496]" pageId="11" pageNumber="14" type="pagination">2002</pagination>

.
</bibRef>
</paragraph>
<paragraph id="8BFC95175E26FF8CFFA3E718FE6B3D17" blockId="11.[8,766,2055,2099]" pageId="11" pageNumber="14">Downloaded from https://academic.oup.com/jid/article-abstract/191/5/654/1234535 by Aerztegemeinschaft fuer Anaesthesie user</paragraph>
</document>